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INTRODUCTION 
The management of acute myocardial infarction (AMI) has been 
improved by the rea~isation that the size of infarction can influence 
mortality (Sobel et al, 1972) and that the infarct size can be altered 
by subse·quent therapy (Maroko et al, 1972). The identification of any 
factor which may have adverse effects on the ischaemic myocardium and 
which is amenable to treatment would therefore have important prognostic 
implications. 
Elevation of circulating free fatty acid (FFA) concentrations is a 
consistent feature (Kurien & Oliver, 1966; Oliver et al, 1968) of the 
profound, non-specific metabolic reaction associated with the onset of AMI 
(Opie, 1975). The FFA rise has been correlated with the development of 
arrhythmias (Oliver et al, 1968) after AMI, and with the severity of 
ischaemic damage (Oliver et al, 1968; Gupta et al, 1969; Russell& Oliver, 
1978) on clinical grounds. The method of quantifying infarct size 
developed by Shell et al (1972) has provided a means of correlating the 
degree of metabolic disturbance with extent of myocardial damage, and of 
assessing the benefits of metabolic interventions. 
The purpose of the studies reported in this thesis was to examine 
in detail the FFA rise in the early phase of AMI and to correlate this 
rise with the development of arrhythmias and other complications of AMI 
and with enzymatically estimated infarct size, thus leading to a more 
rational approach to therapeutic interventions. 
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CHAPTER I 
PATIENT SELECTION AND CLINICAL METHODS 
PATIENT SELECTION 
All patients studied were initially admitted to the coronary care 
unit at Groote Schuur Hospital for a period of at least 3 days. Consent 
was obtained in each case, though all the procedures, other than the 
frequency of blood sampling, were routinely carried out in all patients. 
Criteria for inclusion varied from study to study but in all cases 
patients had to satisfy the following conditions:-
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1. Proven acute myocardial infarction. Acute myocardial infarction was 
defined by the presence of at least 2 of the following features: (a) a 
history of prolonged chest pain suggestive of acute myocardial infarction; 
(b) new Q-waves or typical evolutionary ischaemic ST-T wave changes on the 
electrocardiogram; (c) a characteristic rise and fall in the levels of the 
serum enzymes creatine kinase, amino aspartate transaminase and lactic 
dehydrogenase. 
2. A time lapse of less than 12 hours after the onset of symptoms of 
acute myocardial infarction. This time limit was set because peak plasma 
free fatty acid (FFA) levels after acute myocardial infarction were being 
estimated. The major FFA rise occurs within 12 hours and a very high FFA 
is rarely found beyond this time (Kurien & Oliver, 1966). 
3. No clinical evidence of shock, because this may cause a release of CK 
from skeletal muscle (Sobel & Shell, 1972) and plasma CK activity was being 
measured in order to calculate infarct size. Shock was defined by the 
presence of at least 2 of the following findings: (a) a systolic blood 
pressure of 90 mmHg or less for 30 minutes or more; (b) urine flow of less 
than 30 ml per hour despite a fluid intake of over 100 ml/hour; (c) evidence 
of reduced organ perfusion, as shown by cold, cyanosed peripheries or mental 
confusion. 
4. No intramuscular injections in the week prior to admission, because 
intramuscular injections result in release of CK from skeletal muscle 
(Meltzer et al, 1970; Klein et al, 1973). 
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5. No oral intake of any kind from the time of onset of symptoms of acute 
myocardial infarction. Carbohydrates lower FFA levels in both normal 
subjects (Gordon & Cherkes, 1956) and in patients with elevated FFA levels 
after acute myocardial infarctions (Oliver et al, 1972; Opie et al, 1975). 
For the same reason the only intravenous infusion permitted was either 
normal or half-normal saline. 
6. No prior administration of heparin, clofibrate, catecholamines or 
steroids, which could influence blood FFA levels (Oliver et al, 1968). 
7. No history or evidence of diabetes mellitus, as FFA levels may be 
elevated in this condition (Shafri r & Gutman, 1965). 
BLOOD SAMPLING AND STORAGE 
Blood was withdrawn via an indwelling venous catheter, the tip of 
which was placed either in the superior vena cava or in the right atrium. 
The position of the catheter was checked by X-ray immediately after 
insertion. Sampling via a catheter is better than sampling by repetitive 
venipuncture when CK activity is to be estimated because even minor trauma 
near the sampling site may result in release of skeletal muscle CK and 
distortion of results (Roberts et al, 1975a). The proximal end of the 
catheter was attached to a 3-way tap so that the catheter could serve for 
both the intravenous saline infusion and for sampling of venous blood. 
Prior to sampling the 3-way tap was turned so as to prevent saline entering 
the catheter, and 5 mls of fluid were then withdrawn and discarded to ensure 
that only venous blood, uncontaminated by the infusion, was ultimately 
withdrawn and analysed. 
20 ml samples of blood were withdrawn and 10 mls placed into each of 
2 heparinised plastic tubes, which were then sealed and centrifuged at 
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4000 rpm for 10 minutes. Samples which appeared haemolysed or turbid to 
the naked eye were discarded. The plasma from 10 mls of blood suffice for 
all the analyses carried out in these studies, and the second sample was 
taken as a precaution, in case of loss of the first sample. The determination 
of insulin levels could not be carried out on heparinised samples because 
the laboratory which carried out the insulin estimations reported spuriously 
high results from samples containing heparin. Where insulin levels were 
required 10 mls of the blood were placed in a plastic tube and spun immediately 
for 10 minutes at 4000 rpm, after which the clot was removed from the 
supernatant using an orange stick. 
After spinning, the plasma or serum was poured into plain plastic tubes 
which were sealed and immediately frozen at -10°C. Immediately prior to 
analysis, specimens were thawed rapidly under tap water (Sobel et al, 1972) 
and then spun for 5 minutes at 4000 rpm to ensure that only clear plasma or 
serum was used for analysis. 
Where possible, blood samples were collected hourly up to 12 hours 
after the onset of symptoms, 2 hourly for the next 12 hours, 4 hourly for 
the next 24 hours and then 6 hourly for 24 hours, or until the CK activity 
had returned to near normal levels. 
ROUTINE CLINICAL INVESTIGATIONS 
The following investigations were carried out routinely for each 
patient by the staff of the coronary care unit, and the ~esults were used 
to follow progress in all patients studied. 
1. X-rays. A portable X-ray of the chest was taken when each patient was 
admitted, and daily thereafter for the duration of stay in the coronary care 
unit. Additional X-rays were taken when this was warranted by a change in 
clinical status. 
2. ECG. A 12-lead ECG with a 12 second rhythm was taken on admission and 
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daily thereafter. Further ECGs were taken after any further episode of 
chest pain and whenever a change of rhythm or a conduction defect was 
observed. 
3. Arrhythmia monitoring. Arrhythmias were continuously monitored by an 
Electrodyne computer for the duration of the patient's stay in the coronary 
care unit. All arrhythmias in the preceding eight hours could be displayed 
by the computer, and hard copies of the display were available. The onset 
of any arrhythmia caused an alarm to be activated and a rhythm strip to be 
printed out, so that a record of all arrhythmias experienced in the coronary 
care unit was available for all patients. 
ROUTINE BIOCHEMICAL ESTIMATIONS 
The potassium level was carried out as a matter of urgency, by the 
hospital laboratory, whenever a patient with suspected acute myocardial 
infarction (AMI) was admitted to the casualty department, so that patients 
with low serum potassium levels could receive potassium supplements at the 
earliest opportunity. The full blood count, urea, creatinine, electrolytes 
and cardiac enzymes (Creatine kinase, Lactic Dehydrogenase and Glutamic 
Oxalo-acetic Transaminase) were monitored daily by the hospital laboratory. 
On the day of admission, serum protein, calcium, phosphate, cholesterol, 
urate, bilirubin and alkaline phosphatase levels were also estimated. 
ROUTINE OBSERVATIONS AND RECORDS 
Blood pressure, heart rate, respiratory rate and oral temperature were 
recorded every 4 hours by the nursing staff; observations were recorded 
more frequently if indicated by the clinical situation. Fluid intake and 
uri ne output were carefully monitored. 
A record was kept of all drugs given orally and intravenously. No 
intramuscular injections were given during the stay in the coronary care 
uni t to any patient included in these studies. 
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ROUTINE DRUG ADMINISTRATION 
The following drugs were prescribed routinely for all patients in the 
coronary care unit:-
Morphine 5-10 mg intravenously, whenever required for chest pain; 
Prochlorperazine 12.5 mg, or Metoclopromide 10 mg intravenously as required 
to counteract nausea and vomiting. 
Diazepam 5 mg orally three times daily. All other drugs were prescribed in 
accordance with the clinical needs of the patients. 
CLINICAL STATUS OF THE PATIENTS 
On admission to the coronary care unit, all patients had full histories 
taken and were given a complete physical examination. A complete clinical 
examination was carried out daily. Details relevant to each study are 
included in the appropriate chapter. 
CLASSIFICATION OF THE EXTENT OF MYOCARDIAL DECOMPENSATION BY THE METHOD OF 
KILLIP AND KIMBALL (1967) 
Killip classes provided a clinical estimate of the severity of myocardial 
decompensation after acute myocardial infarction. The 4 classes are defined 
as follows:-
!. No signs of pulmonary or venous congestion. 
II. Mild to moderate heart failure - crepitations over an area of 50% or 
less of the lung fields, development or intensification of a third 
heart sound, tachypnoea or dyspnoea, or signs of right heart failure, 
such as venous or hepatic distension. 
III. Severe heart failure - clinical frank pulmonary oedema. 
IV. Shock - as defined previously. 
SURFACE AREA 
The surface area was determined from the patient's height and weight, using 
a nomogram (Berlyne, 1974). 
8 
STATISTICAL METHODS 
Full details of the statistical methods used are given in Appendix C, 
and are appropriately identified in the text. All statistical tests were 
two-tailed. + Mean values are expressed - standard error of the mean 
+ (- SEM) unless otherwise stated. 
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CHAPTER II 
BIOCHEMICAL METHODS 
10 
1. ANALYSIS OF PLASMA TOTAL CREATINE KINASE ACTIVITY 
Serial measurements of plasma creatine kinase (CK) activity were used 
to calculate estimated infarct size in patients with acute myocardial 
infarction, as described below. The accuracy of this method is largely 
dependent on the accuracy of the estimations of CK activity, and the method 
used is therefore analysed in detail. 
A. METHOD EMPLOYED IN THE ANALYSIS OF PLASMA CK ACTIVITY 
Biochemistry of the reaction mixture 
Plasma creatine kinase activity was estimated using an IL/Harleco 
model 368 CLINICARD analyzer. All reactions and photometric measurements 
were performed in individual disposable cuvettes. 
CK catalyses the following reaction:-
ADENOSINE DIPHOSPHATE (ADP)+ CREATINE PHOSPHATE 
ADENOSINE TRIPHOSPHATE (ATP)+ CREATINE. 
CK 
The formation of ATP and creatine is reversible, but the direction of the 
reaction in which ATP and creatine are produced is preferable because it 
proceeds more rapidly (Rosalki, 1967). The Clinicard Creatine Phospho-
kinase Chemistry is based on a spectrophotometric method, first described 
by Oliver (1955), in which the above reaction is coupled with two additional 
enzyme reactions which link the CK reaction to reduction of oxidized nico-
tinamide adenine dinucleotide (NAD+) (Tanzer et al, 1959) as in the following 
equations: 
HEX OK I NASE 
ATP+ GLUCOSE GLUCOSE-6-PHOSPHATE (G-6-P) + ADP. 
G-6-P + NAD+ G-6-P Dehydrogenase, 6-Phosphogluconic A+ NADH. 
NAD+ is colourless but NADH absorbs Ultra Violet light, and the reaction was 
measured by following the increase in absorbance at 340 nm of NADH over a 
48 second period and solving the equation: 
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dA 
Xu= dt K 
Where Xu= Activity of CK in International Units per litre (i.u./1) 
dA = Change in absorbance 
dt = Change in time 
K = Scaling factor which produced a 
proper numeric readout. 
The accuracy of the electronic circuits in computing this ratio was 2% or 
better, as stated by the manufacturer. 
The pre-packed disposable cuvettes contain the complete substrate in 
lyophilized form. The substrate consists of: 
Creatine Phosphate 
ADP 
Glucose 
Hexokinase 
G-6-P Dehydrogenase 
Magnesium and Manganese ions 
A myokinase inhibitor 
A mercaptan 
The myokinase inhibitor and mercaptan were· included for reasons detailed 
below. 
Procedure 
3 ml of distilled water heated to 42 ! 1°C was used to reconstitute the 
substrate. The accuracy and the repeatability of the dispenser used was to 
<1 %. The cuvette was then sealed and incubated for 8 minutes at 37°C. The 
serum sample was aspirated by a precision dispenser located on the 368 
Clinicard Analyzer and 100 µl was dispensed into the cuvette, which was then 
incubated for a further 8 minutes at 37°C. The 100 µl dispenser was 
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accurate to 0.5% (95% confidence limits) and the temperature limits were 
! 0.25°C for 37°C. After the second 8 minute incubation period, the 
change in absorbance at 340 nm was measured for 48 second,. The light path 
was 1.00 cm at a point on the centre lines of the cells which was 8 mm above 
the base. The relative path length variation was equivalent to less than 
0.2 mA from cell to cell. 
Temperature and conversion factor 
Using the Clinicard Analyzer the chemical reactions were all carried 
out at 37°C. Values were then corrected to 30°C, the standard temperature 
recommended by the International Union of Biochemistry (1965), and the 
temperature at which the constants for evaluation of infarct size have been 
calculated (Shell et al, 1971; Sobel et al, 1972). The factor used to 
convert the results from 37°C to 30°C was ·0.58 (Rosalki, 1967; Jarmakani et 
al, 1976). 
Normal range 
The level of CK activity was determined in 49 normal volunteers, none 
of whom were known to have myocardial or skeletal muscle disease of any 
nature, and who had not indulged in violent physical exercise or had intra-
muscular injections in the preceding week. The individual levels of CK 
activity are given in Table 1. 
at 37°C. 
The range of CK activity was 2-133 i.u./1 
The mean CK activity! Standard Deviation (SD) was ~9 ! 30 i.u./1 at 
37°C. The upper limit of normal for CK activity was taken to be 99.0 i.u./1 
(Mean! 2 SD) at 37°C or 58 i.u./1 at 30°C. 
Reproducibility of results 
A within day reproducibility of 8 measurements in a sample from a normal 
volunteer, from a patient with AMI and from a standard are shown below 
(i.u. / 1 at 37°C). 
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Human serum 
Normal after myocardial 
Observations human serum infarction Standard 
Mean 149 i.u./1* 
(119-179) 
1 59 744 155 
2 55 743 157 
3 49 770 155 
4 53 737 157 
5 51 761 151 
6 55 739 165 
7 52 755 160 
8 52 750 153 
Range 49-59 743-770 151-165 
Mean 53.3 749.9 156.6 
SD 3 .1 11. 5 4.3 
RSD 5. 8~~ 1 • 5~6 2.7% 
*These results were obtained by the manufacturers using a different method. 
B. FACTORS INFLUENCING THE ACCURACY OF THE ESTIMATION OF CK ACTIVITY 
Enzyme stability 
Storage of plasma prior to assay may result in loss of CK activity . . 
A 30% fall in activity was reported by Kar and Pearson (1965a)in serum stored 
at -20°C for 4 weeks, whilst Hughes (1962) and Duma and Siegel (1965) 
reported no loss of activity in serum stored for 2 weeks at -20°C. The 
inclusion of thio~ compounds in the reaction mixture ensure maximal enzyme 
reactivation (Miyada et al, 1975) and, provided these are present, there is 
no loss of CK activity in serum stored at 4°C for 7-10 days (Rosalki, 1967; 
Hess et al, 1968; Schwartz, 1973) or at -18°C for 1 month (Rosalki, 1967). 
The thiol activator used in this reaction mixture, Mercaptoethane, has been 
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shown to activate CK maximally (Hess et al, 1968; Miyada et al, 1975). 
The samples used in the following studies were all frozen at -10°C and 
all assays were carried out within 48 hours. Plasma was used for CK 
determinations with heparin as the anticoagulant, though CK activity is 
similar in corresponding serum and plasma samples (Roberts & Sobel, 1978). 
The choice of anticoagulant was important. Heparin in conventional 
amounts does not affect the CK determination (Rosalki, 1967; Roberts & 
Sobel, 1978), though citrate and large quantities of heparin may inhibit CK 
activity (Sobel, Personal Communication), amd EDTA may sequester magnesium 
required for enzyme activity (Roberts & Sobel, 1978). 
Myokinase 
Myokinase is released from the myocardium after acute myocardial 
infarction (Sobel, 1976, Personal Communication). In the above reaction 
mixture it acts on ADP to produce ATP and adenosine monophosphate (AMP) 
according to the equation:-
ADP + ADP MYOKINASE' ATP+ AMP 
Thus myokinase could activate the auxilliary enzyme systems resulting in 
spurious changes in absorbance, which are not the result of CK activity. 
Oliver (1955) reported that myokinase activity could be inhibited by the 
addition of AMP to the reaction mixture in a proportion of 10:1 with ADP. 
Hess et al (1968) found that AMP, whilst inhibiting myokinase activity also 
inhibited CK activity by up to 35%. These investigators only allowed 
3 minutes to elapse between substrate addition and initial absorbance 
readings, whereas Rosalki (1967) showed that the presence of AMP, in the 
above ratio, causes a delay for linear optical density readings to occur of 
up to 6 minutes. After this time no difference in optical density changes 
was observed in specimens with and without AMP. 
AMP is included as a myokinase inhibitor in the Clinicard reaction 
mixture, and since the absorbance is read after an 8 minute incubation 
period, no inhibitory effect of AMP on CK activity should be observed. 
Haemolysis 
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Haemolysed plasma contains incre,ased concentrations of ATP and G-6-P 
released from the red blood cells when there is more than minimal haemolysis. 
These may influence auxilliary enzyme systems by increasing the absorbance 
and thus the apparent CK activity (Rosalki, 1967) .. Samples in which naked-eye 
haemolysis had occurred were therefore not used in these studies • 
. Other substances causing interference 
Zinc, copper, silver and mercuric ions are inhibitory, as are L-
Thyroxine and citrate to lesser extents. Lipaemic plasma may introduce 
inaccuracies since the turbidity may interfere with the optical density 
readings (Rosalki, 1967), and high concentrations of uric acid can interfere 
with the assay (Sobel, Personal Communication). No patient with high 
plasma uric acid levels or with lipaemic plasma was included in these studies. 
Dilution 
The Clinir.ard CK chemistry has been found by the manufacturers to be 
linear up to activities of 1000 i.u./1 and will read out values up to 
1100 i.u./1. In several instances CK activity in patients with acute 
myocardial infarction reached levels greater than 1000 i.u./1, and where the 
activity in any sample from a given patient was found to be 1000 i.u./1 or 
greater, all the samples from that patient were diluted. 
Simple dilution of plasma prior to assay for CK activity is not possible 
however, because dilution results in a spurious increase in CK activity 
(Graig et al, 1967; Hess et al, 1968; Bray & Ferrendelli, 1968; Thomson, 1969; 
Dobosz, 1974). Graig et al (1967) found that the increase in CK activity 
after dilution was evident even in normal sera, but this finding was not 
confirmed by Bray and Ferrendelli (1968). The mechanism of the dilution 
effect remains unknown (Graig et al, 1967), though the presence of 
inhibitors in plasma or serum has been proposed to explain the dilution 
effect (Menach~ et al, 1966; Wiesmann et al, 1966; Graig et al, 1968; 
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Thomson, 1969; Spikesman & Brock, 1969). On the basis of the dilution 
effect, Thomson (1969) found that inhibitors were only present when abnormal 
levels of CK activity were the result of Duchenne muscular dystrophy, but 
Spikesman and Brock (1969) found the same dilution effect on CK activity 
after myocardial infarction, and concluded that the inhibitors were not 
specific to Duchenne or any other neuromuscular disease. Graig et al (1967) 
were unable to elucidate the mechanism of the dilution effect and suggested 
that the progressive nature of the increase in CK activity with dilution 
militated against the presence of an inhibition in the serum as an explanation 
for this effect. 
Attempts have been made to find a diluent which does not cause an 
increase in CK activity. Graig et al (1967) tested the dilution effect 
of water, Tris buffer, deproteinised serum, serum free of low molecular 
weight components and heat-inactivated serum. Only heat-inactivated serum 
showed no dilution effect, confirming the results of Hess et al (1964). 
Thomson (1969) found no dilution effect using heat-inactivated serum and 
saline to dilute serum from patients with ~cute myocardial infarction, but a 
marked effect using saline to dilute the serum of patients with muscular 
dystrophy. 
In summary, the problem in measuring CK activity greater than 1000 i.u./1 
lies in the fact that dilution of the sample results in increased CK activity. 
The mechanism for this dilution effect remains unknown, though the presence 
of inhibitors to CK activity which are differentially diluted has been put 
forward as an explanation. Several diluents have been studied to try and 
overcome the dilutional effect, but so far none have proved effective. 
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C. STUDIES TO DETERMINE A SUITABLE METHOD OF DILUTING PLASMA WITH HIGH CK 
ACTIVITY 
In order to assess the effects of dilution on CK activity in plasma 
assayed with Clinicard kits, samples from patients with acute myocardial 
infarction were diluted with distilled water, Tris buffer and heat-
inactivated serum and the results compared with those from undiluted plasma 
samples within the linear range of the 368 Clinicard analyzer (0-1000 i.u./1). 
Effect of dilution on plasma samples using Tris buffer 
0.5 ml of plasma from 8 samples were diluted with 2 mls of 0.01M Tris 
buffer pH 7.4 with 0.2% Bovine albumin (Sobel et al, 1972). 
The results were as follows:-
PLASMA CK ACTIVITY i.u./1 AT 37°C 
Diluted in 
Undiluted Tris buffer 
1 653 865 
2 703 825 
3 714 860 
4 802 940 
5 937 1195 
6 946 1420 
7 995 1585 
8 1091 1595 
The results are shown in Fig.1. There was a significant difference 
between the regression line and the line of identity (P<0.05). Statistics 
relevant to this and the following figures are given on page 25. 
The effect of dilution on plasma samples using distilled water (Fig.2) 
0.5 mls of plasma from 10 samples were diluted with 1.0 ml distilled 
water. The results were as follows:-
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PLASMA CK ACTIVITY i.u./1 AT 37°C 
Diluted x 3 
with distilled 
Undiluted water 
1 268 396 
2 366 448 
3 470 554 
4 531 894 
5 554 926 
6 648 956 
7 669 1084 
8 700 1108 
9 766 1084 
10 886 1176 
The effect of dilution on plasma samples using heat-inactivated serum (Fig.3) 
0.5 mls of plasma from 5 samples were diluted with 2 mls of heat-
inactivated serum. The serum was inactivated by heating at 56°C for 
30 minutes (Graig et al, 1967). The results were as follows:-
PLASMA CK ACTIVITY i.u./1 AT 37°C 
Diluted x 5 
in heat-
Undiluted inactivated serum 
1 711 799 
2 718 854 
3 766 1018 
4 822 1010 
5 857 952 
The correlation on the few results obtained (r = 0.71) was so poor 
that this approach was abandoned. 
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In view of these results, no further attempts were made at diluting 
plasma samples prior to assay, and an alternative approach was sought. 
Assay dilution 
Introduction 
Instead of diluting the plasma prior to assay, the concentration of 
plasma in the assay mixture was reduced. 
A possible source of error which may arise with any assay dilution, 
even with the sample volumes recommended by the manufacturers, is that the 
concentration of plasma in the assay mixture relative to the concentrations 
of enzymes and substrate may affect comparative results (Menache, 1967). 
The reason for this is that the protein concentration in the plasma is very 
high compared with enzyme concentration. Menache (1967) found that the 
CK activity in a given sample diminished as the plasma concentration in the 
reaction mixture was increased, and that with high levels of enzyme activity, 
the inhibitory effect of high plasma concentrations increased. Hess et al 
(1968) found the same effect when serum comprised 10% or more of the reaction 
volume, but not when less than 10% of the reaction volume. They reasoned 
that at serum concentrations of 10% or above, the activity of any inhibitors 
present became significant. With the Clinicard system the plasma 
concentration in the reaction volume was ~ever greater than 3.3%, so that no 
inhibitory effect was likely to be apparent. 
Method 
Using Socorex micropipettes, 20 µland 10 µl samples of plasma were 
added to the assay mixture and the results compared with each other and with 
the results when the recommended 100 µl of plasma were added. For CK 
activities greater than 1000 i.u./1 only the results from 20 µland 10 µl 
samples could be compared. The normal volume of the reaction mixture is 
3.0 mls and of the sample 100 µl, a total of 3.1 mls. By reducing the 
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volume of the sample, the total volume was therefore reduced. To compensate 
for this the dilution factor was modified according to the equation for 
calculating the results. 
results is:-
The simplified equation for calculating the 
dA Xu= dt x K. Where Xu = CK activity in i.u./1 
dA = Change in absorbance 
dt = Change in time 
K = Scaling factor 
1 Unit of CK activity is defin~d as that amount of activity which will lead 
to the formation of 1 µM of NADH per minute (Hess et al, 1968). 
is used as the standard unit volume for plasma assay. 
More specifically the equation is as follows:-
µM/Min/L. NADH = A/Min x6~ 99 x dilution factor x 1000 
1 Where6-:-22 x dilution factor x 1000 = K 
6.22 = Extinction coefficient for NADH 
Dilution factor= Total Reaction Volume 
Plasma Volume 
Dilution factors 
(a) Using 100 µl of plasma 
Substrate volume = 3.0 ml 
Plasma volume = 0 .1 ml 
Total reaction volume= 3.1 ml 
Dilution factor 3.1 = 0 .1 = 31. 
One litre 
(b) Using 20 µl of plasma 
Substrate volume = 3.0 ml 
Plasma volume = 0.02 ml 
Total reaction volume= 3.02 ml 
D·1 t· f t 3 · 02 151 i u ion ac or= 0 _02 = 
151 Multiplication factor=~ = 4.87 x normal dilution factor. 
When 20 µl of plasma were added to the assay, the result was therefore 
multiplied by a factor of 4.87. 
(c) Using 10 µl of plasma 
Volume = 3.0 ml 
= 0.01 ml Plasma volume 
Total reaction volume= 3.0 ml 
D·1 t· f t 3· 01 301 i u ion ac or= 0.01 = 
301 Multiplication factor=~ = 9.7 x normal dilution factor. 
When 10 µl of plasma were added to the assay, the result was therefore 
multiplied by a factor of 9.7. 
Results 
(a ) Comparison of CK activity in undiluted plasma and in plasma 
diluted x 4.87 (Fig.4) 
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26 samples were compared "undiluted" (100 µl of plasma added to the 
assay) and diluted x 4.87 (20 µl of plasma added to the assay). The 
results were as follows:-
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PLASMA CK ACTIVITY i.u./1 AT 37°C 
Undiluted Diluted x 4.87 
1 57 50 
2 64 56 
3 77 76 
4 78 70 
5 84 78 
6 103 93 
7 126 115 
8 127 129 
9 153 155 
10 155 126 
11 174 169 
12 223 217 
13 232 239 
14 254 259 
15 261 262 
16 262 262 
17 183 285 
18 293 304 
19 300 290 
20 318 316 
21 320 321 
22 340 352 
23 383 375 
24 414 412 
25 579 536 
26 692 716 
(b) Comparison of CK activity in undiluted plasma, in plasma diluted 
x 4.87, and in plasma diluted x 9.7 (Fig.5) 
8 undiluted samples were compared with X 4.87 dilution and x 9.7 
dilution (10 µl of plasma added to the assay). The results are as 
follows:-
PLASMA CK ACTIVITY i. u. /1 AT 37°C 
Undiluted Diluted x 4.87 Diluted x 9.7 
1 64 56 64 
2 84 78 81 
3 155 126 154 
4 320 321 294 
5 383 375 369 
6 414 412 384 
7 579 536 534 
8 692 716 708 
(c) Comparison of CK activity in undiluted plasma and in plasma 
diluted x 9.7 (Fig.6) 
At levels of CK activity greater than 1000 i.u./1 it was not 
possible to compare undiluted with diluted samples. A comparison was 
therefore made of 23 samples diluted x 4.87 and x 9.7 to include samples 
with CK activity greater than 1000 i.u./1. 
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PLASMA CK ACTIVITY i. u. /1 AT 37°c 
Diluted x 4.87 Diluted x 9.7 
1 56 64 
2 78 81 
3 126 154 
4 321 294 
5 375 369 
6 412 384 
7 536 534 
8 655 638 
9 686 728 
10 716 708 
11 886 834 
12 934 926 
13 1039 1029 
14 1071 1048 
15 1188 1217 
16 1225 1285 
17 1578 1649 
18 1948 1998 
19 2221 2212 
. 20 2325 2415 
21 2347 2492 
22 2474 2503 
23 2630 2677 
When the very high levels of CK activity were included, the two 
dilutions differed significantly, but no difference was observed for values 
of 1500 i.u./1 and less. 
Statistics of the regression line and the line of identity 
1 . Dilution in Tris buffer (Figure 1) 
a = -436.3 Sy.x = 85.4 
b = 1. 84 Sb = 0.2 
r = 0.96 Sob = 0.283 
t = 2.97 P<0.05 
2. Dilution in distilled water (Figure 2) 
a = 6. 51 Sy.x = 104 
b = 1.46 Sb = 0 .19 
r = 0.94 SDb = 0.27 
t = 1.7 Not significant (NS) 
3. Assay dilution - undiluted and diluted X 4.87 (Figure 4) 
a = -6.08 Sy.x = 12.76 
b = 1 . 01 Sb = 0.02 
r = 0.995 Sob = 0.028 
t = 0.35 (NS) 
4. Assay dilution - undiluted and diluted x 9.7 (Figure 5) 
a = -6.56 
b = 0.98 
r = 0.995 
t = 0.47 (NS) 
Sy.x = 20.85 
Sb = 0.03 
Sob = 0.042 
(Figs.1-5) 
5. Assay dilution - diluted x 4.87 and diluted x 9.7 (Figure 6) 
a = 
b = 
r = 
-18 .1 
1.03 
1 
t = 2.1 P<0.05 
Sy.x = 37.34 
Sb = 0.01 
Sob = 0.014 
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Discussion of dilution methods 
Plasma dilution in Tris buffer, heat-inactivated serum or distilled 
water gave results which were clearly unacceptable, while assay dilutions 
using 20 µl of plasma (dilution x 4.87) and 10 µl of plasma (dilution x 9.7) 
gave results which compared well with undiluted plasma. Within the limits 
of comparison diluted and undiluted plasma (0 - 1000 i.u./1) the regression 
line did not differ significantly from the line of reference whether a 
dilution of 4.87 or 9.7 is used. A dilution of 9.7 compared with a 
dilution of 4.87 resulted in a regression line different from the line of 
reference (P<0.05); it is possible that pipetting errors could account for 
some of this difference (Hess et al, 1967), and since the percentage error 
is greater with smaller volumes and plasma CK activity greater than 
2500 i.u./1 was never encountered, a dilution of 9.7 was not needed and 
not used. 
Within the comparable range O - 1000 i.u./1, a dilution of 4.87 
varied by a maximum of 5% at the very lowest levels of CK activity to a 
minimum of 0.07% at 500 and 600 i.u./1 when compared with undiluted CK 
activity. Projecting the regression line to the level 2000 i.u./1, 
though not acceptable for statistical purposes, predicts an error of 0.8% 
when comparing undiluted with diluted plasma (x 4.87); since these errors 
are well within the standard error of the assay method, assay dilution using 
20 µl of plasma added to the assay mixture was adopted as the method to be 
used when plasma CK activity exceeded 1000 i.u./1. 
2. ANALYSIS OF PLASMA MB-CK ISOENZYME ACTIVITY 
Method employed 
MB-CK analysis was carried out using MERCK-1-TEST CK-MB kits. These 
have been found to be specific and their results reproducible (Wurzberg 
et al , 1977) • The reaction temperature was 25°C. 
The collection of specimens for analysis of MB-CK activity was 
carried out as for total CK, and the precautions regarding storage, 
haemolysis and the presence of interfering substances was the same. 
Dilution is required for samples in which total CK activity exceeds 
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800 i.u. / 1 at 25°C, otherwise the antibody is exhausted whilst M subunits 
are still active. 
Plasma was added to the reaction mixture and incubated at 25°C for 
7 minutes in a water bath, as recommended by the manufacturers. The rate 
of the reaction was then measured using a Gilford 300 N spectrophotometer 
(light wavelength 340 nm) with a Gilford 4008 Datalister over a period of 
5 minutes. Values for CK-MB equal to or exceeding 4% of the total CK 
activity were considered to be elevated (Varat & Mercer, 1975). 
Reproducibility of the method 
In order to test the accuracy of the method and the within-day 
reproducibility, a control serum (Boehringer, mean level of CK-MB activity 
51 i.u./1, range 40.8 - 61.2 i.u./1) was assayed 5 times by the MERCK-1-
TEST CK-MB test. 
No. tiA/Min Conversion factor MB-CK 
1 0.0450 1333 U/1 60 
2 0.0450 1333 U/1 60 
3 0.0425 1333 U/1 57 
4 0.0425 1333 U/1 57 
5 0.0450 1333 U/1 60 
Range 57-60 i.u ./1 
Mean 59 i. u. /1 
SD 1.6 
RSD 2. 7~~ 
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Boehringer assay the control serum using a chromatographic method so that 
the results are not directly comparable. 
3. BIOCHEMICAL ANALYSIS OF PLASMA GLUCOSE 
Methods used 
Plasma glucose was estimated using an IL/Harleco model 368 Clinicard 
analyzer and the 32100 Clinicard glucose chemistry. The chemistry uses 
the reaction of 0-toluidine, a primary aromatic amine, in hot glacial 
acetic acid, with the terminal aldehyde group of glucose. One hundred 
micro litres of plasma are added to the chemistry and the reaction mixture 
is incubated at 90°C for 16 minutes, at the end of which time a blue-green 
condensation product of 0-toluidine and glucose is produced. The 
absorbance of the reaction mixture is then measured at 630 nm against a 
200 mg/100 ml standard run concurrently. The normal fasting range for the 
0-toluidine method is reported as being 70-122 mg/100 ml (Cooper & McDaniel, 
1970). Plasma glucose levels were only used for comparative purposes 
and a normal range for the local population was therefore not established. 
Requirements for accurate determinations 
The manufacturers recommend that the plasma be separated from the 
cells immediately after collection, and th~t only non-turbid, non-
haemolysed plasma should be used. The method is not specific for 
glucose and therefore xylose, mannose, fructose and galactose will react 
with 0-toluidine and give spuriously high results, whilst haemoglobin, 
hypochlorites, high levels of bilirubin and the filler in oxazepam 
preparations also interfere with the reaction (Young et al, 1972). The 
manufacturers state that bilirubin levels below 25 mg/100 ml do not affect 
the reaction, and no patient in the study had abnormally high bilirubin 
levels. Samples were well spun so that no cells were present in the 
plasma, and haemolysed samples were not used. 
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Performance specifications (as determined by the manufacturers) 
The coefficient of variation was 0.7 to 2.6% for within-day 
reproducibility, and 2.6% to 4.8% for day-to-day reproducibility, using 
samples with normal and samples with elevated glucose levels. Comparison 
of a manual 0-toluidine method with the Clinicard chemistry in 63 samples, 
with levels ranging from normal to grossly elevated, gave a correlation 
coefficient of 0.993. Recovery of glucose added to human plasma varied 
from 100% at low levels to 86% when 300 mg/100 ml of glucose was added. 
The results are linear for plasma glucose values ranging from O mg/100 ml to 
400 mg/ 100 ml, and values higher than 400 mg/100 ml were not found in the 
s tudies which were carried out. 
All determinations of plasma glucose were carried out within 48 
hours of sampling, and results expressed as mg per 100 mls of plasma. 
4. BIOCHEMICAL ANALYSIS OF PLASMA FREE FATTY ACIDS 
Method used 
The method of Dole and Meinertz (1960) was used for the extraction 
and titration of long chain or free fatty acids (FFA) from plasma. Plasma 
i s added to a mixture of water, heptane and isopropyl alcohol and shaken, 
after which the mixture is allowed to stand. There is rapid separation 
of the mixture into 2 phases: an upper "heptane" phase and a lower 
acqueous phase. The long chain free fatty acids are then found distributed 
predominantly in the upper, non-polar phase, whereas the other acids, which 
are more polar, remain in the lower phase. Enough acid must be added to 
the lower, ncqueous phase to bring the pH to 2.5, otherwise the distribution 
of long chain free fatty acids to the upper phase is impaired. Quantitative 
analysis is carried out by titrating an aliquot of the upper phase against 
a base. 
Solutions used 
(a) Doles mixture 
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This is a mixture of 40 parts Iso-propyl alcohol, 10 parts heptane 
and 1 part of 1N sulphuric acid. 
(b) Nile blue indicator 
100 mg of Nile blue dye were dissolved in 100 ml of Carbon Dioxide-
free water, filtered, and diluted to 500 mls with distilled water. This 
was washed with iso-octane until the washings were colourless (Stock 1). 
Each 10 mls of stock 1 were then further diluted to 100 mls with CO2-free 
water as required (Stock 2), For titration purposes 10 mls of stock 2 
were diluted to 100 mls with absolute alcohol, and the pH was adjusted 
to 8.0 using 0.1N sodium hydroxide, If the indicator is acid the blank 
titration will be excessively high; if it is neutral it will take up 
carbon dioxide, in which case the titration values for the FFA extracts will 
be too low, since part of the acidity of the extract will be neutralized 
by the bicarbonate buffer in the indicator solution. 
(c) 0.01N Sodium hydroxide 
A stock of 5N sodium hydroxide (200 gms dissolved in 1 litre) was 
prepared, and the 0.01N sodium hydroxide solution used in the titration 
was prepared fresh daily by dissolving 1 ml of the stock solution in 500 mls 
of carbon dioxide-free water, The solution was standardised using 0.1 mls 
of normal hydrochloride acid with phenolphthaline as an indicator. 
(d) Palmitic acid standard 
A palmitic acid standard was distributed in the extraction system 
with every set of analyses. Palmitic acid (molecular weight 256) was made 
up into a solution containing 6.0 mM/1 by dissolving 76.8 grams in 500 mls 
of heptane. A one in six silution of this stock mixture gave a working 
standard containing 1.0 mM/1, 
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Procedure 
(a) Plasma was defrosted immediately prior to the separation of free fatty 
acids and kept on ice. 
(b) 0.6 mls of plasma were pipetted into a 25 ml quick-fit test tube. 
(c) 3 mls of Doles mixture were added, and the stoppered test tube was then 
shaken for 5 minutes. 
(d) 1.2 mls of distilled water and 1.8 mls of heptane were then added and 
the mixture shaken for a further 5 minutes. 
(e ) The mixture was allowed to stand for at least 5 minutes after shaking to 
allow the phases to separate. 
( f ) 1 ml of the upper phase was then titrated with 1 ml of the Nile blue 
indicator against 0.01N sodium hydroxide, whilst being continuously 
agitated by a stream of nitrogen. Each plasma sample was extracted twice 
and the mean of the two results taken. 
The palmitic acid standard was prepared by adding 0.6 mls of the 
solution in heptane to Doles mixture, but later only 1.2 mls of heptane were 
added so that the total volume of heptane would not exceed 1.8 mls; a 
further 0.6 mls of water were then added to maintain the total volume at 
3.6 mls. A blank, which was used with each set of analyses, was prepared 
by adding 0.6 mls of distilled water inste~d of 0.6 mls of plasma to the 
extraction system. 
0.01N sodium hydroxide was titrated against the extraction mixture 
using a syringe attached to a micrometer screw gauge. Each unit on the 
syringe micrometer corresponded to 0.0002 ml of sodium hydroxide; the 
number of units on the screw gauge rather than the volume of sodium hydroxide 
required to neutraiise the FFA extract was recorded on each occasion. 
Acceptable values for the blank and the palmitic acid standard were 5 
(r ange 5 to 15) micrometer units and 124 (range 118 to 130) micrometer units 
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respectively. 
Before each set of analyses 0.01N sodium hydroxide was titrated 
directly against the working standard (0.2 mls of palmitic acid standard 
+ 0.6 mls heptane+ 0.8 mls Nile blue dye), so that all extracted values 
could be corrected against this 100% standard. Analysis was carried 
out within 48 hours of plasma samples being withdrawn. 
Calculation of FFA concentrations in millimoles per litre (mM/1) 
The total volume of heptane in the extraction mixture= 0.6 + 1.8 mls = 2.4 mls 
2.4 mls of heptane extracts FFA from 0.6 mls of plasma. 
1 ml of heptane contains 0.6 2.4 = 0.25 mls of FFA solution. 
Volume of FFA solution= 0.25 mls 
Strength of FFA solution (unknown) = a 
Volume of sodium hydroxide solution =S units dispensed by micrometer 
syringe x 0.0002 mls 
Strength of sodium hydroxide solution= 0.01N. 
Thus: 0.25a = 0.01 x 0.0002 e 
0.000002 
a=----e= 0.25 0.000008 emM/ml. 
a= 0.000008 x 1000 = 0.008 e mM/1. ' 
The value for the blank is subtracted from both the value obtained 
for the unknown FFA concentration and the value obtainea for the standard. 
Since the standard is 1.0 mM/1, the unknown value is divided by the 
standard value to give the FFA concentration in mM/1: 
Plasma FFA Unknown value - blank value =---------------Standard value - blank value mM/1 
Interfering substances 
Exceptional quantities of lactic, acetic, aceto-acetic and beta-
hydroxybutyric acids interfere with the procedure, giving spurious high 
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values. The presence of lactic acid is most important in the clinical 
setting, but it was not possible to determine lactic acid levels in the 
patients studied. 
Storage 
Separated plasma was stored for up to 48 hours at --10°C. Storage 
in this way did not alter the results when compared with plasma estimated 
immediately (Rifkind, 1966; Kurien & Oliver, 1966). 
Normal values 
The upper limit of normal for plasma FFA as determined in 100 healthy 
adults, was 0.8 mM/1 (Oliver et al, 1968). 
5. BIOCHEMICAL ANALYSIS OF INSULIN 
Insulin was analysed by the Department of Endocrinology of the 
University of Cape Town. Serum insulin was measured by radio-immunoassay 
by a modification of the method of Hales and Randle (1963), using kits 
supplied by the Radiochemical Centre, Amersham. The upper limit of 
normal in healthy, fasting su~jects, as determined by the Department of 
Endocrinology, University of Cape Town was 9 micro units/ml. 
6. ANALYSIS OF PLASMA POTASSIUM 
Plasma potassium was estimated in the Biochemistry Laboratory of 
Groote Schuur Hospital. The normal range is 3.5 - 5.0 mM/1. 
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7. THE FFA/ALBUMIN MOLAR RATIO 
The albumin concentration was determined by the Hospital Laboratory 
and the result expressed as grams per 100 ml of serum. 
to mM/ 1 as follows: 
ygm albumin/100 ml= 10 ygm/litre 
This is converted 
10 y ) 
= 68000 mol/litre (68000 = molecular weight of albumin 
10y X 1000 
= 68000 mM/litre 
= 10y 
68 
mM/litre 
The FFA concentration in mM/1 was then divided by the albumin 
concentration in mM/1 to give the FFA/albumin molar ratio. Serum drawn at 
the same time as that of the peak FFA was sent to the laboratory to 
determine the albumin concentration. 
8. BIOCHEMICAL RESULTS 
FFA, glucose and insulin results in all patients are listed in 
Appendix A. 
Table 1 CK ACTIVITY (i.u/1) MEASURED AT 37°C IN 49 NORMAL 
VOLUNTEERS 
CK CK CK 
No. activity No. activity No. activity No. 
1 25 13 21 25 25 37 
2 3 14 18 26 29 38 
3 2 15 13 27 51 39 
4 48 16 27 28 7 40 
5 7 17 34 29 79 41 
6 47 18 30 30 54 42 
7 38 19 86 31 8 43 
8 27 20 32 32 45 44 
9 58 21 55 33 133 45 
10 24 22 32 34 77 46 
11 7 23 26 35 11 47 
12 93 24 16 36 32 48 
49 
Mean 39 i.u./1 
S.D. !30 
Range 2 - 133 i.u./1 
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Figure 1 
Plasma CK activity in undiluted plasma and in plasma 
diluted x 5 in O.OlM Tris buffer. The regression line 
differs signifioantZy from the tine of identity. 
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...J 
c~ 
·- ::> 
L.[) -X>-
1500 
]S: 1000 
::J -
_.J t--
· - u 
-0 <( 
<(~ 
2u (f) 
<( ~ 
_J~ 500 
()_ ~ 
Z-c, 
<i c.> 2~ 
::> 1n 
I~ Q-111-----..------.. 
0 500 1000 
UNDILUTED PLASMA 
CK ACTIVITY (I.U./L) 
Plasma CK aotivity in undiluted plasma and in plasma 
diluted x 5 in distilled water. 
37 
C _J 
--
. 
lD :J 
X . . 
1500 
E-~ ::J 
-S ~ ~1000 
:-= l/l -
-0-u> 
<( 2 r-
2 ro u 
Cf).> <( 
...... 
<( ~ ~ 
_J C 
o_ . - u 500.ac...----"T'"-----, 
500 1000 1500 
Figure 3 
UNDILUTED PLASMA 
CK ACTIVITY I.U./L 
Plasma CK activity in undiluted plasma and in plasma 
diluted x 5 in heat-inactivated serum. 
38 
/ 
Figure 4 
800 
Regression Line 
y = 6-08 + 1 ·0lX 
0-f'------------------
0 20 40 60 
PLASMA CK ACTIVITY (I.U/L) when 
100 JJL of plasma was added to the reaction 
mixture 
800 
Plasma CK activity when 100 µl of plasma and when 20 µl 
of plasma (x 4.87 'dilution') were added to the Clinicard 
reaction mixture. 
39 
>-0 
t-W 
-o 
~o 
u <I: 
<I: 
800 
600 
400 
Q ~ 200 
Cf) 
<I: <I: 
~ _J 
Cf) 0.... 
<I: _J 
_J ::::i.. 
0.... 0 
N 
Figure 5 
0 
• 20 µI added to reaction mixture ( x4 ·87 dilution ) 
O 10 fJ I " " " " ( x9 -7 d ilution) 
200 
#, 
oQ,(:-
~ ~ 
0 
- ~Q, v 
400 
Regression Line 
10 µLadded 
y=6 ·56+0·98x 
600 
PLASMA CK ACTIVITY (1.U./Ll when lOOµL 
plasma added to reaction mixture 
800 
Plasma CK activity when 100 µl of plasma and 20 µl 
(x 4.87 'dilution') O!' 10 µZ (x 9. 7 'dilution') 
we r e adde d to t he CZinicaPd Peaction mixtu!'e. 
40 
w 
a::: 
::J 
I-
x 
~ 
z 
§ 3000 
~ 
w 
a::: 
Q 
0 2500 
w 
0 
0 
<( 
<f) 
~ 2000 
<( 
L 
<f) 
<( 
_J 
Q. 
_J 1500 
::i.. 
Q 
z 
w 
I 
3 1000 
>-1-
~ 
t-
u 
<( 
~ 500 
u 
Figure 6 
500 1000 1500 2000 2500 3000 
CK ACTIVITY (J.UJL)WHEN 20µ1 PLASMA WAS ADDED TO 
REACTION MIXTURE 
41 
Plasma CK activity when 20 µl of plasma (x 4.8? 'dilution') 
and when 10 µl of plasma (x 9.? 'dilution') were added to 
the Clinicard reaction mixture. 
CHAPTER III 
THE ESTIMATION OF MYOCARDIAL INFARCT SIZE BY 
SERIAL MEASUREMENTS OF BLOOD CREATINE KINASE 
ACTIVITY 
Review of the literature and practical application of 
the method 
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1. BACKGROUND TO THE USE OF CREATINE KINASE AS A 
MARKER OF MYOCARDIAL ISCHAEMIC INJURY 
The principle that serum enzymes may be elevated in response to 
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tissue injury (Wohlgemuth, 1908; Warburg & Christian, 1943) was first applied 
to cardiology by Karmen et al (1954), who demonstrated an increase in serum 
glutamic oxalo-acetic transaminase (SGOT) and lactic dehydrogenase (LDH) 
activity in patients with recent myocardial infarction. Dreyfus et al 
(1960a) first reported raised levels of creatine kinase (CK) activity after 
myocardial infarction, and their findings were rapidly confirmed (Dreyfus 
et al, 1960b; Forster & Escher, 1961; Stick & Tsirimbas, 1961; Stick & 
Tsirimbas, 1962; Hess & MacDonald, 1963). 
Investigation of the association between the magnitude of peak SGOT 
and LDH changes following coronary artery occlusion and the extent of 
myocardial infarct size suggested a definite relationship (Lemley-Stone 
et al, 1955; Nydick et al, 1955; Strandjord et al, 1959; Nachlas et al, 1964) 
but the correlation between the two was not close. Bang and LaDue (1962) 
showed that the maximal enzyme rise in patients who survived their infarction 
was half that of patients who died. Neither SGOT nor LDH is specific for 
the myocardium however (Sobel & Shell, 1972), so that raised enzyme activity 
after myocardial infarction may reflect release not only from the myocardium, 
but from other components in the heart involved in the inflammatory response, 
such as fibroblasts, marginating white cells and other blood elements 
(Kjekshus & Sobel, 1970), and from non-cardiac sources (Wilkinson, 1970; 
Agress & Kim, 1960). Furthermore, the magnitude of the enzyme peak in serum 
is dependent on a number of variable, namely the rate at which the enzyme 
is released into the circulation, the space in which it is distributed and 
the rate at which it is cleared from the circulation (Wilkinson, 1970; 
Posen, 1970). Thus direct comparison of peak enzyme values and anatomical 
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infarct size cannot be expected to have a high degree of correlation. 
Serum CK activity is subject to many of the limitations described 
for SGOT and LOH, but of these three enzymes, it is the most sensitive and 
the most specific marker of myocardial ischaemic injury. The assay of CK 
by the back reaction with thiol activation, as described, is highly 
sensitive (Sobel & Shell, 1972). Serum CK activity is elevated in virtually 
all patients with acute myocardial infarction (Goldberg & Winfield, 1972; 
Roberts et al, 1975a), and is detectable from 4-6 hours after the onset of 
myocardial damage (Ahamuda et al, 1976). In the heart CK is not present 
i n any tissue other than myocardial cells, and is therefore not released by 
other components involved in the inflammatory process after myocardial 
infarction (Kjekshus & Sobel, 1970). In contrast, LOH levels in the blood 
after AMI are frequently higher than the total amount of LOH present in the 
normal heart, possibly due to release from the blood elements involved in 
t he inflammatory response (Sobel, 1975). CK levels in plasma are not 
dependent on renal function or renal blood flow because CK in plasma is not 
cleared via the kidney (Roberts et al, 1975b), but by the reticulo-endothelial 
system (Painter et al, 1977). 
CK is present in tissue other than the myocardium; highest values 
are found in skeletal muscle, heart, brain and the gastrointestinal tract, 
whilst minimal amounts are found in the lung, kidney, liver and spleen and 
none at all in red blood cells (Roberts et al, 1975b). Significant amounts 
are also found in the thyroid (Dawson & Fine, 1967). The most important 
extracardiac source of CK is skeletal muscle. Thus serum CK activity is 
i ncreased in patients with muscular dystrophy and inflammatory muscle 
disease (Danowski et al, 1968), with alcohol intoxication (Lafair & Myerson, 
1968), with hypothermia (Maclean et al, 1968; Carlson et al, 1978a), with 
diabetes mellitus (with or without ketoacidosis) and with convulsions 
(Savignano et al, 1969). CK activity also rises after intramuscular 
injections (Meltzer et al, 1970; Klein et al, 1973), after surgery (Klein 
et al, 1973) and after vigorous exercise (Griffiths, 1966; Vejjajiva & 
Teasdale, 1965). Serum CK activity may also be elevated in patients 
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with pulmonary thromboembolism, cerebral vascular disease, pancreatitis, 
shock (Sobel & Shell, 1972), hypothyroidism (Roberts & Sobel, 1978), and 
after electrical cardioversion (Konttinen et al, 1969; Mandecki et al, 1970; 
Forssell et al, 1975; Ehsani et al, 1976; Reiffell et al, 1978). CK 
may be released from the myocardium in the absence of myocardial infarction 
by conditions such as pericarditis and myocarditis, but not in 
uncomplicated heart failure,(Hess et al, 1964), and also by investigative 
and therapeutic measures such as cardiac catheterization (Michie et al, 
1970; Roberts et al, 1976), and radiotherapy (Muggia et al, 1970). 
Whilst the applicability of total serum CK as a marker of myocardial 
ischaemic injury is restricted by these factors, it remains more specific 
than SGOT and LDH as a marker of ischaemic myocardial injury, since the 
extracardiac sources of CK are less numerous and easier to exclude 
(Sobel & Shell, 1972). 
The isoenzymes of creatine kinase 
The inaccuracies introduced by the use of total serum CK activity can 
be avoided by the use of the cardiospecific isoenzyme of CK, MB-CK. 
Creatine kinase exists in the form of dimers of the subunits Mand B 
respectively. In 1964 three isoenzymes were distinguished (Burger et al, 
1964; Deul & Van Bremen, 1964; Sjovall & Voight, 1964), the dimer MM, 
found predominantly in skeletal muscle, the dimer BB, found predominantly 
in the brain and the hybrid dimer MB, found in the myocardium. The, 
distribution of CK and its isoenzymes in huma~ tissue is as follows (Roberts et al, 
1975b; Jockers-Wretou et al, 1975):-
CK isoenz}'.mes uo 
Tissue Total CK (i.u./1) MM MB BB 
Skeletal muscle 3200 1oma 0 0 
Heart 680 86~0 14~o 0 
Brain 180 0 0 1oma 
GI tract 140 0 0 1oma 
Lung 13 ss~o 0 1 s~o 
Kidney 9 B9~o 0 11~0 
Liver 2 0 0 1oma 
Spleen 2 0 0 1oma 
Red cell lysates 0 0 0 0 
Uterus 10 20~0 2ma 6mo 
Aorta 5 smo 2ma 0 
Pancreas 2 smo 0 smo 
Ogunro et al (1977) found no MB isoenzyme in uterus however and 
Varat and Mercer (1975) have found up to 3% MB-CK activity in skeletal 
muscle. 
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CK-MB is confined mainly to the myocardium and is not raised by 
intramuscular injections or other skeletal muscle trauma, uncomplicated 
congestive cardiac failure (Roberts et al, 1975a), pericarditis (Fleg et al, 
1977) or in neck, thoracic, abdominal, genito-urinary or orthopaedic 
surgery (Roberts & Sobel, 1976). It is not elevated after cardiac 
catheterization (Roberts et al, 1976), or in patients with pneumonia, 
chronic lung disease and pulmonary emboli (Smith et al, 1976) even though 
total CK may be increased. 
Apart from myocardial ~nfarction, conditions in which MB-CK activity 
may occasionally be enhanced are hypothermia (Carlson et al, 1978a), cardiac 
massage, electrical injuries, severe drug intoxication, polymyositis, 
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dermatomyositis and Reye's syndrome (Merck Brochure). MB-CK is also 
consistently elevated in patients with muscular dystrophy (Kar & Pearson, 
1965b) , and though some may be released by the dystrophic heart, the main 
cause may be that the normal differentiation of skeletal muscle with 
increasing foetal maturity fails to occur, and as a result the normal 
progression of isoenzyme profiles within skeletal muscle, from BB in the 
early foetal phase to MM and MB at or before term and MM alone by birth 
also fails to occur (Eppenberger et al, 1964). The MB-CK isoenzyme 
activity is raised after acute myocardial infarction (Van der Veen & 
Willebrands, 1966; Wagner et al, 1973), and is both sensitive (Wagner et al, 
1973; Smith et al, 1976), and is relatively specific (Roe et al, 1972; 
Konttinen & Sommer, 1972; Konttinen & Sommer, 1973; Wagner et al, 1973; 
Roberts et al, 1975a; Smith et al, 1976) for this condition. An accurate 
and practical quantitative method for measuring MB-CK only became available 
in South Africa in late 1977. 
Previously published methods for the differentiation of the CK 
isoenzymes were based broadly on two techniques: firstly, electrophoretic 
separation with subsequent measurement via NADPG fluorescence, or via 
reduction of tetrazolium salts to formazanes (Somer & Konttinen, 1972; 
Smith, 1972; Roe et al, 1972; Klein et al, 1973; Elevitch, 1973), and 
secondly, ion exchange chromatography (Mercer, 1974; Ne~lon & Henderson~ 
1975; Henry et al, 1975; Wong & Smith, 1975). A method in which the MB 
isoenzyme is specifically activated with dithiothreithol has also been 
reported. The electrophoretic methods all suffer from lack of sensitivity 
and are laboriously time consuming (Ogunro et al, 1975) whilst quantitation 
of isoenzymes by fluoroscanning is inaccurate and irreproducible due to 
uneven substrate diffusion (Roberts et al, 1974). Ion-exchange 
chromatography and dithiothreitol activation yield false low values for the 
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MB-isoenzyme (Kudirka et al, 1975; Wong & Smith, 1975; Ogunro et al, 1977) 
and there may be insufficient separation of the isoenzymes. The selective 
activation method has been shown to lack specificity (Vacca, 1977). 
Recently a highly specific immunological method allowing rapid, 
quantitative estimation of MB-CK activity has been reported (Wurtsburg et al, 
1977), and has been shown to be highly sensitive (Vacca, 1977). This method 
only became available towards the completion of these studies and was 
therefore not used extensively. 
2. THE CALCULATION OF INFARCT SIZE FROM SERIAL 
MEASUREMENTS OF CK ACTIVITY IN THE BLOOD 
Using CK as the biochemical index of myocardial infarction, Shell et al 
(1971) developed a model which provided a quantitative assessment of infarct 
size in conscious dogs by analysis of serial changes in serum CK activity. 
The basis for this model was the following evidence:-
(a ) CK depletion from the myocardium was directly proportional to histo-
logically estimated infarct size in the rabbit (Kjekshus & Sobel, 1970) 
and in the dog (Maroko et al, 1971). 
(b) The fraction of CK released from the centre of the infarcts in the above 
two studies was relatively constant. 
An assumption was then made that the change in serum CK activity at 
any given time was the result of the combined effect of .an appearance . 
function (i.e. release of CK from the heart into the circulation) and a 
disappearance function (i.e. the removal of CK from the circulation, 
Shell et al, 1971). 
49 
A. Calculation of infarct size based on diiect measurement of 
myocardial CK (Shell et al, 1971) 
By direct measurement of myocardial CK, an equation was derived whereby. 
infarct size could be ·calculated: 
Where: 
Where: 
= myocardial CK concentration (i.u./gm) in normal 
left ventricular muscle determined by biopsy of non-
ischaemic myocardium. 
= myocardial CK concentration (i.u./gm) in the centre 
of infarcts 24 hours after coronary art~ry occlusion. 
= total amount of CK (i.u.) depleted from a given 
heart subjected to coronary artery occlusion. 
= total left ventricular CK (i.u.) expected in the 
homogenate from a normal ventricle of known weight. 
=[CKN] x left ventricular weight in grams. 
= -total left ventricular CK (i.u.) measured in the 
homogenate from a heart subjected to coronary artery 
occlusion 24 hours earlier. 
In the dog the value for myocardial CK concentration in the centre of 
infarcts 24 hours after coronary occlusion, [CK<l, was consistently 25% of 
that in normal ventricle [CKN] and the value for [CK~ -[CK~ was 800 i.u./gm 
(Sobel et al, 1977a). Since this value was constant only the CK depletion 
(CK0 ) needed to be calculated in order to determine infarct size, without 
resorting to necropsy studies. 
B. Calculation of CK depletion (CKD) from serial changes in 
serum CK activity (Shell et al, 1971) 
The calculation is based on the following model: 
CK release from the heart= serial changes in plasma CK activity+ CK 
disappearance from the circulation. 
The following information is required: 
i. The actual volume in which CK is distributed after entering 
the circulation (the distribution volume, DV). This is 
calculated as a proportion of body weight. 
ii. The proportion of CK depleted from the myocardium which 
appears in the CK distribution (PCK). 
50 
iii. The fractional disappearance rate of CK from the circulation (Kd). 
iv. Serial, observed values of CK activity in the blood after AMI. 
With the above information CK0 can then be calculated as follows: 
CKR is derived as follows: 
t = Time after onset of myocardial infarction (minutes). 
f(t) = CK appearance function. This is the rate at which CK appears 
in the blood (i.u./mg/min). 
t 
Ef(t)dt = The integrated appearance function (i.u./ml). This represents 
0 
CK 
r 
the CK concentration released from the heart which would have 
been observed in the blood if no clearance of CK occurred. It 
is dependent on t. 
t 
= Cumulative CK serum entry/ml= Ef(t)dt at any given time. 
0 
CKR = Total cumulative CK serum entr~ · 
C. Calculation of estimated infarct size (EIS) 
EIS= 
1 
= CK X DV X 1 X 1 x body weight r 
PCK (CKN] -(CK~ 
DV 1 1 K (ml) (CK-g-eg) x-- X [CKN] [CKI] = (Kg) (i.u.) PCK 
K = The proportionality constant. 
EIS= CK x K x body weight (CK-gram-equivalents) r 
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A CK-gram-equivalent (CK-g-eq) is that quantity of tissue from which CK 
depletion has occurred equal in magnitud~ to CK depletion in one gram 
of myocardium exhibiting homogeneous necrosis (Sobel et al, 1972). 
D. Values used with this model 
Values used initially 
Initially the following values were used with this model to 
estimate infarct size in man (Sobel et al, 1972): 
680 i.u./gram 
180 i.u./gram 
These values were obtained from myocardial samples obtained 4-24 hours 
post-mortem. 
DV = 11.4% body weight 
PC K = 0. 3 
These values had been observed in the dog. 
Kd = 0.001 ! 0.0001 (mean! SEM). 
52 
This value was estimated from the fractional disappearance rates observed 
i n 24 patients with a single, discrete peak of CK elevation after acute 
myocardial infarction. In later studies all these values were modified. 
Modification of the values for DV, PcK, CKN and CKI 
Roberts et al (1975b) calculated the values for DV and PCK in man, 
with the following results: 
DV = 44 mls/kg (the approximate plasma volume). 
PCK = 0.15 
Using myocardial samples analysed 90 minutes after death, the following 
values of[CK~ and [CK~ were obtained (Roberts & Sobel, as quoted by 
Bleifeld et al, 1977): 
[CK~ = 1300 i.u ./gm 
(CKI] = 195 i.u./gm 
Modification of the fractional decay rate (Kd) 
Sobel et al (1972) used a mean Kd of 0.001 ! 0.0001 (mean! SEM, 
n=24) when calculating infarct size in man. Norris et al (1975) pointed 
out that the standard deviation for this values, 0.0005, was so great that 
over-and under-estimations of 50% and 100% were likely to occur. They 
therefore proposed a method for individualizing Kd for each patient. 
Values for serum CK activity were plotted against time on they 
axis on semi-log paper. The values where log CK activity declined rapidly 
and uniformly were used for the calculation. It was inferred that when 
t he decline was linear enzyme release from the myocardium had ceased, 
and Kd was therefore independent of CK release. Five or more 
values had to be used, and a line of best fit was calculated together 
with the 95~6 confidence limits for the slope. 
Since error in calculating the integrated appearance function of 
CK is identical to the calculating error in the determination of Kd, cases 
where the 95% confidence limits were greater than! 15% were arbitrarily 
excluded. 
E. The proportionality constant, K, for calculating EIS using 
MB-CK activity-identification of misleading information in 
the literature 
Whilst reviewing the literature concerning the calculation of EIS, 
it became apparent that the proportionality constant, K, for MB-CK was 
incorrectly reported in three key publications (Roberts et al, 1975b; Shell 
& Sobel, 1976; Ahamuda et al, 1976). 
-1 K was reported as being 4.1 x 10 for MB-CK, which is similar to K 
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-1 for total CK (5.9 x 10 ). By the method of enzymatic estimation, infarct 
size is the product of K, body weight and CK release (Roberts et al, 1975b; 
Shell & Sobel, 1976; Ahamuda et al, 1976; Sobel et al, 1976) and, in the 
absence of extracardiac CK, total CK release is approximately ten times 
greater than MB-CK release (Ahamuda et al, 1976). If the value for K were 
similar in both instances, the calculated infarct size based on MB-CK would 
be approximately ten times smaller than that based on total CK. The 
correct K value for MB-CK was calculated using the relevant data from these 
same papers (Roberts et al, 1975b; Shell & Sobel, 1976; Ahamuda et al, 1976): 
K = DV x --1--
PMB-CK 
DV = 44 ml/kg 
PMB-CK = 0.15 
[MB-C~] = 96 i.u./g 
[MB-CK~= 25 i.u./g 
1 
X 
44 K = --------,-0 .15 (96-25) = 4 .1 
(ml) (CK-g-eg) 
(Kg) (i.u.) 
This value corresponds to the one quoted by Sobel et al, 1976. 
In reply to a letter pointing out this error (Tansey, 1977), the 
relevant authors (Ahamuda, Roberts & Sobel) acknowledged that their reported 
values for K might have caused confusion and explained that in their own 
laboratory a further step in the calculation was used, one not mentioned in 
the literature. They used constants of similar magnitude and multiplied 
the result for MB-CK by the ratio of total myocardial CK to MB-CK, thus 
achieving the same result. They agreed, however, that the notation, as 
described above, was "clear, correct and desirable since it obviated the need 
for an implicit additional computational step". 
3. LIMITATIONS OF THE MEfHDD OF CALCULATING ESTIMATED 
MYOCARDIAL INFARCT SIZE FROM SERIAL PLASMA CK MEASUREMENTS 
The practical application of the model described above is dependent 
on certain premises with respect to the specificity of CK as an index of 
myocardial necrosis, the fractional disappearance rate of CK, the distribution 
volume of CK and the proportion of CK appearing in the circulation after 
AMI. The basis for these premises requires further analysis as they are 
fundamental to the accuracy of the calculation. 
Plasma CK and MB-CK as indices of irreversible myocardial 
necrosis 
The calculation of infarct size on the basis of serial measurements 
of plasma CK activity was based on the observation that the appearance of 
CK in the peripheral circulation correlated well with CK depletion from 
infarcted myocardium in the rabbit (Kjekshus & Sobel, 1970) and in the dog 
(Maroko et al, 1971). Increased plasma CK activity should therefore 
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only reflect release from irreversibly injured myocardial cells, because 
if CK were released from damaged cells which subsequently recovered, there 
would be a variable overestimation of EIS in each case. Whilst the 
evidence that CK release only occurs after irreversible cellular damage is 
strong, there have been conflicting reports in the literature. 
Myocardial necrosis can only be detected histologically after 4 to 8 
hours (Sommers & Jennings, 1964) though biochemical criteria may provide 
earlier evidence (Rose et al, 1976), but enzyme release from isolated rat 
hearts has been . found soon after coronary artery ligation (Hearse & Humphrey, 
1975), before the biochemical or histological diagnosis of necrosis can be 
made. Opie (1979) has postulated that metabolic changes and enzyme release 
precede necrosis, and that any relationship between the metabolic events 
underlying enzyme release and those underlying necrosis would only be 
indirect. 
The degree of functional recovery of the arrested rat myocardium 
has been shown to depend in part on the levels of the high energy phosphate 
adenosine triphosphate (ATP), and creatine phosphate (CP) which can be 
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maintained (Hearse & Stewart, 1974). Spieckermann et al (1973) found 
enzyme protein release proportional to ATP depletion in myocardial cells 
which were not irreversibly damaged, and ·Gebhardt et al (1977) argued 
that enzyme release may be related to intracellular energy levels and 
cellular membrane integrity rather than cell death. Sakai et al (1975) 
concluded that CK release after 20 minutes total ischaemia in the guinea 
pig heart was not necessarily due to irrev~rsible damage because of the 
rapid recovery of mechanical activity observed following reperfusion. 
Despite some conflicting evidence from studies on anoxic isolated rat hearts, 
Hearse and Humphrey (1975) concluded that the onset of major myocardial 
enzyme release reflected irreversible cellular damage. 
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Total CK and MB-CK measured in patients after cardiac surgery were 
both invariably raised even in the absence of ECG or radionucleotide scan 
evidence of myocardial necrosis (Klein et al, 1976). During surgery, 
however, the myocardium was subjected to a number of gross insults, namely 
hypothermia, frequent defibrillation, cardiac bypass and direct trauma. 
Hypothermic coronary perfusion was associated with good functional recovery 
and high intracellular energy levels in the rat heart (Hearse & Stewart, 
1974) and was thus an unlikely cause of the elevated enzyme levels after 
cardiac surgery. The effects of defibrillation, of cardiac bypass and 
of direct trauma, especially the latter, may well account for the raised 
enzyme levels observed after cardiac surgery. 
There are other reports of patients in whom MB-CK levels were elevated 
in the probable absence of myocardial necrosis. MB-CK was elevated in 
patients after prolonged atrial tachyarrhythmias (Varat & Mercer, 1975), 
and in 2 out of 60 patients after coronary bypass grafting (Delva et al, 
1978). Total CK was not raised in any of these reported cases, and the 
absence of minimal necrosis could not be excluded by the conventional 
methods used. Using technecium-99m pyrophosphate scans to exclude 
myocardial necrosis, Righetti et al (1977) demonstrated a significant rise 
in MB-CK in 6 patients after coronary bypass grafts. In the remaining 31 
of their 41 patients with raised MB-CK post-operatively, there was 
objective evidence of irreversible myocardial damage. Marmer et al (1979) 
excluded myocardial necrosis using haptoglobin levels in 5 patients who had 
raised MB-CK levels during documented myocardial ischaemia. Total CK, with 
normal values up to 12 i.u./1,was not elevated in these patients, and the 
maximum rise in MB-CK found was 17% of the total CK level. The time at 
which these small rises of MB-CK peaked after ischaemia were up to 12 hours 
earlier than the times of peaking after acute myocardial infarction. In 
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contrast, several studies have reported the absence of MB-CK in experimental 
myocardial ischaemia and in patients with angina, but no evidence of 
infarction (Konttinen & Sommer, 1972; Roe et al, 1972; Roberts et al, 1974; 
Roberts et al, 1975a; Roberts et al, 1976). 
The evidence in favour of CK release reflecting myocardial necrosis 
is strongly suppor~ed by the studies of Conrad et al (1979). Cellular 
potassium loss was used as a marker of irreversible injury as it has been 
shown that cells which are reversibly damaged can recover potassium whilst 
irreversibly damaged cells cannot (Jennings et al, 1964). Potassium is 
also an excellent marker of myocardial cellular integrity because 98% is 
intracellular (Blesa et al, 1970). Potassium loss after various periods 
of anoxia in rabbit myocardium correlated well with loss of creatine 
kinase and also with loss of functional recovery of the myocardium. Despite 
these good correlations a small amount of enzyme, amounting to approximately 
0.1% of total tissue enzyme content, was lost without any evidence of 
irreversible cellular damage after 20 minutes anoxia. Hearse et al (1973) 
found an early peak of CK release after 10 to 60 minutes anoxia in the 
isolated perfused rat heart which amounted to 2 - 5% of total enzyme 
released after 8 hours anoxia. They proposed that this early rise was 
due to changes in cellular membrane permeability, whilst the bulk of the 
enzyme rise reflected massive ultrastructural damage. 
Available evidence, therefore, indicates that CK and MB-CK release 
from the myocardium accurately reflect myocardial necrosis, though a very 
small but variable proportion of total CK may be released by cells which 
are not irreversibly damaged. Alternatively available methods may not 
be sensitive enough to detect all evidence of irreversible cellular damage. 
Quantitation of infarct size using total CK release may however be liable 
to slight overestimation. 
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The fractional disappearance rate of CK (Kd) 
In the calculation of Kd from the terminal portion of the plasma CK 
activity curve (Norris et al, 1975) the assumption was made that there was 
a monoexponential decline in CK activity after acute myocardial infarction. 
This in turn was based on the following assumptions: 
( i ) CK is released from the heart into a non-physiological, 
1 compartment model; 
(ii ) The isoenzymes of CK have identical fractional disappearance rates; 
(jii ) When the decay of plasma CK is monoexponential, there is no more CK 
being released into the circulation. 
These assumptions were based on evidence that, after an initial mixing stage, 
there was a monoexponential decay rate for CK in the conscious dog 
following intravenous injections of CK (Shell et al, 1971; Rapaport, 1975; 
Roberts & Sobel, 1977). The assumption was also made that the decay rate 
of CK was exponential in man after acute myocardial infarction (Sobel et al, 
1972). In common with other enzymes (Dunn et al, 1958) and proteins 
(Schultze & Heremans, 1966) however, CK may be distributed in an extra-
vascular as well as a vascular compartment, in which case a bi-exponential 
curve fit to plasma CK activity would be expected to conform more clearly 
to observed values than a mono-exponential fit (Witteveen et al, 1975; 
Sobel et al, 1977b). Norris et al (1975) discounted the presence of 
extravascular distribution on the basis that it was if this were present 
CK decay would initially be rapid and would then decline slowly, a pattern 
they saw in only two out of more than 60 patients. Studies by Sobel et al 
(1977b) however, showed that after an intravenous injection the CK activity 
curves were fitted more accurately by a bi- than a mono-exponential curve. 
It was only the very early portion of the CK time-activity curve after peak 
values which did not behave mono-exponentially however (Sobel et al, 1977a). 
59 
Using bi-exponential curves, they calculated a faster rate of elimination 
of CK activity from the circulation and a higher recovery of CK released 
from the heart. Resupply of the vascular pool from extravascular sources 
would be one explanation for the slower rate of elimination when a mono-
exponential fit was used. 
Carlson et al (1978b) proposed a bi-exponential elimination curve 
on the basis that if CK clearance through the reticulo-endothelial system 
(in which CK elimination may occur) was slower than reticulo-endothelial 
blood flow, then the distribution phase may add to the elimination. Their 
studies showed CK clearance to be slower than reticulo-endothelial blood 
flow and the elimination half life of CK to be significantly longer using 
a bi-exponential than a mono-exponential model. Cairns and Klassen (1977) 
compared a bi-exponential with a mono-exponential fit in 25 cases where 
dogs had been injected with partially purified myocardial CK. There was 
better correlation in 7 of the 25 cases using the bi-exponential curve fit, 
but in only one case was the improvement significant, so the authors 
concluded that the mono-exponential expression for CK decay in plasma was 
only minimally improved using the bi-exponential expression. This is 
important from a practical viewpoint, because the parameters for a two 
compartment model can only be derived after intravenous injection of a 
bolus of CK and not from CK curves after acute myocardial infarction 
(Sobel et al, 1977b) because of the possibility of continued CK release 
from the heart and because the CK activity present in both compartments 
prior to infarction is unknown. 
Initially is was thought that when the decay of plasma CK activity 
was mono-exponential there could no longer be any continuing release of CK 
from the heart into the circulation (Sobel et al, 1972; Norris et al, 1975) 
but recent experiments have shown that this is not necessarily true. 
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Sobel et al (1977b) found that CK activity in plasma decayed more slowly 
after myocardial infarction in the dog than after an intravenous bolus of 
purified or crude CK extracted from the myocardium. Similar results were 
found by Cairns et al (1978). CK extracted from the myocardium had 
different physical properties from CK released into plasma after AMI; 
CK harvested from plasma in dogs after AMI and injected into other dogs 
had a decay rate different from that found after injection of myocardium-
extracted CK (Sobel et al, 1977b), but significantly faster than the decay 
rate found after AMI. Since the contribution from any extravascular 
compartment will be the same in all cases it seems -likely that continued 
release from the myocardium contributes to the slower decay rate after AMI. 
Slutsky (1977) has provied that it is possible for CK release from the 
myocardium to continue throughout the period of CK decay with kinetics 
which still allow a mono-exponential expression for the decay to be used. 
Since liberation of CK from as little as 1 gm of myocardium after peak CK 
could reduce the elimination rate by as much as 50% (Roberts et al, 1977), 
estimates of the fractional disappearance rate (Kd) from the terminal 
portions of CK time-activity curves will be much lower than the true 
fractional disappearance rate. 
The use of total CK introduces a further source o( error in the 
estimation of Kd in that the individual CK isoenzymes have different 
fractional disappearance rates (Rapaport, 1975). There is therefore, a 
further reason why the total CK activity should not decay mono-exponentially. 
The CK-MB isoenzyme has a higher rate of decay than the MM isoenzyme, so 
that decline in total CK activity should approximate to exponential with 
an early rapid phase and a later slow phas~ of decline. Norris et al (1975) 
found this pattern in only 2 out of 50 cases in man and concluded that the 
different decay rates of the 2 isoenzymes were not an important factor in 
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the calculation of Kd for total CK activity. 
Kd is dependent ultimately on the mechanism responsible for the 
disappearance of CK activity, and the evidence suggests that this mechanism 
is not dependent on any specific organ and is therefore not dependent on 
renal blood flow (Roberts et al, 1975b). There is evidence to suggest 
that CK disappearance may depend on overall reticulo-endothelial system 
activity (Roberts et al, 1975b; Sobel et al, 1976a; Ahamuda et al, 1976; 
Sobel et al, 1976b). Inhibition of the reticulo-endothelial system by 
zymosan brought CK disappearance virtually to a standstill (Roberts et al, 
1975b), but it is possible that an action of zymosan outside the reticulo-
endothelial system caused this effect (Sobel et al, 1976b) and this aspect 
of the problem still requires investigation. Painter et al (1977) have 
shown that in dogs CK is cleared by removal of protein, rather than by 
independent denaturation or inhibition of CK enzyme activity. 
Since one of the objects of calculating infarct size is to determine 
the effectiveness of interventions in limiting infarct size, it is important 
to know whether Kd is constant in any given patient when no treatment is 
given, when routine non-cardiac drugs are given, and when the patient 
experiences haemodynamic changes. Kd did not change significantly from 
day to day in individual cases as determined by repeated injections of CK 
in dogs and in man, and from extentions of myocardial infarction in man 
(Roberts et al, 1975b; Ahamuda et al, 1976; Roberts & Sobel, 1977; 
Cairns & Klassen, 1977). The following table shows the effects of some 
haemodynamic and pharmaceutical interventions on Kd in the dog (Roberts 
et al, 1975; Roberts & Sobel, 1977; Cairns & Klassen, 1977): 
Type of intervention 
Control 
Tachycardia (induced by pacing or isoproterenol) 
50% increase in cardiac output 
Bilateral renal artery occlusion 
Nephrectomy and renal artery occlusion contra-
laterally 
Hepatic artery occlusion 
Cardiac artery occlusion 
Thiamol anaesthesia (Barbiturate) 
Reticulo-endothelial blockade with Zymozan 
Lignocaine infusion 
Methyl prednisolone 
Nembutal (30 mg/kg) 
Valium (1 mg/kg) 
Morphine (2 mg/kg) 
Valium (0.1 mg/kg) 
Morphine (0.2 mg/kg) 
Propranolol (0. 3 mg/kg or 2.0 mg/kg) 
Effect on Kd 
~ 1 m6 variation 
1 m6 reduction 
None 
None 
None 
7 - 15% increase 
None 
70-90~6 reduction 
8mo reduction 
None 
None 
52~6 reduction 
46~o reduction 
48% reduction 
8~6 reduction 
1 m6 reduction 
23~o reduction 
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The administration of valium and morphine in therapeutic doses did not change 
Kd substantially as compared with control values. 
Sobel et al (1977b) have proposed the use of a mean value for Kd 
derived by analysis with a two-compartment model after intravenous 
injection of CK in order to provide more ac~uracy by accounting for more CK 
than when individualised values for Kd using a one-compartment model are 
used. The enormous variability of Kd from patient to patient and dog to 
dog found in the studies by Norris et al (1975) and Cairns et al (1978), 
especially after pharmacologic intervention (Cairns & Klassen, 1977; 
Roberts & Sobel, 1977) appear to support the contention of Norris et al (1975) 
and Roe and Starmer (1975) that individualised values for Kd minimize the 
errors which may occur in the calculation of infarct size. 
The distribution volume (DV) 
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The distribution volume for CK is difficult to measure in individual 
patients (Norris et al, 1975), but was assumed to approximate to plasma 
volume (44 ml/kg body weight; Roberts et al, 1975b). In view of the 
possible extravascular distribution of CK (Dunn et al, 1968; Schultze & 
Heremans, 1966), the actual distribution volume may be greater. If it can 
be assumed that the extravascular distribution approximates to a fixed 
proportion of body weight (as in the case of the plasma volume), then relative 
infarct size between patients will not be affected. 
The distribution volume for total CK is only a mean value, since the 
3 isoenzymes have significantly different distribution volumes (Rapaport, 
1975), and a further error is therefore introduced. The distribution 
volume of the MB fraction is greater than that of the MM fraction (Rapaport, 
1975), but the distribution volume used in the calculation of infarct size 
for both total CK and MB-CK is nevertheless assumed to be the same (Roberts 
et al, 1975b). 
More important is the p~obability that the distribution volume may 
vary during the time a patient is under study. Expansion of the plasma 
volume will lead to underestimation, and contraction of the plasma volume 
to overestimation of myocardial infarct size (Cairns & Klassen, 1977). 
Diuretics are known to cause large changes in plasma volume (Norris et al, 
1975) and it is possible that propranolol may expand the plasma volume 
(Cairns & Klassen, 1977), though the latter possibility requires further 
investigation. It is therefore important to know whether any pharmaco-
logical intervention alters plasma volume during the time when plasma CK 
levels are being determined, but no studies concerning this problem have so 
far been published. 
The proportion of CK released from the myocardium which appears 
in the circulation (PCK) 
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The proportion of CK entering the circulation compared with the amount 
of CK released by the myocardium is called the serum entry ratio (SER). 
Since the initial studies of Shell et al (1971), it has been noted that 
the serum entry ratio in dogs is low, only a small proportion of the CK 
depleted from the myocardium reaching the circulation. Shell et al (1971) 
calculated the SER in dogs as being 0.3 ±0.2, whilst Roberts et al (1975b) 
observed the ratio to average 0.15 within a range of! 0.016 (SEM). The 
reason for this low ratio has not yet been fully explained explained; 
local inactivation in necrotic tissue may play a role (Ahamuda et al, 1976) 
but the proportion which is degraded locally remains unknown (Norris et al, 
1975) . 
The role of the cardiac lymphatic system in controlling the SER has 
been increasingly emphasized (Szabo et al, 1974; Sobel et al, 1976b; 
Clarke et al, 1978). In the dog a significant proportion of CK (and 
other enzymes) released from the myocardium reaches the circulation via the 
lymphatic system (Malmberg, 1972a; Malmberg, 1972b; Gervin et al, 1974), 
though some enzymes released from the heart appear to enter the systemic 
venous circulation directly (Szabo et al, 1974; Pasyk et al, 1971). The 
exact proportion of CK entering the circulation via the lymphatics is 
unknown, but Malmberg (1972a) estimated that between 30~ and 50% of trans-
aminase activity after myocardial infarction in the dog reached the 
circulation via this route. Experimental studies in man and dog have 
shown that CK activity is lost at a more rapid rate when exposed to lymph 
than to plasma or whole blood, both in vitro and in vivo (Robinson et al, 
1975). Clarke et al (1978) confirmed the role of the lymphatic system 
in the transport of myocardial CK in the dog, and showed that CK is de-
activated more rapidly in lymph than in blood in vitro (4% and 78% 
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remaining active after 5 hours incubation respectively). Lymph in vivo 
did not deactivate CK as actively as lymph in vitro. They determined that 
the deactivation of CK in lymph in vitro was primarily due to thiol 
oxidation, and was not due to enzymatically mediated proteolysis. 
The flow of cardiac lymph is about 300 times less than coronary 
blood flow (Sobel et al, 1976b), being approximately 1.5 - 4.0 ml/hr in the 
unanaesthetized dog (Miller et al, 1964), so that CK remains exposed to 
lymph for a prolonged period of time. Variations in lymphatic flow may 
therefore alter the SER and affect the calculation of infarct size. 
Physiological factors which may alter myocardial lymph flow include age-
related thickening of endocardial portions of the heart (McMillar & Lev, 
1959), variations in systemic venous pressure (Wegria et al, 1963), 
expansion of extracellular volume in association with congestive cardiac 
failure, amongst other causes (Uhley et al, 1969), and lymphatic 
obstruction related to myocardial injury (Kline et al, 1964). 
Any situation in which the blood flow to the ischaemic portion of 
the myocardium is increased following the onset of myocardial infarction 
will affect the serum entry ratio by accelerating the rate at which CK is 
washed out of the myocardium and thus the rate of flow through the 
lymphatics (Walters et al, 1977). If this increased CK activity in the 
cardiac lymphatics is not diverted to the circulation (Gervin et al, 1974), 
washed-out CK may still alter the SER by entering the circulation by a 
route which by-passes the lymphatic system. This phenomenon of re-
perfusion may occur spontaneously, because although coronary occlusion is 
the most likely cause of acute myocardial infarction in man, post-mortem 
studies have shown that the occlusion does not always persist (Baroldi, 
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1969; Walston et al, 1970; Roberts & Buja, 1972). Vatner et al (1978) 
suggest subtotal coronary occlusion, alternating coronary spasm and 
relaxation and a dynamic process with clot formation and lysis as 
mechanisms for coronary artery reperfusion in man. 
A good correlation has been found between infarct size calculated 
from myocardial CK depletion and infarct size calculated from serum CK 
curves in the dog (Shell et al, 1971; Bleifeld et al, 1977; Norris et al, 
1975; Vatner et al, 1978). In the latter study, reperfusion was 
specifically excluded. Gervin et al (1974) found that CK activity in 
myocardial lymph reached extremely high peaks 2 hours after reperfusion in 
the dog, without, however, finding any significant increase in serum CK 
activity. Bresnahan et al (1974) also found that reperfusion did not 
interfere with infarct size calculation from serial blood CK activity. 
Roe and Starmer (1975) suggested that the situation may nevertheless 
arise where, following a successful pharmacological or haemodynamic 
intervention, the CK washed out may not be diverted to lymph, and the 
subsequent increase in circulating CK activity would then be misinterpreted 
as being the result of a larger infarct than is in fact present. This 
could be the explanation for the results of studies carried out in the dog 
by Jarmakani et al (1976), who found that whilst anatomical infarct size 
was reduced in animals which were reperfused, there was no difference in 
calculated infarct size between the reperfused and the permanently occluded 
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groups of dogs. They concluded that infarct size could not be calculated 
using total CK measurements whether there w~s reperfusion or not. Using 
only the MB-CK isoenzyme however, there was no disparity between anatomical 
and calculated infarct size. Since some of the animals in the study 
developed heart failure, it is possible that extracardiac CK may have been 
responsible for the results observed when total CK was used. 
67 
The only study of the effects of reperfusion on infarct size which 
compares anatomical infarct size, infarct size determined by myocardial CK 
depletion and infarct size estimated by serial blood measurements of CK 
activity was carried out by Vatner et al (1978). They found a more 
rapid rise in blood CK in dogs which were reperfused; the earlier the re-
perfusion the more rapid was the rise in CK. Infarct size calculated from 
myocardial depletion correlated well with anatomical infarct size whether 
or not the dogs were reperfused, but infarct size calculated from serial 
blood CK measurements was larger in reperfused than nonreperfused dogs, 
though the correlation with anatomical infarct size remained linear. Thus 
more CK was released into the blood per unit myocardium in dogs who 
underwent reperfusion. 
Reperfusion thus alters the serum entry ratio and may occur 
spontaneously, by the mechanisms described above (Vatner et al, 1978) or as 
a result of pharmacologic (Shell & Sobel, 1973a) or haemodynamic (Shell & 
Sobel, 1973b) manipulations. SER has also been shown to vary according 
to whether an infarct is homogenous or scattered (Cairns et al, 1978). 
There was a linear inverse ratio between SER and infarct size in homogeneous 
infarcts, but no such relationship in scattered infarcts, which exhibited 
a significantly higher SER and a significantly earlier cumulative CK plateau 
than homogeneous infarcts. All other studies mentioned above were 
carried out in homogeneous infarcts, though there is evidence that infarcts 
in humans need not be homogeneous (Levine & Ford, 1950), and that platelet 
emboli (Jorgensen et al, 1978) may produce scattered myocardial infarctions 
similar to those produced experimentally by Cairns et al (1978). In such 
a situation, the mean SER of 0~15 used in the calculation of infarct size 
would appear to be a large source of error. 
In experiments where the serum entry ratio in dogs has been measured 
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directly, the ratio has been constant (Shell et al, 1971; Bresnahan et al, 
1974; Shell & Sobel, 1974; Shell & Sobel, 1973b), though slight variations 
have been found following such interventions as the administration of 
propranolol (Shell & Sobel, 1973b), reperfusion of the myocardium 
(Bresnahan et al, 1974) and acceleration of heart rate by ventricular 
pacing (Shell & Sobel, 1973b). Small variations in the amount of CK 
washed out of the myocardium, as observed in the above studies, would not 
seriously affect the calculation of infarct size using a mean SER of 0.15, 
but clearly individualised serum entry ratios would result in greater 
accuracy, and would appear to be essential when non-homogeneous infarcts 
occur. 
Other potential sources of error in the calculation of infarct size 
Initially blood samples were drawn every 2 hours in order to determine 
CK activity for the calculation of infarct size in man (Sobel et al, 1972). 
Less frequent sampling was thought to result in gross inaccuracies, but 
Norris et al (1975) showed that the results obtained from 4 hourly sampling 
varied by only 0% to 3% from those obtained from 2 hourly sampling, and the 
4 hour sampling interval is now the method of choice. 
The calculated infarct size is sensitive to variation in the 
myocardial CK depletion parameter, CK0 (Roe & Starmer, 1975). The value 
for man initially quoted by Sobel et al (1972) had a range about the mean 
of! 15.9% (! 1 SD), representing an enormous potential variation. This 
variation is due primarily to 2 factors; individual variation from one 
heart to another (Roe & Starmer, 1975) and technical variation in the 
recovery of CK from the myocardium (Roe & Starmer, 1975; Sobel et al, 1977). 
The influence of the latter factor can to some extent be modified when each 
individual research group determines CK depletion from the myocardium after 
acute myocardial infarction in post-mortem specimens, using the same 
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homogenising procedure in each case and analysing the CK in the same way 
as the plasma CK was analysed, as was done in this study. 
CK activity starts to rise approximately 4 hours after the onset 
of myocardial infarction (Bleifeld et al, 1976) but it is not unusual for 
patients to arrive in hospital much later after the onset of their symptoms, 
so that CK levels are already raised. Bleifeld et al (1976) maintain 
that if the first CK sample exceeds 10% of the final peak value, the 
cumulated activity of CK, and therefore infarct size, cannot be calculated 
accurately, and that the error increases with increasing level of the 
initial CK. In contrast Sobel (Personal Communication) states that 
sizing of infarcts is relatively uninfluenced by omission of early data 
points, provided that the peak value has not been missed, and he suggests 
that in such cases it is valid to assume a time at which the rise in CK 
might reasonably have been expected to start. 
4. CORRELATION BETWEEN CALCULATED INFARCT SIZE AND 
ANATOMICAL INFARCT SIZE, HAEMODYNAMIC PARAMETERS, 
CLINICAL FEATURES, MORBIDITY AND MORTALITY AFTER 
ACUTE MYOCARDIAL INFARCTION 
The sources of error inherent in the method of calculating infarct size 
from serial measurements of CK activity in blood must limit the accuracy 
of the method, so that its validity can only be verified by comparison with 
anatomical and clinical data. 
Comparison between infarct size estimated by serial CK measurements 
in blood and infarct size determined by myQcardial CK depletion 
and by direct anatomical measurement 
CK depletion from the myocardium was found to correlate well 
with anatomical infarct size in the rabbit (Kjekshus & Sobel, 1970) and in 
the dog (Maroko et al, 1971). Shell et al (1971) found a good correlation 
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between enzymatically estimated infarct size and myocardial CK depletion in 
dogs with infarcts ranging from 300 mg to 54 grams, and similar results 
were obtained by Cairns et al (1978). The validity of using total CK in 
these estimations was supported by the findings of Roberts et al (1975b) 
that a good correlation existed between enzymatically estimated infarct 
size measured with total CK and MB-CK, provided that extracardiac sources 
of CK were carefully occluded. 
Studies in patients dying shortly after AMI, but after the necessary 
CK rise and fall had been completed, showed a good correlation between 
enzymatically estimated infarct size and anatomical infarct size (Bleifeld 
et al, 1977). The mean difference between the two measurements of infarct 
size was 7 gms, and large infarcts were accurately distinguishable from 
small infarcts. Rogers et al (1977a) found that the percentage of 
abnormally contracting left ventricle, as determined angiographically in 
patients, correlated well with infarct size estimated by serial measurement 
of blood MB-CK activity. 
Other reports do not confirm the accuracy of CK estimated infarct 
size. Jarmakami et al (1976) found a good correlation between anatomical 
and estimated infarct size in dogs, though the enzymatic method, using 
total CK, overestimated infarct size, and the correlation had a large 
standard error. Correlation was best when there was no reperfusion, or 
only a short period of reperfusion (15 minutes), of the infarcted area. The 
authors felt that the use of total CK was not an accurate way of determining 
i nfarct size, but most of the dogs in their study had heart failure and 
this could account for the presence of extracardiac CK and the resulting 
overestimation of infarct size. Having minimised the possibility of 
extracardiac CK, Vatner et al (1978) found that infarct size was only 
overestimated in the presence of reperfusion. 
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A comparison of enzymatically estimated infarct size and anatomical 
infarct size after experimental myocardial infarction in dogs showed a 
good correlation only when the infarcts were small (Roe et al, 1977). The 
authors compared the early method of Shell et al (1971), the modification 
for ~d introduced by Norris et al (1975) and the further modifications of 
Roberts et al (1975b). In each subsequent study there was an improvement 
over the previous study in the correlation between enzymatically estimated 
and anatomical infarct size provided that only infarcts smaller than 13 gms 
were considered and that the MB-CK isoenzyme, rather than total CK, was used. 
Furthermore, all the three methods overestimated infarct size, the Shell 
method resulting in the largest and the Roberts method in the least over-
estimation. It was not possible to distinguish large fro~ small infarcts 
by enzymatic estimation. 
A possible explanation for this observation is that a small, well-
perfused infarct may lose the same amount of CK into the circulation as a 
large, poorly-perfused infarct. This theory was supported by the finding 
of Swain et al (1978) who found a poor overall correlation between histo-
logically and enzymatically estimated infarct size except when small infarcts 
of 16 gms or less were considered. Using microspheres to estimate 
regional myocardial blood flow they found that large infarcts had a central 
zone with markedly reduced regional myocardial blood flow even 24 hours 
after coronary occlusion, suggesting a possible cause for the failure of all 
CK to be released into the circulation. 
Cairns et al (1978) found a good corr~lation in dogs between CK 
release and increasing infarct size until approximately 20% of the myocardium 
was involved, after which the CK release fell. In man, however, there 
was a good correlation between estimated infarct size, anatomical infarct 
size and prognosis, as described below (Bleifeld et al, 1977). Cairns et 
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al (1978) have therefore suggested that the fall-off in CK release 
observed in the dog may not occur in man until a percentage of the 
myocardium incompatible with survival has been lost, so that a valid 
estimation of large and small infarct sizes can be made by serial blood 
CK measurements. 
Estimated infarct size and prognosis 
Enzymatically estimated infarct size correlates well with morbidity 
and mortality after acute myocardial infarction. Infarct size was 
significantly larger in patients who died than in patients who survived 
AMI, both during the period of hospitalization (Mathey et al, 1974; 
Bleifeld et al, 1977) and in the 6 months following infarction (Sobel et al, 
1972). The 6-month mortality associated with estimated infarcts ,65 CK-
g-eq was 67% compared with 5% for infarcts <65 CK-g-eq (Sobel et al, 1972). 
Even better prediction was found using the infarct size index (ISI), which 
is the estimated infarct size (CK-g-eq) divided by the surface area in 
square metres (m 2), and is expressed as CK-g-eq/m2 (Shell & Sobel, 1976). 
In the study by Shell and Sobel (1976) 67% of patients had ISI less than 40, 
with a 6 month mortality of 3%, whilst patients with ISI ~ 40 had a 
mortality of 68%, a highly significant result when tested against an overall 
mortality of 23%. Survivors in this study had a significantly lower 
infarct size index than non-survivors. Infarct size index provided a 
better prognostic index than clinical classification as determined by 
Scheidt et al (1970), except in class IV patients, where cardiogenic shock 
might have resulted in extracardiac CK release and inaccuracy ,in ISI 
determination. 
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Estimated infarct size and ventricular performance 
Cardiogenic shock occurs when 32% to 40% of the left ventricle 
becomes infarcted (Harnarayan et al, 1970; Page et al, 1971), and patients 
who develop shock early, within 6 hours of acute myocardial infarction, have 
a more extensive area of necrosis as estimated at post-mortem, then patients 
i n whom shock develops over a longer period of time (Caulfield et al, 1976). 
The cumulative effect of a small infarct in a patient who has had a previous 
i nfarct may lead to shock. The incidence of, and mortality as result 
of,heart failure might therefore reasonably be expected to increase with 
i ncreasing estimated infarct size. Several studies have shown that the 
degree of left ventricular dysfunction is related to estimated infarct size, 
using both clinical and haemodynamic parameters. Sobel et al (1972) 
found that survivors of acute myocardial infarction who had clinical 
evidence of heart failure had a significantly higher mean estimated infarct 
size (91 ! 8 SEM CK-g-eq) than survivors with minimal or no heart failure 
( 31 ! 4 SEM CK-g-eq). In patients who died with heart failure, mean 
i nfarct size (! SEM) was 109 ! 10 CK-g-eq, and one patient who died 
without heart failure had an estimated infarct size of 50 CK-g-eq. The 
presence or absence of pulmonary venous congestion or pulmonary oedema on 
a chest X-ray taken within 24 hours of hospitalization is considered to 
be the most important prognostic factor for both early and late survival 
after acute myocardial infarction by Norris and his co-workers (Norris 
et al, 1969). Separating 31 patients into two groups according to 
whether pulmonary congestion or oedema was present or absence on chest 
X-ray, Norris et al (1975) found that patients free from congestion had a 
mean cumulated CK release (CK) which was half that in patients with r 
evidence of congestion or oedema (P<0.001). Thomson et al (1977) found 
that death due to cardiac failure occurred significantly more often in 
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patients with large than with small estimated infarct size, but only during 
the hospital phase, there being no prognostic value in estimated infarct 
size after recovery. Inoue et al (1977) measured the duration of the CK 
appearance function f(t) and found a shorter period of CK release in 
patients without clinical heart failure. They found that the major release 
of enzymes after infarction occurs · during the period of chest pain, and that 
a longer duration of chest pain was associated with the development of heart 
failure. 
Using haemodynamic data estimated infarct size was shown to 
correlate well with impaired left ventricular function (Kostuk et al, 1973; 
Rogers et al, 1976). Mathey et al (1974) divided their patients into 3 
groups according to the admission pulmonary artery diastolic pressure. 
Patients in group I had a normal pulmonary artery diastolic pressure (<12 mmHg), 
patients in group II a slightly elevated pressure (12-20 mmHg) and patients 
in group III a grossly elevated pressure (>24 mmHg). Group I patients 
had a mean estimated infarct size of 17 CK-g-eq, and a normal cardiac index 
and left ventricular stroke work index. One patient in this group died 
of cardiac rupture, giving an overall mortality of 4%. Patients in group II 
had a mean estimated infarct size of 42 CK-g-eq with a 21% mortality. 
Cardi ac index and left ventricular stroke work index were slightly reduced. 
Mean infarct size in group III patients was 99 CK-g-eq, the mortality was 
60% , and cardiac index and left ventricular stroke work index were 
s ignificantly reduced. After later studies which produced essentially the 
s ame results (Bleifeld et al, 1976), the authors concluded that "in 
i ndividual patients estimated infarct size alone cannot be used to predict 
prognosis, but with haemodynamic data gives an estimation of the functional 
state and reserve of the residual myocardium". 
Hori et al (1979) found an excellent inverse correlation between 
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enzymatically estimated infarct size and ejection fraction, which in turn 
correlates well with the percentage of non-contracting ventricle as 
estimated angiographically. Using stroke volume index (Swan et al, 1972) 
as their haemodynamic parameter, Shell and Sobel (1976) found that both 
stroke volume index and infarct size index correctly predicted survival or 
mortality, and that the mortality rate prediction associated with a 
combination of the two indices was not significantly different from the 
mortality rate prediction using either parameter alone. They felt that 
"the prognostic power of CK infarct size index suggests that the estimate 
of infarct size corresponds to a biologically significant determinant of 
outcome". 
Estimated infarct size and ventricular dysrhythmias 
Ventricular arrhythmias are, along with heart failure, the 
predominant cause of death in patients with acute myocardial infarction 
(Friedberg, 1968). A relationship has been demonstrated between enzymati-
cally estimated infarct size and the development of ventricular arrhythmias. 
Bloor et al (1975) found a lowering of the ventricular fibrillation threshold 
with increasing infarct size in the experimental animal. Roberts et al 
(1975c) found a significant increase in ventricular premature beats, coupled 
beats, ventricular tachycardia and the peak frequency of ventricular 
premature beats with increasing infarct size index in patients during the 
first 10 hours after hospitalization. An increased incidence of ventricular 
tachycardia and ventricular fibrillation was also found by Bleifeld et al 
(1976) in patients with EIS greater than 65 CK-g-eq compared with patients 
with EIS less than 30 CK-g-eq, but in this study the possible role of the 
poorer haemodynamic status of patients with larger infarcts was emphasized. 
In 38 patients with AMI admitted within 6 hours of onset of symptoms the 
persistence and severity of ventricular dysrhythmia in the first 20 hours 
hospitalization correlated well with !SI especially when patients with 
previous infarcts were excluded (Cox et al, 1976). In these studies the 
correlation between infarct size and ventricular arrhythmias were only 
demonstrated in the short term, but a preliminary report from a recent 
study (Ehsani et al, 1978) has shown that enzymatically estimated infarct 
size predicts ventricular electrical instability for as long as one year 
after the initial infarct in patients up to 60 years of age. 
Conclusion 
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The method of calculating infarct size using serial measurements of 
blood CK activity after acute myocardial infarction is valid in that 
relative infarct sizes in man can be estimated with accuracy, though the 
estimated infarct size may not correspond absolutely with anatomical infarct 
size. Sources of error inherent in the model can be minimised by careful 
patient selection and by individualising as many of the parameters involved 
as possible. 
Good correlations exist between enzymatically estimated infarct size and 
prognosis, arrhythmias, cardiac performance and morbidity. Sobel (1976) 
has shown that there is strong evidence for a causal basis to these 
correlations. 
The CK method for estimating infarct size appears to be a valid and 
valuable index with which to assess metabolic, haemodynamic and pharmacolo-
gical events occurring shortly after acute myocardial infarction. 
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5. CALCULATION OF ESTIMATED INFARCT SIZE AND 
INFARCT SIZE INDEX PRACTICAL DETAILS 
The derivation of the equation for the calculation of estimated infarct 
size has been discussed in detail. 
Estimated infarct size = CK 
r 
X K X body weight (CK-g-eq) 
A.Calculation of CKr 
i. Equation used and definition of terms 
The cumulative CK serum entry per ml (CKr) is calculated by integrating 
the appearance function f(t) at any given time. CK activity was measured 
in i.u./1 so the final calculated value of CKr was divided by 1000. 
t 
CKr = 1: 
0 
Where: 
t 
f(t) dt (the integrated appearance function) = l: (DE/DT + Kd E) DT 
0 
DE = change in CK activity over the preceding time interval DT 
DT = the exact time interval in minutes 
-
E = the mean CK activity during the time interval DT 
Kd = the fractional disappearance rate of CK from blood 
ii. Calculation of Kd (Norris et al, 1975) 
The terminal portion of the CK time-activity curve was expressed as a 
semi-logarithmic plot, the highest value being that which was nearest to 
80% of peak activity (Sobel et al, 1977b). At least 5 points had to be 
used, and values approaching zero were excluded because tt is impossible to 
determine whether CK activity will return to below normal levels or not 
(Norris et al, 1975). The line of best fi-t was calculated so that the 
95% confidence limits for the slope(! 2 deviations were <15% of the value 
for the slope (Norris et al, 1975). 
calculations are given in Appendix C. 
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B. The proportionality constant, K 
i. The equation 
. DV K = -----------
PCK ( (CK~ 
(ml) (CK-g-eg) 
(Kg) (iu.) 
Where: 
DV = the distribution volume of CK/unit body weight (ml/kg) 
= 44 ml/kg 
?8 
t2 
PCK = proportion of CK released into the blood compared with CK depleted 
from myocardium (i.u./CK-g-eq)/(i.u./g) 
= 0.15 (i.u./CK-g-eq) / (i.u~/g) 
[CKN]= CK activity in a homogeneous section of normal myocardium (i.u./g) 
[CKU = CK activity in a homogeneous section of infarcted myocardium (i.u./g) 
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Values for [CKN] and (CK~ as determined by Sobel et al (1972) and Roberts 
& Sobel (1977) have beeen quoted above. Since the CK-g-eq used to express 
infarct size are not absolute units, but are dependent on the assay 
conditions (Bleifeld et al, 1977), [CKN] and [CK~ were determined by the 
same method as that used to measure plasma CK activity. 
ii. Method used in the analysis of myocardial CK activity 
The CK activity in normal myocardium was determined from samples of 
left ventricle grossly normal to the naked eye, from 5 hearts. with no 
clinical or post-mortem evidence of myocardial disease of any description. 
The CK activity in infarcted myocardium was determined from samples 
taken from the centre of an area of homogeneous infarction, as determined 
macroscopically, from 5 hearts taken from patients who had died 24 hours 
to 7 days after acute myocardial infarction. 
analysed within 12 to 24 hours post-mortem. 
Samples were taken and 
The tissue was minced with scissors and 200 mg was added to 5 mls of 
homogenizing medium consisting of 0.25M sucrose, 0.001M neutralised sodium 
-3 
ethylenediaminetetra-acetic acid, and 1 x 10 M mercaptoethanol, pH 7.0 
(Shell et al, 1971). The tissue sample was homogenised with 4 x 15 second 
bursts of an Ultra Turrax homogeniser, speed 6. The homogenate was then 
0 
centrifuged at 16000 g for 10 minutes at O C to -3°C, after which the 
supernatant was decanted and immediately analysed as described. 
i ii. Results 
MYOCARDIAL CK CONCENTRATION (i.u./g) at 30°C 
Normal ventricle (CKN] Infarcted ventricle (CKI] 
1 717 42 
2 804 166 
3 710 137 
4 579 237 
5 569 156 
Mean± SEM 676±45 i.u./g 148±31 i.u./g 
BO 
iv. The calculation of K 
The proportionality constant K, was calculated using the above values 
for (CKN] and (CK~ and the values for PCK and DV as determined by Roberts 
et al (1975). 
44 
K = 0.15 (676 - 148)~ 0 · 56 
(ml) (CK-g-eg) 
(Kg) (i.u.) 
This value for K was used in all calculations of estimated infarct size. 
c.Calculation of infarct size index (Shell & Sobel, 1976) 
Infarct size index (ISI) = Estimated infarct size (CK-g-eq/m
2) 
surface area 
Surface area was determined from a nomogram using the height and the weight 
of the patient (Berlyne, 1974). 
6. CALCULATION OF ESTIMATED INFARCT SIZE AND INFARCT 
SIZE INDEX AN EXAMPLE 
Table 1 gives the details of the serial CK activities and the 
calculation of r f(t)Dt for .patient No.28. 
a. CK activity - baseline values (upper limit of normal= 60 i.u./1) have 
been subtracted in all cases. The initial CK value recorded had already 
risen above normal, but omission of early data points has relatively little 
effect on the calculation of infarct size by this method (Sobel, Personal 
Communication). CK activity after 52 hours was within normal limits. 
b. CKr 
t 
CKr = b f(t)dt 
f(t) = DE/DT + Kd x mean CK activity (E) 
CK activity and E f(t)DT are shown plotted against time in Figure 1. 
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c. Calculation of Kd 
i. Semi-log plot of the relevant points 
Samples number 11 to 22 inclusive were used for the calculation of Kd. 
CK activity 16 hours post-infarction (770 i.u./1, sample No.11) was 84% 
of the peak (917 i.u./1). 
Log E of the CK activity was plotted against time (Figure 1) and the 
line of best fit was determined. 
ii. Statistics of the line of best fit 
Details of the statistical methods are given in Appendix C. 
a= 3.48 Sa = 0.04 
b = -0.04 Sb = 0.00095 
r = 0.99 S.y.x = 0. 04 
95% confidence limits for the slope= -0.04 ! 0.0019 (5%) 
CK activity (E) was then determined from the line of best fit. 
Equation for the line of best fit: Y = 3.48 + (-0.04) X 
t1 = 16 hours E 
t2 = 52 hours E 
tx = 36 hours E 
iii. Calculation of Kd 
Kd = E(tz) -
(t2-t1)x60 
d. Duration of CK release 
(t1) = 794 i.u./1 
Ct2) = 38 f.u./1 
Ctx) = 174 i.u./1 
794 38 
174 X 36 X 60 
. -1 
= 0.002 mins 
This was the time from the onset of symptoms until the CK release curves 
reached a plateau (see example Figure 1). 
e. Calculation of estimated infarct size 
EIS = CKr x K x Wt (CK-g-eq) 
CKr = 1924.62/1000 = 1.925 
K = 0.56 
Weight = 87 kg 
EIS = 1.925 X 0.56 X 87 = 94 CK-g-eg 
f. Calculation of infarct size index 
EIS 
ISI = surface 
EIS= 94 CK-g-eq 
Weight= 87 kg 
Height= 180 cm 
Surface area= 2.05 m2 
ISI = 2.~t = 46 CK-g-eg/m2 
7. SPECIAL CONDITIONS CONCERNING INFARCT SIZE ESTIMATION 
IN PATIENTS 5, 6, 11 and 33 
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Patient No.5 died after only 15 hours in the coronary care unit, so 
that insufficient time elapsed for the calculation of EIS by the CK method. 
Infarct size was therefore measured at post-mortem, and the infarcted 
portion of the myocardium, as carefully determined by a. pathologist, 
weighed 110 gms. Whilst this estimate was not necessarily comparable, 
there is evidence that enzymatically calculated infarct size would have 
been of the same magnitude, since CK activity at 14 hours post-infarction 
. 
was already 875 i.u./1 above normal in this patient, and all patients with 
CK activities of this order 14 hours post-infarction had EIS much greater 
' 2 than 65 CK-g-eq, and thus ISI greater than 40 CK~g-eq/m, (Appendix B). 
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The inclusion of this patient was therefore felt to be justified. 
Patients 6 and 33 had definite myocardial-infarctions, as determined 
by the appropriate ECH and enzyme changes. CK activity in both cases 
di d not rise sufficiently to follow the standard pattern of rise and fall, 
and the decay constant, Kd, could not be calculated from the terminal 
portion of the curve. Accurate determination of EIS was therefore 
impossible; instead EIS was calculated using Kd = 0.002, this being twice 
t he mean Kd proposed by Sobel et al (1972) for calculating infarct size in 
man and similar to the highest values noted in other patients in this 
study. Using a value for Kd larger than might be expected, EIS for both 
pa tients was less than 65 CK-g-eq, ~ppendix B) and both have therefore been 
included as patients with small infarcts. 
Patient No.11 had an extension of his infarct approximately 24 hours 
after the initial episode. Two figures are therefore given for this 
patient, the first figure relating to the initial episode and the second 
f igure to the combined initial episode plus the extension. 
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CK activity, total cumulative CK release ([f(t)dt) and Log E 
CK activity plotted against time after the onset of acute 
myocardial infarction. (Patient No. 28). 
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CHAPTER IV 
DIRECT CURRENT EXTERNAL CARDIOVERSION, AND ITS EFFECT 
ON PLASMA TOTAL CREATINE KINASE AND MB-CK ISOENZYME ACTIVITIES 
87 
INTRODUCTION 
Since external direct current (DC) cardioversion was shown to be a 
safe and effective method for the treatment of cardiac arrhythmias in man 
(Lown et al, 1962) a number of studies have reported a variable rise in 
total CK activity following cardioversion (Hunt & Bailie, 1968; 
Konttinen et al, 1969; Mandecki et al, 1970; Forssell et al, 1975; 
Eschani et al, 1976; Reiffel et al, 1978). The importance of the 
questions raised by these observations to clinical practice are two-fold: 
is the extent of the rise in total CK activity sufficient to obscure the 
diagnosis of myocardial infarction and the calculation of estimated infarct 
size by means of plasma CK activity, and does the rise in CK activity 
indicate that damage has occurred to the myocardium? 
The extent of the rise was significant enough to interfere with the 
diagnosis of myocardial infarction and the calculation of infarct size 
in the studies of Hunt and Bailie (1968), Konttinen et al (1969), 
Mandecki et al (1970), Ehsani et al (1976), whilst only a few insignificant 
rises were observed by Forssell et al (1975) and Reiffel et al (1978). 
Whether or not the rise in CK represents myocardial damage is more 
controversial. Histological examination of hearts from experimental 
animals which have undergone repeated direct current cardioversion has 
shown evidence of myocardial necrosis (Dahl et al, 1974; Warner et al, 1975) 
but the cumulative electrical energy used in these studies was up to 
4000 watt-seconds, far in excess of the maximum 750 watt-seconds reported 
in clinical studies (Hunt & Bailie, 1968; _Ehsani et al, 1976). Elevation 
of the relatively cardiospecific MB-CK isoenzyme (Roberts et al, 1975), 
which was associated only with irreversible ischaemic myocardial injury 
in the dog (Ahmed et al, 1976), has been shown to be nil, or minimal, in 
the clinical setting (Ehsani et al, 1976; Reiffel et al, 1978). 
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Thus total CK was elevated after cardioversion in most clinical 
studies, but did not appear to reflect myocardial ischaemic injury in the 
clinical setting, as it did in experimental studies where the cumulative 
electrical energy was much greater than that used in clinical practice. 
Scope of the present study 
One of the patients whose infarct size was estimated by means of 
serial plasma CK activities developed ventricular fibrillation and 
required a single direct current shock of 400 watt-seconds to convert him 
to sinus rhythm. The primary aim to this study was to determine whether 
this level of electrical energy was sufficient to elevate plasma CK to a 
degree which would make calculation of estimated infarct size inaccurate. 
During the course of the study, it was noted that most patients 
received cumulative electrical energies in excess of the 750 watt-seconds 
reported in the literature, so that the relationship between total 
electrical energy, plasma total CK, and plasma MB-CK activities was also 
investigated. 
Patients and Methods 
The study was carried out on 9 patients admitted to the coronary 
care unit for elective cardioversion of supraventricular arrhythmias. 
There were 8 males and one female, aged from 30 to 66 years. None of the 
patients had clinical or electrocardiographic evidence of acute myocardial 
ischaemia, using the criteria defined in Chapter I. There was no 
history of intramuscular injections or of skeletal muscle trauma in the 
week prior to cardioversion and no intramuscular injections were given 
throughout the study period. Digoxin and all antiarrhythmic therapy 
had been stopped for at least 48 hours prior to cardioversion. Intravenous 
diazepam in doses ranging from 20 mg to 80 mg were used as sedation, and 
i nformed, written consent was obtained in each case. 
/ 
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Cardioversion was carried out using a defibrillator with paddles 
applied to the upper sternum and cardiac apex. The total number of 
shocks given to a patient varied from two to six, and the cumulative 
energy from 80 to 1400 watt-seconds, as required to effect cardioversion, 
which was successful in 5 patients. 
Venous blood samples were collected immediately prior to cardio-
version and then 4-hourly for a period of 24 hours, unless the patient was 
discharged sooner. Blood was sampled, stored and analysed within 
24 hours as described above. 
RESULTS 
Clinical details and results are shown in Table 1. Two patients 
(numbers 2 and 8) had pre-cardioversion CK activities above the upper limit 
of normal (60 i.u. / 1). A rise in total CK activity was seen in all 
patients, but in 2 patients (numbers 4 and 6) the rise in CK activity did 
not exceed the normal limits. Total CK activity in the 24 hour period 
after cardioversion is shown for each patient in Figure 1. Where normal 
values were exceeded, a rise in CK activity was found by 4 hours, and peak 
levels of activity were found from 8 to 20 hours after cardioversion. 
Patient No.1 was discharged 16 hours after cardioversion whilst plasma CK . 
activity still appeared to be rising and it is not known whether the 
maximum value recorded would have been the peak value. None of the 
elevated levels of CK activity had returned to normal by 24 hours, or 
whenever the last estimation was made. 
There was no correlation between the · number of shocks given or 
between the cumulative electrical energy administered and the peak level 
of CK activity (r = 0.136 and r = 0.50 respectively). There appeared to 
be an association between the extent of the enzyme rise and the number of 
400 watt-second shocks administered (Figure 2), but the numbers were too 
90 
small to permit statistical analysis. Four patients received no 400 
watt-second shocks; in two cases CK activity did not rise above the upper 
limit of normal and in no case did peak CK activity exceed 155 i.u./1 
irrespective of the number of shocks or the cumulative electrical energy. 
Patient No.9 received 5 shocks totalling 800 watt-seconds and peak CK 
activity was 132 i.u./1, just over twice the normal limit. All three 
patients receiving one 400 watt-second shock had peak CK activities above 
200 i.u./1 but not exceeding 400 i.u./1, whilst the 2 patients receiving 
one or more 400 watt-second shocks had very high CK peaks. 
Initial MB-CK was less than 3 i.u./1 in all cases and there was no 
rise in MB-CK activity subsequent to cardioversion in any of the 9 patients. 
DISCUSSION 
In five of the 9 patients the cumulative electrical energy was greater 
than the maximun of 750 watt-seconds reported in previous studies concerned 
with enzyme elevation after direct current cardioversion (Hunt & Bailie, 
1968; Konttinen et al, 1969; Mandecki et al, 1970; Forssell et al, 1975; 
Ehsani et al, 1976; Reiffel et al, 1978). A significant rise in total 
CK activity was found in 7 of the 9 patients, but there was no relationship 
between the peak level of CK activity and the total cumulative electrical 
energy or the number of shocks delivered. Instead, highest levels of CK 
activity were observed in patients receiving one or more 400 watt-second 
shocks, whilst lower energy shocks had little or no effect on total CK 
activity, irrespective of their frequency or the resulting cumulative 
electrical energy. 
The lowest reported percentage of patients exhibiting a rise in total 
CK activity was 6% in the study of Reiffel et al (1978) where only one of 
18 patients exhibited a small significant rise in CK activity above pre-
cardioversion levels. Maximum cumulative electrical energy was 600 watt-
91 
seconds; more than 200 watt-seconds were only required in 4 patients, 2 of 
whom received 225 and 250 watt-second shocks respectively and 2 of whom 
received 600 watt-second shocks. Although the information was not given, 
it seems likely that only one of these latter 2 patients could have 
received a 400 watt-second shock, and it was this patient who exhibited 
the significant rise in CK activity. Forssell et al (1975) found a 
rise above normal in two of 12 patients receiving up to 650 watt-second 
shocks; whether or not 400 watt-second shocks were given is not recorded, 
but no CK rise exceeded twice the upper limit of normal. Mandecki et al 
(1970) found no significant CK rise in all of 43 patients given one 
electrical shock of 150 watt-seconds, whilst 9 of 16 patients receiving 
two or more DC shocks had elevated CK activities, in three cases to 
between 5 and 15 times the upper limit of normal. Cumulative electrical 
energy was not stated, but it was implied that 400 watt-second shocks 
were given to at least one patient. Blood samples were only take 90 
minutes and 24 hours after cardioversion, so that peak CK activities may 
have been missed. 
Konttinen et al (1969) reported a rise in CK activity in 24% of 34 
patients, 7 of whom received a total energy of 600 watt-seconds and none 
of whom received a 400 watt-second shock~ Four patients had a rise which 
was less than twice the normal CK level, in 2 cases the rise was three 
times and four times the normal level, and 2 patients, both of whom 
received a total of 600 watt-seconds, had 20-fold rises or more. Hunt 
and Bailie (1968) and Eshani et al (1976) found CK rises in 75% and 30% 
of cases respectively. Maximum cumulative energy was 750 watt-seconds 
in both studies and no too watt-second shocks were given. 
Konttinen et al (1969) and Mandecki et al (1970) felt that the amount 
of enzyme leakage might be related to the total electrical energy given, 
92 
but other studies do not support this idea (Hunt & Bailie, 1968; 
Eshani et al, 1976; Reiffel et al, 1978). In the present study there 
was no correlation between peak CK activity and the number of DC shocks or 
the total electrical energy given. 
No rise in MB-CK was found in any of the 9 patients. This suggests 
that patients receiving up to five shocks with cumulative electrical 
energy of up to 1400 watt-seconds do not suffer irreversible myocardial 
injury, assuming that MB-CK is a specific marker for irreversible injury 
in patients as it was shown to be in the dog by Ahmed et al (1976). 
Though the same may be true in man, the issue is not without controversy, 
as described in Chapter III. Although studies in dogs (Dahl et al, 1974; 
Warner et al, 1975) have shown myocardial necrosis after cardioversion, 
ten consecutive 400 watt-second shocks were given, a level never reported 
in clinical practice, so that no comparison can be made between these 
experimental and clinical studies. The results of the present study are 
in accordance with those of Reiffel et al (1978) who found no rise in 
MB-CK activity after cardioversion, but not with those of Ehsani et al 
(1976) who found a small but significant rise in 2 of 30 patients. 
The conclusion drawn from this study is that, following DC cardio-
version, infarct size cannot be measured accurately using total plasma CK 
activity, especially when shocks of 400 watt-seconds have been given. The 
lack of an association between the cumulated electrical energy or the 
number of shocks and the subsequent peak CK activity means that no correction 
factor can be formulated to take account of the additional CK rise following 
cardioversion in patients with AMI. As a result, no patients who had 
required cardioversion was included in the following studies. A total 
electrical energy of up to 1400 watt-seconds did not cause a rise in MB-CK, 
which can therefore be used to estimate infarct size in patients who have 
undergone cardioversion. 
Ta
bl
e 
1 
DE
TA
IL
S 
OF
 
9 
PA
TI
EN
TS
 
UN
DE
RG
OI
NG
 
DI
RE
CT
 
CU
RR
EN
T 
CA
RD
IO
VE
RS
IO
N 
En
er
gy
 o
f 
No
. 
o
f 
T
ot
al
 C
K 
(iu
/1
) 
D
os
e 
o
f 
in
di
vi
du
al
 
40
0 
w
a
tt
-
C
um
ul
at
iv
e 
B
ef
or
e 
Pe
ak
 l
ev
el
 
P
at
ie
nt
 
IV
 
No
. 
o
f 
sh
oc
ks
 
se
c
o
n
d 
w
a
tt
-
c
a
rd
io
-
a
ft
er
 c
a
rd
io
-
No
. 
Se
x 
Ag
e 
C
li
ni
ca
l 
de
ta
il
s 
v
a
liu
m
 
sh
oc
ks
 
w
a
tt
-s
ec
s 
sh
oc
ks
 
se
c
o
n
ds
 
v
e
rs
io
n 
v
e
rs
io
n 
M
 
56
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
80
 m
g 
4 
20
0 
3 
14
00
 
42
 
69
6*
 
.
,-
40
0 
40
0 
40
0 
2 
M
 
60
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
40
 m
g 
4 
50
 
1 
95
0 
89
 
32
7 
..
 
H
yp
er
te
ns
io
n 
20
0 
30
0 
40
0 
3 
M
 
56
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
20
 m
g 
6 
50
 
1 
12
00
 
41
 
21
9 
M
ild
 c
o
n
ge
st
iv
e 
he
ar
t 
10
0 
fa
il
ur
e 
15
0 
20
0 
30
0 
40
0 
4 
M
 
66
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
65
 m
g 
3 
50
 
0 
45
0 
41
 
52
 
D
ia
be
te
s 
10
0 
Pa
ge
ts
 d
is
ea
se
 
30
0 
H
ep
at
ic
 c
ir
rh
os
is
 
5 
M
 
42
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
20
 m
g 
4 
50
 
2 
10
50
 
15
 
17
17
 
20
0 
40
0 
40
0 
6 
M
 
66
 
A
tr
ia
l 
fl
ut
te
r 
20
 m
g 
2 
20
 
0 
80
 
27
 
40
 
60
 
7 
F 
30
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
40
 m
g 
4 
50
 
1 
75
0 
39
 
22
4 
M
it
ra
! 
pr
os
th
es
is
 
10
0 
20
0 
40
0 
8 
M
 
54
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
30
 m
g 
3 
50
 
0 
35
0 
82
 
15
5 
H
yp
er
te
ns
io
n 
10
0 
M
ild
 c
o
n
ge
st
iv
e 
he
ar
t 
20
0 
fa
il
ur
e 
9 
M
 
48
 
A
tr
ia
l 
fi
br
il
la
ti
on
 
50
 m
g 
5 
50
 
0 
80
0 
6 
13
2 
M
it
ra
! 
an
d 
a
o
rt
ic
 
10
0 
pr
os
th
es
is
 
15
0 
20
0 
30
0 
~
 
*
M
ax
im
um
 C
K 
a
c
ti
vi
ty
 r
e
c
o
rd
ed
. 
Pe
ak
 m
ay
 b
e 
hi
gh
er
. 
M
B-
CK
 e
le
va
ti
on
 z
e
ro
 
th
ro
ug
ho
ut
. 
~
 
1800 
~ 1600 
:) 
>-~ 1400 
t-
u 
<( 
t}5 700 
<( 
z 
~ 
w 
z 500 
~ 
w 
er 
u 
_J 
~ 
8 
<( 
2 
CJ) 
<( 
_J 
CL 
300 
100 
0 
0 4 8 12 16 20 24 
HOURS AFTER CARDIOVERSION 
* MAXIMUM CK. ACTIVITY RECORDED. PEAK MAY BE HIGHER 
Figure 1 
Plasma total creatine kinase levels ~n the 24 hours after 
DC cardioversion in 9 patients. 
94 
I 
0 
o 1500 
n::: () 
-_J n::-.,.. 
w~ 
I- ::::: 
~ z 1000 
0 
~-
u~ 
_JW 
<{> 
I-
~ 500 
~ 
<{ 
w 
Cl.. 
Normalj60 
Range L 0 
Figure 2 
NO 400 
WATT-SECOND 
SHOCKS. n •4 
1 400 WATT- 2 or3 400 
SECOND SHOCK WATT-SECOND 
n •3 SHOCKS. n•2 
*MAX.CK ACTIVITY RECORDED 
PEAK MAY BE HIGHER 
Rise in totaZ CK activity after DC cardioversion 
according to the number of 400 watt-second shocks given. 
95 
CHAPTER V 
FREE FATTY ACIDS AND ACUTE MYOCARDIAL ISCHAEMIA 
AND INFARCTION 
A REVIEW OF THE LITERATURE 
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INTRODUCTION 
The recognition that acute myocardial infarction (AMI) causes severe, 
gen~ralised stress with resulting profound metabolic disturbances has 
only occurred within the past 20 years (Opie, 1971). During this time, 
the effects of AMI on the autonomic nervous system and on the endocrine 
system, as reflected by alterations in the metabolism of free fatty acids, 
glucose, insulin and catecholamines, have been extensively investigated 
and reviewed (Opie, 1968, 1971, 1972a; Oliver, 1972; Opie 1972b; Vetter 
et al, 1974; Opie, 1975; Mueller & Ayres, 1978). 
The observation that free fatty acids (FFA) were elevated as part of 
the generalised metabolic response to acute myocardial infarction in man 
was first made by Kurien and Oliver (1966), since when much research has 
been carried out to determine whether or not this response is harmful to 
the ischaemic myocardium. 
here. 
The results of this research are reviewed 
NORMAL FREE FATTY ACID METABOLISM IN MAN 
Free fatty acids are the major source of energy for the heart, and 
other organs, in normal man (Ganong, 1977; Cahill Jnr. 1974). In the 
fasting state, FFA supply 60% of the fuel for oxidative metabolism (Opie 
et al, 1971a), glucose, lactate, pyruvate, ketone bodies and amino acids 
supplying the remainder (Schlant, 1974). In the fed state the FFA 
contribution diminishes and that of glucose rises (Opie, 1972a). 
FFA are released into the circulation from stored triglycerides by 
the following pathway (adapted from Ganong, 19.77 and Prakash et al, 1972):-
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ADENYLATE CYCLASE ACTIVATED BY: 
(1) CATECHOLAMINES (Gordon & Cherckes, 1956; Carlson et al, 1965; 
Pinter et al, 1967) 
(Activated by the adrenal 
medulla and sympathetic 
post-ganglionic nerve 
endings) 
\ 
(2) GLUCAGON 
(3) ADRENOCORTICOTROPHIC HORMONE 
(4) THYROID STIMULATING HORMONE 
\ .,, .,, ( 5) LEUTEINISING HORMONE 
\ .,, / ( 6) SEROTONIN 
\ / (7) VASOPRESSIN y/ 
I 
ADENOSINE t 
TRI PHOSPHATE 
(ATP) 
~~A_DE_N_Y_L_A_TE--C_Y_CL_A_S_E ___ ........ CYCLIC ADENOSINE MONOPHOSPHATE 
(CYCLIC AMP) 
/ 
/ 
/ 
/ 
Jt INACTIVE HORMONE ~ ~ ~ ACTIVE HORMONE PROTEIN KINASE r- SENSITIVE LIPASE ~  ... ia---------------~ SENSITIVE LIPASE 
I 
TRIGLYCERIDES 
ACTIVITY REDUCED BY: 
( 1) INSULIN 
(2) PROSTAGLANDIN E 
FREE FATTY ACIDS 
+ 
GLYCEROL 
t 
I 
I 
I 
I 
ACTIVATED INDEPENDENT 
OF CYCLIC AMP BY: 
(1) GROWTH HORMONE 
(2) GLUCOCORTICOIDS 
(3) THYROID HORMONE 
In the circulation FFA are bound to albumin (Goodman, 1958), and 
uptake of FFA by the myocardium is proportional to the concentration in 
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the circulation (Dole, 1956; Evans et al, 1963; Mj~s, 1971; Nimmo et al, 1976). 
In the cell FFA are. metabolised to acetyl coenzyme A, which enters the 
citric acid cycle in the mitochondria (Schlant, 1974). 
Plasma FFA concentrations may be raised in obesity (Opie & Walfish, 
1963), in diabetes (Shafrir & Gutman, 1965), in the fasted state (Opie, 
1972a), and by stimulation of the sympathetic nervous system and catecholamine 
release secondary to nicotine, caffeine (Cahill Jnr. 1974) and stress 
(Pinter et al, 1967). Reduction of plasma FFA concentrations may occur 
after ingestion of food, carbohydrate having the major influence (Dole, 1956). 
CIRCULATING FREE FATTY ACID CONCENTRATIONS AFTER ACUTE 
MYOCARDIAL INFARCTION 
Since Kurien and Oliver (1966) first described a rise in FFA 
concentrations in patients with AMI their observations have been confirmed 
by other studies, including those of Oliver et al (1968), Janusjewicz et al 
(1971), Christensen and .Videbaek (1974), Vetter et al (1974) and Opie et al 
(1975). 
The initial account described a rise in FFA concentrations occurring 
within the first 12-24 hours of AMI, with concentrations returning to normal 
levels over the ensuing 48 hours (Kurien & Oliver, 1966), so that in this 
study abnormal levels could be found for up to 72 hours post-infarction. 
In a later study, where three or more serial measurements of serum FFA were 
made in 50 patients after AMI (Oliver et ai, 1968), very high FFA 
concentrations were noted at 6 hours post-infarction, mean levels were within 
normal limits after 12 hours, and no individual value was above the normal 
limit after 36 hours post-infarction. Insufficient samples were taken to 
assess FFA concentrations within 6 hours. Vetter et al (1974) were able 
to measure FFA concentrations in 16 patients within one hour of AMI; in 
four patients samples were obtained within 15 minutes. All values were 
elevated above the normal range, and at 2 hours post-infarction mean FFA 
concentrations reached a peak of about twice the upper normal limit of 
0.8 ml/1 (Oliver et al, 1968). Here measurements were only made during 
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the first 5 hours. Opie et al (1975) made serial measurements in 9 patients 
with AMI for up to 66 hours after admission. They confirmed the rise in 
FFA concentrations after AMI, but their measurements were timed from the 
moment of admission, rather than from the onset of symptoms, so that an 
accurate assessment of FFA concentrations relative to the time of 
infarction was not possible. Individual values within 20 hours of admission 
showed enormous variability however. 
Thus elevated FFA concentrations have been found within one hour of 
myocardial infarction, with peak values occurring from 2 to 12 hours and 
mean values returning to normal from 6 to 72 hours post-infarction, there 
being considerable fluctuations in FFA concentrations in individual 
patients. 
FACTORS WHICH DETERMINE FFA CONCENTRATIONS AFTER ACUTE 
MYOCARDIAL INFARCTION 
Several factors may be involved in causing the raised FFA concentrations 
reported in the acute phase of myocardial infarction. Opie (1971, 1975) 
has emphasized the role of stress in such patients, in whom pain and anxiety 
may lead to adrenal cortical and medullary stimulation (Levi, 1969) with 
consequent catecholamine-mediated lipolysis_ and elevation of circulating 
FFA concentrations. These patients might also have poor appetites 
initially, so that the effect of fasting on FFA concentrations (Opie, 1972a) 
may contribute to the overall effect. 
The evidence that catecholamine-mediated lipolysis is responsible for 
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the major rise in FFA after AMI is very strong. Several studies have 
shown that catecholamine concentrations are elevated after AMI in the blood 
(Gazes et al, 1959; McDonald et al, 1969; Siggers et al, 1971; Griffiths & 
Leung, 1971; Januszewicz et al, 1971; Lukomsky & Uganov, 1972; Christensen 
& Videbaek, 1974; Vetter et al, 1974) and in the urine (Valori et al, 1967; 
Januszewicz et al, 1968; Jewitt et al, 1969; Gupta et al, 1969; Lukomsky & 
Uganov, 1972; Prakash et al, 1972). 
When Kurien and Oliver (1966) first described the rise in FFA 
concentrations after AMI, they stated that myocardial necrosis per se was 
unlikely to be the cause of the rise in view of the return of the FFA 
concentrations to normal whilst myocardial necrosis was still occurring. 
They postulated that catecholamines released locally from myocardial 
s ympathetic nerve endings as well as from the adrenals might be the cause. 
This theory is supported by the finding that plasma noradrenaline levels 
are elevated within one hour of myocardial infarction and remain so for at 
l east 12 hours (Griffiths & Leung., 1971), and by the observations of 
Vetter et al (1974), that catecholamines were increased within 30 minutes 
of the onset of symptoms. Januszewicz et al (1971) found significantly 
hi gher plasma noradrenaline levels on the first than on the tenth day of 
acute myocardial infarction, with a highly significant positive correlation 
bet ween plasma noradrenaline and plasma FFA concentrations, whilst 
Christensen and Videbaek (1974) could only predict serum FFA levels if both 
the plasma noradrenaline and basal insulin concentrations were known. Both 
s tudies revealed no correlation between FFA and adrenaline concentrations. 
Vetter et al (1974) showed a correlation between plasma-total-catecholamines 
and plasma FFA ( r = 0.66); they noted a delay between the maximum rise in 
catecholamine concentration and FFA and suggested that this may be due to 
r educed cardiac output resulting in poor perfusion of adipose tissue with 
slow release of FFA. They concluded that in their study "noradrenaline 
activation of adenyl cyclase in adipose tissue, and thence of lipolysis 
with resulting release of FFA, probably made the main contribution to the 
early rise in FFA". 
Urinary excretion of adrenaline and noradrenaline was increased 
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by up to 350% and 800% of the normal mean levels respectively in 4 patients 
studied by Valori et al (1967), and levels could remain elevated for up to 
20 days. Similar observations were made in a later, extended study of 55 
patients (Jewitt et al, 1969). Gupta et al (1969) could find no relation-
. 
ship between 24-hour urinary noradrenaline excretion and plasma FFA levels, 
or between individual values of urinary adrenaline and plasma FFA, and 
though there was a relationship between the rate at which mean values of 
urinary adrenaline and plasma FFA concentration fell from day to day, this 
was not however applicable to individual patients. Once daily fasting 
samples were taken for estimation of FFA levels and, as the authors point 
out, these need not correlate with 24-hour urinary catecholamine excretion, 
especially in view of the known fluctuations in FFA concentrations after 
AMI. 
Plasma FFA concentrations appear to be related to plasma-
catecholamine, and specifically plasma-noradrenaline, concentrations after 
AMI, lending support to the theory that catecholamine-mediated lipolysis 
is the major determinant of plasma FFA concentrations in AMI. The negative 
findings of Gupta et al (1969) are not necessarily contradictory in view 
of the observations in other studies (Klein et al, 1968; Januszewicz et al, 
1968; Prakash et al, 1972) that urinary catecholamine levels need not 
reflect plasma-catecholamine levels, especially in patients with complica-
tions of AMI who have a decreased renal blood flow. 
ELEVATED CIRCULATING FREE FATTY ACID CONCENTRATIONS AND TOXICITY 
TO THE ISCHAEMIC MYOCARDIUM 
103 
The relevance of the elevated FFA concentrations found in patients 
wi th AMI lies in their possible toxicity to the ischaemic myocardium, as 
observed in both the experimental and the clinical setting. FFA metabolism 
i n the ischaemic and the anoxic myocardium are described first. 
Free f atty acids and metabolism in the ischaemic 
and anoxic myocardium 
Lack of oxygen impairs the utilization of FFA as a myocardial fuel 
(Scheuer, 1967), and in the anoxic rat myocardium the only pathway known 
to provide energy is anaerobic glycolysis, for which glucose is the sole 
exogenous substrate. In anoxic conditions, FFA uptake by the myocardium 
i s reduced because it cannot be utilized but there is intracellular 
accumulation of FFA (Evans, 1964). In dogs there is an increased uptake 
of glucose by the ischaemic myocardium relative to that of FFA after 
coronary artery ligation, which is associated with decreased oxygen 
uptake (Opie et al, 1973). Coronary artery ligation in dogs did not lead 
to a complete switch to anaerobic glycolysis and away from FFA utilization 
(Owen et al, 1969); glucose uptake by the ischaemic zone was increased 
fourfold and, by infer ence, FFA uptake reduced by the same amount. These 
f i ndings were felt to be in keeping with the concept that in myocardial 
in fa rction a central zone of total ischaemia may be surrounded by zones with 
l essening degrees of ischaemia and thus varying proportions of aerobic and 
anaerobic metabolism (Owen et al, 1969; Opie, 1975). 
Glucose is therefore important to the ischaemic myocardium and 
ess ential to the anoxic myocardium for the production of energy, but studies 
have shown that elevated circulating FFA concentrations may increase uptake 
of FFA by the myocardium (Ballard et al, 1960; Carlsen et al, 1961; 
Scot t et al, 1962) and decrease glucose uptake (Shipp et al, 1961) so that 
the relative contribution of glucose to energy production decreases 
(Havel et al, 1964). 
FFA/albumin molar ratio and the toxic effects of FFA 
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Spector (1971) has stressed the role of the FFA/albumin molar ratio 
in regulating FFA utilization by the tissues. Serum albumin in animals 
was found to have six high energy, or strong, binding sites for FFA and a 
number of weaker ones (Spector et al, 1969); saturation of these binding 
sites resulted in an increased concentration of unbound circulating FFA. 
There was an exponential relationship between increases in the FFA/albumin 
ratio and FFA entry into the cell (Spector, 1968). 
Experimentally it has been shown that the FFA/albumin molar ratio 
rather than the absolute circulating FFA concentration is the determining 
factor in the genesis of FFA toxicity in the ischaemic myocardium. 
Willebrands et al (1973) found an increased incidence of arrhythmias and 
greater impairment of myocardial function with increasing FFA/albumin molar 
ratios in both ischaemic and non-ischaemic isolated rat hearts, whilst 
de Leiris et al (1975) found that increasing the ratio increased enzyme. 
release from ischaemic, isolated rat hearts. Mj~s (1975) demonstrated 
that a decrease in the FFA/albumin molar ratio led to diminished myocardial 
extraction of FFA by infusing FFA-free albumin in dogs, but Kostis (1973) 
was unable to show an increase in the ventricular fibrillation threshold 
despite very high FFA/albumin molar ratios. Opie (1975) has reviewed 
the significance of the FFA/albumin molar ratios in several experimental 
studies in great detail. 
The results of animal experiments may not be relevant to man because 
the albumin levels differ and the relative binding capacity may vary 
(Kurien et al, 1971). In man, assuming constant serum albumin level of 
4 mg/ 100 ml, any increase in FFA concentrations above 1.2 mM/1 (or an 
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FFA/ albumin molar ratio of greater than 2) will result in a rise in the 
concentration of circulating unbound FFA (Kurien & Oliver, 1970). 
Free fatty acids and myocardial oxygen consumption 
High free fatty acid concentrations were found to increase 
myocardial oxygen consumption (MV02) by 40% in isolated perfused rat hearts 
in comparison with low FFA concentrations (Challoner & Steinberg, 1966a). 
Comparison of these results with subsequent in vivo studies is difficult 
because FFA was the only substrate supplied and because myocardial 
mechanical function, an important determinant of MV02, was not studied. 
Myocardial oxygen consumption was also shown to rise after elevation of 
serum-FFA to high concentrations in both non-ischaemic and ischaemic 
globally-perfused working pig hearts (Liedtke et al, 1978). In contrast, 
Opie (1973) found that a high FFA/albumin molar ratio of linoleic acid had 
no effect on MV02 in the perfused rat heart in non-working, working and 
ischaemic conditions. 
Mjds (1971a) found that increased FFA extraction by the myocardium 
of intact dogs resulted in increased oxygen extraction and increased MV02 
without any increase in coronary blood flow. This is contrary to the 
results of previous animal (Feinberg et al, 1962) and human (Lombardo et al, 
1953; Messer et al, 1962) studies in which increased myocardial oxygen 
demand was met by increased coronary blood flow rather than increased 
_myocardial oxygen extraction. Subsequently Mjds (1971b) studied the 
effect of isoproterenol in the intact dog. Both MV02 and FFA 
concentrations rose significantly after isoproterenol infusion; abolishing 
the isoproterenol-mediated FFA rise with either a nicotinic-acid analogue 
or high concentrations of intravenous glucose reduced MV02 by 30%. Whilst 
the nicotinic-acid analogue totally abolished the FFA rise, intravenous 
glucose only reduced it by 44%, but both agents were equally effective 
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in decreasing MV0 2 . The explanation for this was that intravenous 
glucose might also decrease the myocardial uptake of FFA. In all the 
above studies, plasma FFA/albumin molar ratios were elevated well above the 
physiological range. Most et al (1973) carried out a study in intact 
anaesthetized dogs in which plasma-FFA concentrations were elevated to 
between 1.6 mM/1 and 3.6 mM/1, which were considered to be within the range 
seen clinically. No change in the haemodynamic situation or in MVOz 
occurred; comparing these results with those of Mjds (1971a), the authors 
suggest that a matter of degree rather than one of disagreement might be 
involved. 
Controlled myocardial ischaemia in the open-chest dog caused 
ventricular dilatation and an increase in MVOz (Kjekshus & Mjds, 1972). 
Subsequent elevation of plasma FFA concentrations increased the degree of 
dilatation and possibly the degree of anaerobic metabolism with no other 
change in mechanical function or in MVOz. The authors interpreted their 
results as suggesting that the mechanism whereby high plasma FFA concen-
trations increased ventricular dilatation was identical to that whereby 
MVOz was increased in the normally perfused heart (Mjds, 1971a) and not due 
to a primary depressive effect on myocardial contractility, and that in the 
hypoxic heart high FFA concentrations increased the oxygen requirements in 
competition with the oxygen requirements for mechanical activity. This 
conclusion is contrary to that of Henderson et al (1970a) who found a 
depression of both mechanical performance and MVOz in oxygenated isolated 
perfused rat hearts, and could not exclude a primary depressive effect on 
the myocardium. The possibility that these hearts were somehow oxygen-
limited could not be excluded by the authors themselves, so that their 
conclusions may be invalid. 
Mjds et al (1974) showed that in closed-chest dogs with coronary 
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art ery occlusion, inhibition of lipolysis reduced the norepinephrine-
mediated rise in MV02 by 48%. The rise in arterial FFA concentrations 
and i ncreased myocardial FFA extraction were abolished and there were no 
haemodynamic changes . The fraction of MV02 attributable to lipolysis 
i n this study was larger than that observed when a similar increase in 
myocardia l FFA extraction was induced by infusion of triglycerides and 
heparin in the absence of norepinephrine (Mj~s, 1971a). The difference 
was felt to be due to the added effect on MV02 of increased endogenous 
lipol ysis by norepinephrine, as previously suggested by Challoner ?nd 
Steinberg (1966a , 1966b), in addition to the effect of circulating FFA. 
l·lj~s et al (1974) also observed that aftei inhibition of lipolysis there 
was a substantial decrease in myocardial FFA extraction which was not 
accounted for by the decreased MV02, and they concluded that only an increase 
i n FFA concentrations above the requirement for mechanical activity would 
i ncrease MV02. 
Ro_gers et al (1977b) were unable to detect a rise in MV02 after 
heparin-induced elevation of FFA concentrations up to 2.75 mM/1 in ·patients 
with a history suggestive of ischaemic heart disease. They postulated 
that there was no increase in MV02 in these patients because the FFA were 
stored as triglycerides in the myocardium and not oxidized. Dagenais and 
Jalbert (1977 ) also increased FFA concentrations by heparin infusion in 
patients wi th well-documented ischaemic heart disease and found no 
resulting increase in oxygen extraction by the myocardium or in MV02, 
either at rest or during atrial pacing. Patients who developed angina 
during pacing prior to FFA elevation had no change in the severity of their 
symp toms subsequently. Mean FFA concentrations rose to 1.83 mM / 1 after 
heparin infusion and peaks between 2.6 and 3.1 mM/1 occurred in three of 
the patients. The authors could not explain the difference in the results 
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between this study and previous animal studies. The method whereby FFA 
concentrations were elevated by heparin infusion alone might explain some 
of the differences, in that FFA concentrations in dogs cannot be increased 
in this way . 
Simonsen and Kjekshus (1978) elevated FFA concentrations by infusing 
isop roterenol in one group and by infusing Intralipid and heparin in a 
second group of patients with coronary artery disease who underwent atrial 
pacing. Pacing alone increased MV02 by 66% over control levels, whilst 
increasing heart rate to the same level by isoproterenol infusion alone 
increased MVOz to 142% above control values. MV02 increase was 23% and 
81% respectively when the same procedures were carried out during the 
infusion of an antilipolytic agent, which all but abolished the FFA rise. 
After isoproterenol stimulation, FFA contributed 50% to the increase in MVOz. 
Elevating FFA concentrations with Intralipid and heparin did not increase 
MV0 2 in the resting state, in keeping with the findings of Rogers et al 
(1977b), but during pacing MVOz rose by 81% as compared with 38% when no 
lipids were administered. When isoproterenol was infused at the same time 
as the lipids, MVOz rose by 91% of the control value during pacing compared 
with 67% during isoproterenol infusion alone. FFA concentrations in 
this study were within the limits observed during AMI. Several patients 
experienced angina at rest during simultaneous isoproterenol and lipid 
administration but not when these were administered separately, suggesting a 
synergistic effect. The conclusions drawn were that MV02 was closely 
related to the myocardial uptake of FFA and that catecholamines can sensitize 
the heart to FFA without increasing FFA uptake. The major part of the 
increased MV02 during catecholamine stimulation, as might be experienced 
during the early phase of AMI, was accounted for by the increased FFA uptake 
by the myocardium. 
Sensitization of the myocardium to free fatty acid 
by catecholamines 
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Opie et al (1971b) noted that elevation of circulating FFA concen-
t r ations to up to 10.0 mM/ 1 in open-chest dogs with coronary artery 
l igation did not increase the frequency of ventricular arrhythmias, but 
t hat a combined adrenaline infusion significantly increased the incidence 
of ventricular ectopic beats. They therefore proposed the theory that 
ca techolamines may sensitize the myocardium to the effects of elevated FFA 
concentrations. This theory is supported by evidence from studies in 
which catecholamines exacerbated the toxic effects of high FFA concentrations 
i n dogs with experimental myocardial ischaemia (Kjekshus & Mj~s , 1972; 
Kjekshus & Mj~s, 1973 ) and Opie (1975) concluded that catecholamine-
medi ated stimulation of endogenous lipolysis or increased myocardial 
extracti on of circulating FFA might account for such sensitization. 
Simonsen & Kjekshus ( 1978) found evidence for catecholamine sensitization 
i n patients with ischaemic heart disease but without any associated FFA 
up t ake by the myocardium. 
Intracellular free fatty acids and mechanisms of toxicity 
Kurien and Oliver (1970) put forward the hypothesis that FFA toxicity 
occurred because of intramyocardial breakdown of stored triglycerides to 
FFA by local catecholamine activation of a lipase. This hypothesis is 
s upported by the observations that in the under-perfused left ventricle, 
there was greater incorporation of labelled FFA into myocardial triglyceride 
and decreased incorporation into tissue (Scheuer & Brachfeld, 1966), and 
tha t there was a greater efflux than influx of FFA from the ischaemic zone 
i n coronary artery ligated dogs (Opie et al, 1973). Experimental evidence 
that endogenous lipolysis promotes the effects of ischaemia is indirect and 
i nconclusive however (Opie, 1975). 
Kurien et al (1971) further proposed that in patients with AMI 
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previous ischaemic episodes might have already resulted in high intra-
myocardial triglyceride concentrations, quoting the study of Wartman et al 
(1956 ) as support. During AMI the high local release of noradrenaline 
could stimulate lipolysis (Kruger et al, 1967) resulting in very high 
intracellular FFA concentrations requiring relatively little supplementation 
from circulating FFA levels to lead to toxicity. In this way, they could 
exp l ain the discrepancy between the high plasma-FFA concentrations required 
to produce arrhythmias and impair myocardial function in animal experiments, 
as described below, compared with the much lower plasma-FFA concentrations 
observed in patients with AMI. 
t~echanisms of FFA toxicity in animals include the following. In 
vitro studies have shown that FFA anions may combine with intracellular 
cations to produce soaps which may have a detergent effect on cellular 
enzymes and membranes which could result in loss of potassium from the 
cel l (Pande & Mead, 1968; Connor et al, 1963). In the perfused rat heart 
FFA have been observed to uncouple oxidative phosphorylation, thus raising 
tissue oxygen requirements (Challoner & Steinberg, 1966b). Intermediates 
of FFA metabolism which accumulate in the heart subsequent to impaired 
oxidation may have a deleterious effect. Long-chain acetyl-coenzyme A 
esters increased in concentration (Shug et al, 1975; Liedtke et al, 1978) 
in the ischaemic myocardium and affected energy metabolism by inhibiting 
tQe transport of ADP and ATP across the mitochondrial membrane (Shug et al, 
1975) . Long-chain carnitine esters were also increased in the ischaemic 
myocardium (Liedtke et al, 1978) and have been shown to effect transport 
mechanisms in cardiac membranes (Wood et al, 1977). Opie (1975) ~uoted 
studies which suggested that the duration of the plateau of the action 
potential of the myocardium was dependent on cytoplasmic ATP produced 
by gl ycolysis, which would be reduced if FFA were the predominant exogenous 
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fuel. On this basis he suggested that raised FFA concentrations might 
shorten the duration of the plateau of the action potential in the 
ischaemic myocardium thus increasing the likelihood of ectopic activity, but 
he stressed that sufficient data was not yet available to support this 
possible mechanism. 
PLASMA FREE FATTY ACIDS AND ARRHYTHMIAS AFTER ACUTE MYOCARDIAL 
INFARCTION - EXPERIMENTAL AND CLINICAL STUDIES 
Free fatty acids and arrhythmias after acute 
myocardial infarction - clinical studies 
Describing the elevation of FFA concentrations in 20 patients with 
AMI, Kurien and Oliver (1966) noted that of three patients dying on the 
day of admission one had the highest FFA concentrations recorded in the 
study (1.75 mM/1) and a fourth patient who died on the fourth day of 
admission had the second highest FFA concentration recorded (1.52 mM/1). 
The authors also gained the impression that arrhythmias developed more 
frequently in patients with very high serum-FFA levels, so a study was 
established to determine the relationship between serum-FFA concentrations 
and arrhythmias in patients with AMI (Oliver et al, 1968). Significantly 
more patients with serum-FFA concentrations of 1.2 mM/1 or greater within 
the first 24 hours of AMI had arrhythmias of all kinds, including atrial 
arrhythmias , ventricular premature beats, second or third degree heart block, 
ventricular tachycardia, ventricular fibrillation and complete heart block, 
when compared with patients having lower FFA concentrations. The number 
of patients with the above arrhythmias increased significantly with 
increasing FFA concentrations. Hospital mortality was higher in patients 
with serum-FFA concentrations of 1.2 mM/1 or greater and also increased 
significantly with increasing FFA concentrations. 
Although Gupta et al (1969) found an increased incidence of serious 
cardiac arrhythmias and poorest prognosis . in patients with AMI who had 
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initial plasma-FFA values greater than 1.0 mM/1, they could not establish 
a direct role for FFA in the production of arrhythmias because of the 
direct relationship found between plasma-FFA and urinary adrenaline 
excretion. There was no evidence to show that FFA concentrations did not 
merely reflect the acute metabolic disturbances in AMI, and the authors 
suggested that studies in which either FFA or catecholamine concentrations 
were reduced after AMI might have important clinical implications. In 
this same study plasma-FFA concentrations were artificially elevated to 
between 1.3 to 1.8 mM / 1 for up to 20 minutes by intravenous injection of 
heparin in 4 patients without the development of serious arrhythmias. A 
further clinical study which may support the findings of Oliver et al 
(1968 ) was that of Prakash et al (1972) who found that 6 of 9 patients 
with left ventricular failure, arrhythmias, shock or death after AMI had 
FFA values of 1.1 mM/ 1 or higher, whilst all of the patients who had none 
of the above complications had plasma-FFA levels of less than 1.1 mM/1. 
All patients with complications were grouped together, so that the actual 
number of patients developing arrhythmias is unknown. 
A number of clinical studies do not support the independent role 
of increased plasma-FFA concentrations in the production of arrhythmias 
a fter AMI. Rutenberg et al (1969) investigated 84 patients with AMI, most 
of them admitted within 8 hours of the onset of symptoms, and could find no 
relationship between the serum-FFA concentration on admission and 
subsequent arrhythmias. They found that patients with a persistently 
normal serum-FFA level were more likely to have an uncomplicated course, 
and that when complications occurred serum-FFA were likely to be elevated, 
but that these levels bore no relationship to the admission FFA concentra-
t ion. They too suggested that increased FFA concentrations at the time 
of complications might merely be a reflection of the catecholamine response. 
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Likewise Hagenfeldt & Wester (1973) could find no association between 
plasma-FFA levels and arrhythmias. 
In view of the suggestion by Kurien et al (1969) that administration 
of heparin to patients with AMI might not be safe because of its effect in 
enhancing lipolysis and elevating FFA concentrations, the effect of heparin 
administration on arrhythmias after AMI was investigated by Gupta et al 
(1969), Russo et al (1970) and Nelson (1970). In all cases standard 
therapeutic doses of heparin were used and in most cases peak plasma-FFA 
of well over 1.2 mM / 1 (and in some cases over 2.0 mM / 1) were achieved 
with no increase in ventricular arrhythmias. 
An association between the initial FFA concentration, taken within 
24 hours of the onset of AMI, and serious ventricular arrhythmias was 
therefore found in three clinical studies (Oliver et al, 1968; Gupta et al, 
1969; Prakash et al, 1972), but was not confirmed in two other studies 
(Rutenberg et al, 1969; Hagenfeldt et al, 1973). The limitations of all 
these studies are similar however. The admission FFA level may not reflect 
the peak FFA level after AMI, which might have occurred early (Vetter et al, 
1974), before the patients were admitted to hospital. Alternatively, in 
view of the fluctuation of FFA levels after AMI (Oliver et al, 1968), the 
infrequent sampling may have resulted in subsequent peaks being missed. 
All patients in these studies were allowed to eat normally and were given 
medications as required, both being factors which may influence FFA levels. 
The absence of an association between the artificial elevation of plasma-FFA 
concentrations with heparin and arrhythmias, in the absence of a concurrent 
generalised metabolic response, as demonstrated by Gupta et al (1969), 
Russo et al (1970 ) and Nelson (1970 ) may also be explained. It is possible 
that catecholamines sensitize the myocardium to the effects of FFA - if so, 
elevation of plasma-FFA in isolation after AMI may not induce arrhythmias 
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at the level achieved. Alternatively, elevated FFA concentrations may 
merely reflect the generalised metabolic response to AMI and other factors, 
such as catecholamines, may be responsible for arrhythmias (Gupta et al, 
1969; Oliver et al, 1968; Rutenberg et al, 1969). 
Free fatty acids and arrhythmias after acute myocardial 
infarction - experimental studies 
The results of the clinical trials are contradictory with respect to 
FFA and arrhythmias, but the clinical circumstances and possible errors due 
to the time of sampling as outlined above, may have contributed to these 
results. Much of the variability found in clinical studies may be eliminated 
in experimental studies, but nevertheless the relationship between plasma-FFA 
levels and arrhythmias after experimental myocardial infarction is equally 
confused. 
Kurien et al (1969) produced serum-FFA concentrations of between 
4.0 and 6.0 mM/1 in dogs with experimental myocardial infarction by 
simultaneous infusions of Intralipid and heparin and found an increased 
frequency of cardiac arrhythmias. Neither Intralipid nor heparin infusion 
alone was associated with arrhythmias in the doses used. When the 
expected rise in FFA concentrations was abolished or reduced by pretreatment 
with protamine sulphate, there was a corresponding decrease in the frequency 
of ventricular arrhythmias. Prota~ine sulphate had no intrinsic anti-
arrhythmic properties. The authors concluded that the association of 
raised serum-FFA concentrations and ventricular arrhythmias in dogs with 
experimentally produced myocardial infarction without an associated rise in 
catecholamines ( though these were not measured) suggested a direct toxic 
effect of FFA on the myocardium. 
In their carefully controlled definitive study in dogs (Kurien et al, 
1971), the same authors made the following observations. Arrhythmias only 
occurred after elevation of FFA concentrations in the presence of myocardial 
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ischaemia or infarction, and FFA concentrations of 3.0 mM/1 or more were 
generally required. The maximal frequency of ventricular ectopic beats 
occurred 10-30 minutes after the peak FFA concentrations were achieved, 
in keeping with an earlier suggestion (Kurien et al, 1969) that an intra-
cellular effect of FFA rather than absolute plasma levels might be 
responsible for inducing arrhythmias. FFA concentrations had a cumulative 
e ffect, with a greater quantity or more severe arrhythmias being associated 
with prolonged elevation of FFA. Arrhythmias could be abolished by 
s uppressing lipolysis. ' In the same study, noradrenaline was infused into 
dogs with raised FFA concentrations and the effect on arrhythmias was observed. 
The authors noted that after noradrenaline there were early arrhythmias which 
appeared to be due to the haemodynamic changes. Later arrhythmias 
occurred when the blood pressure and heart rate had stabilised, and could 
be abolished by inhibiting lipolysis and thus reducing FFA concentrations 
without reducing the noradrenaline levels. There was therefore considerable 
evidence for the independent effect of FFA in producing arrhythmias in dogs 
with myocardial infarction. 
The clinical relevance of this study may be questioned in view of 
the much higher plasma-FFA concentrations required to produce arrhythmias 
i n dogs than found in patients after AMI (Oliver et al, 1968). Furthermore, 
FFA are more loosely bound to albumin in dogs than in man, so that a much 
higher unbound proportion of FFA with consequent increased uptake by the 
myocardium will occur in the dog. Kurien and his co-authors argued that 
no analogy could be made between the toxic effects of high FFA concentrations 
i n dog and man because the infarcting human myocardium was likely to have 
higher concentrations of triglyceride than the dog. Local release of 
noradrenaline in the myocardium of patients with AMI, which is higher than 
i n dogs, has been shown to activate a lipase (Kruger et al, 1967), which 
could lead to lipolysis of stored intracellular triglycerides resulting in 
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a high intracellular FFA concentration which might only require a 
rel atively small increment from circulating FFA to produce toxic effects. 
Experiments in which dog hearts were infiltrated with triglyceride prior 
to vascular occlusion made them more prone to early arrhythmias and more 
s ensitive to the effect of catecholamines. 
In order to counter the argument that Intralipid-heparin elevation 
of FFA concentrations does not reflect the mechanism of FFA elevation in 
AMI, Oliver and Yates ( 1971 / 72) used a technique whereby appropriate 
proportions of the individual fatty acids in a stable complex with albumin 
were infused into dogs with myocardial infarction. Arterial levels of 
FFA between 1.2 and 2.1 mM/ 1, similar to those in patients with AMI, were 
achieved and 6 of 9 dogs developed serious ventricular arrhythmias within 
t he hour after infusion. This was only a preliminary report, however. 
Three experimental studies have been reported which do not support 
t he above findings. The first was that of Opie et al (1971b) where 
i ncreased . FFA concentrations of up to 6.8 mM/ 1 in greyhounds with experi-
mentally produced myocardial infarction were not associated with ventricular 
arrhythmi as, except in 3 of 4 dogs given simultaneous infusions of 
adrenaline. Increased FFA uptake by the hearts in these experiments were 
shown by measuring arterio-venous differences and by histology. 
Differences in experimental technique, as detailed by the authors and also 
~y Oli ver and Yates (1971 / 72) and Oliver (1972), may explain the discre-
pancies in the findings of this study and those of Kurien et al (1969) 
and Kurien et al (1971). Elevation of FFA concentrations was induced 
i n the same way and comparable levels (2.0 to 6.0 mM/1) were achieved. 
Whilst Kurien et al used mongrel dogs, which in many cases were under-
nourished, Opie et al used greyhounds, with their different life history 
and habits, physiological hypertrophy of the heart and possible different 
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feeding. Oliver and Yates (1971/72) suggested that Opie's experiments 
were carried out in circumstances of reduced sensitivity to induction 
of arrhythmias, the dogs having higher heart rates and higher serum 
potassium and albumin levels than those of Kurien et al (1971). 
Furthermore, the latter used the more physiological closed-chest preparation 
in which the main circumflex artery was occluded by a balloon catheter 
with stimulation of the arterial sympathetic nerves, whilst Opie et al 
(1971b) used an open-chest model requiring pericardiectomy in which a 
branch of the anterior descending artery was ligated with interruption 
of the arterial sympathetic nerves. Local catecholamine concentrations 
might have been increased in the studies of Kurien et al and decreased 
in those of Opie et al (Oliver 1972). 
In a subsequent study by Opie and Lubbe (1975) in 27 closed-chest 
dogs with electrolytically induced thrombosis of a coronary artery and 
elevation of FFA with Intralipid and heparin, there was little difference 
in the incidence of ectopic beats when these dogs were compared with controls 
within one hour of vascular occlusion (50% and 41% respectively). It was 
not possible to precipitate serious arrhythmias by Intralipid-heparin 
elevation of FFA concentration 2 to 3 days post-thrombosis in 6 dogs. 
Most et al (1976) found no significant increase in ventricular 
ectopic beats or more serious ventricular arrhythmias after Intralipid-
. heparin-induced FFA elevation in close-chest pigs with balloon-catheter 
occlusion of the left anterior descending artery. They presented evidence 
to support their argument that the coronar~ circulation of the pig resembles 
that of man more closely than the coronary circulation of dogs, and they 
attempted to induce arrhythmias in animals both with and without ventricular 
excitability prior to elevation of FFA concentrations. Ventricular 
fibrillation occurred in one of 17 pigs after elevation of FFA levels, but 
otherwise FFA did not influence the appearance of arrhythmias. FFA 
concentrations of between 1.86 and 5.0 rnM/1 were achieved, but serum-
albumin levels were not measured. 
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The experimental results of Kurien et al (1971) could not be 
reproduced by Opie et al (1971b), where marked differences in experimental 
design were apparent, nor by Opie and Lubbe (1975) in dogs or Most et al 
(1 976) in pigs in studies where similar experimental methods were used. 
The FFA/ albumin ratio was not monitored in any of these studies however, 
and their relevance to the clinical situation is questionable in view of the 
very high plasma- FFA concentrations (up to 6.0 mM / 1) achieved, levels far 
higher than those previously demonstrated in man after AMI (Oliver et al, 
1968 ) . As in the clinical studies described above, experimental studies 
have produced conflicting evidence for the role of plasma-FFA concentrations 
i n producing ventricular arrhythmias after acute myocardial infarction. 
The effect of reducing circulating FFA concentrations by 
i nhibition of lipolysis on ventricular arrhythmias after 
acute myocardial infarction 
In view of the possible arrhythmogenic effects of FFA after AMI, 
Oliver et al (1972 ) suggested that lowering excess FFA levels might produce 
a less toxic metabolic environment, and showed that a nicotinic-acid 
analogue reduced plasma-FFA concentations both in healthy men and in patients 
wi th AMI. They proposed that clinical trials with nicotinic-acid 
analogues in patients with AMI might help to determine the relationship 
bet ween high FFA concentrations and ventricular arrhythmias. 
Rowe et al (1975) conducted a controlled double-blind trial of a 
ni cotinic-acid analogue in 70 patients with .AMI, having established its 
effic acy in lowering FFA concentrations in a previous study (Rowe et al, 
1973 ) . The results were not conclusive. Significantly fewer patients 
treated early (within 5 hours of onset of symptoms) whose FFA concentration 
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fell rapidly and then remained within normal limits for 20 hours had 
ventricular tachycardia when compared with patients whose FFA levels were 
not as rapidly or consistent+y reduced. In patients treated later 
(5 to 12 hours post-infarct), there was no difference in the incidence of 
ventricular arrhythmias between treated and control groups. In assessing 
their results, the authors recognised several limitations. The incidence 
of serious ventricular arrhythmias diminishes rapidly after the onset of 
AMI, so that in their group of patients admitted and treated within 5 hours 
there might have been an increase in early serious arrhythmias in the 
placebo group with bias in favour of the treated group. The nicotinic-
acid analogue was not entirely satisfactory in that only 50% of patients 
treated early had adequate control, and the time taken to absorb the 
analogue was not known. There was also some evidence that the nicotinic-
acid analogue acted by inhibition of lipolysis at the myocardial level, 
independent of plasma-FFA concentrations. The possibility that the 
analogue might have primary antiarrhythmic properties was considered, and 
further stressed by Opie and Lubbe (1975). An important observation in 
the study of Rowe et al (1975) was that plasma-catecholamine levels were 
not reduced by the nicotinic~acid analogue, so that its effect, if any, 
on the relationship between plasma-FFA concentrations and ventricular 
arrhythmias was independent of the effects of catecholamines. 
Whilst otherwise inconclusive, this important pilot study showed a 
reduction in the number of patients with ventricular tachycardia when 
treatment with an agent which rapidly lowered FFA concentrations to within 
normal limits was initiated within 5 hours and continued for 24 hours. 
A subsequent experimental study (Smith & Duce, 1975) showed reduction in 
phase III arrhythmias after administration of a nicotinic-acid analogue 
and reduction of FFA concentrations in dogs. Whilst the clinical and 
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experimental evidence for the antiarrhythmogenic effect of elevated 
plasma-FFA after AMI is not conclusive, the available results of studies 
with nicotinic-acid analogues tend to swing the balance in favour of such 
an effect. 
FREE FATTY ACIDS, EXTENSION OF MYOCARDIAL ISCHAEMIC INJURY 
AND OTHER COMPLICATIONS OF ACUTE MYOCARDIAL INFARCTION -
EXPERIMENTAL AND CLINICAL STUDIES 
Experimental studies 
In vitro studies on isolated perfused rabbit hearts (Severeid et al, 
1969) have shown a depressant effect of free fatty acids. Depression of 
contractility of rat papillary muscle by FFA was demonstrated by Henderson 
et al (1970b) in the presence of hypoxia and anoxia. Under these 
circumstances, glucose partially counteracted the depressant effect of FFA. 
FFA had no depressant effect in normally oxygenated papillary muscle in 
this study though such an effect was observed by Henderson et al (1970a) in 
experiments using beating rat hearts, but the possibility that these 
hearts were oxygen-limited could not be excluded however. Most et al 
(1972 ) were able to demonstrate a depressive effect of increased FFA levels 
on the isolated hypoxic rat papillary muscle. 
Ventricular dilatation produced by controlled myocardial ischaemia 
in open-chest dog preparations was significantly increased by raising 
blood-FFA concentrations from a mean of 0.36 mmM/1 to a mean of 3.69 mM/1 
(Kjekshus & Mj~s, 1972). Reduction of FFA concentrations to initial 
levels reversed the dilatation completely, suggesting that elevated FFA 
concentration impair myocardial function in the dog in vitro. 
The same authors (Kjekshus & Mj~s, 1973) investigated the effect of 
plasma-FFA on the magnitude and extent of myocardial ischaemic injury, 
which was monitored by means of epicardial ST segment elevation. This 
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technique has been shown to provide rapid and reproducible determination 
of ischaemic injury in the same animal (Maroko et al, 1972). Using e-
pyridyl-carbinol, an antilipolytic agent which inhibits catecholamine-
induced lipolysis, in doses which did not alter haemodynamic status, it 
was found that both the extent and magnitude of ST elevation which occurred 
after coronary artery occlusion in open-chest dogs were reduced. e-
pyridyl-carbinol abolished the additional elevation and extension of ST 
segments which occurred with FFA elevation or isoproterenol infusion after 
coronary artery occlusion. Pre-treatment with this antilipolytic agent 
prior to coronary artery ligation decreased the creatine kinase depletion 
of the resulting infarcted myocardium, which is a measure of the extent of 
myocardial necrosis (Kjekshus & Sobel, 1970; Maroko et al, 1971). Thus 
inhibition of catecholamine-mediated lipolysis decreased the extent of 
myocardial ischaemic injury in this study, but the effect on circulating 
FFA was not detailed so it is not known whether the beneficial actions of 
inhibition of lipolysis were peripheral or intracellular. 
Most et al (1974) could not confirm an FFA-mediated change in the 
rate of diminution of the ST segments after myocardial infarction in· 
closed-chest pigs. Elevation of FFA concentrations to nearly 3.0 mM/1 at 
one hour or at 2 hours post-infarction did not alter the rate of fall of 
the elevated ST segments, whilst isoproterenol infusion at these times 
. caused a significant rise in the ST segments. FFA concentrations rose 
significantly when isoproterenol was infused at one hour post-infarction, 
but fell when the infusion was carried out at 2 hours, so that it was 
difficult to argue that the isoproterenol effect was even .partially mediated 
by raised FFA concentrations. FFA levels rose to peak values and back 
to control levels within one hour in all cases, so that the short duration 
of the FFA rise might have been responsible for the negative results. 
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Kjekshus (1974) carried out experiments to determine whether any 
antilipolytic-induced reduction in the extent and magnitude of ST segment 
elevation and diminution in myocardial CK depletion represented a 
sufficient salvage of myocardial tissue to improve ventricular function 
after experimental coronary occlusion~ There was significantly less 
impairment of cardiac output in dogs pre-treated with the antilipolytic 
agent prior to coronary artery occlusion than in untreated dogs, but again 
FFA concentrations were not monitored. 
Free fatty acid levels were assayed in a study to determine the effect 
of the antilipolytic p-Chlorophenoyisobutyrate (CPIB) on epicardial ST 
segment elevation in dogs after coronary artery occlusion and isoproterenol 
infusion (Mj~s et al, 1976). Pre-treatment with CPIB significantly 
reduced the rise in ST segments and FFA concentrations occurring after 
coronary artery occlusion alone and the much higher rise occurring after 
coronary artery occlusion with concurrent isoproterenol infusion. 
Reduction in circulating FFA concentrations was associated with a 
proportionate decrease in myocardial blood flow, so that the beneficial 
effect reflected in the diminished rise in arterial FFA concentrations, 
whose toxic effect was additional to that of the infused isoproterenol. 
The clinical significance of this study may be limited because there are 
several references, as quoted by the authors, to indicate that the anti-
·lipolytic effect of CPIB is considerably less in man than in animals. This 
may not be a contraindication to the use of CPIB in man if the main 
purpose of treatment is merely to reduce excess circulating fatty acids 
(Kjekshus, 1975), rather than to abolish lipolysis altogether. 
Further evide~ce of FFA toxicity to the myocardium came from the 
study of Liedtke et al (1978) in which excess FFA concentrations caused 
significant impairment in myocardial function (specifically, in mean 
aortic pressure, left ventricular systolic pressure, left ventricular 
work and epicardial motion) in both normal control and ischaemic pig 
hearts. Impairment in ischaemic hearts when FFA concentrations were 
elevated was significantly greater than that produced by the ischaemia 
alone. 
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Most of the experimental evidence indicates that raised FFA concen-
trations impair myocardial function after coronary artery occlusion, 
whether in isolated rabbit or rat hearts, or dog and pig hearts in vivo. 
Some of the evidence is presumptive, in that inhibition of lipolysis 
proved beneficial in studies where FFA concentrations were not measured. 
The evidence of FFA toxici~y in non-ischaemic hearts is conflicting, as 
is the evidence that FFA elevation increases myocardial ischaemic injury 
as reflected in elevation of epicardial or precordial ST segment elevation. 
Clinical studies 
Two clinical studies have been carried out specifically to determine 
the effect of lowering plasma-FFA on precordial ST segment elevation in 
man with ischaemic heart disease (Luxton et al, 1976) and with acute 
myocardial infarction (Russell & Oliver, 1978). Precordial ST segment 
changes correlate well with changes in underlying myocardial ischaemic 
injury (Reid et al, 1971; Madias et al, 1975). 
Luxton et al (1976) lowered plasma-FFA with a nicotinic-acid analogue 
in a double-blind cross-over study in 12 men with stable angina pectoris 
who were exercised to the point of pain. FFA concentrations were 
significantly lower in treated than in control patients from 30 minutes 
prior to exercise until 20 minutes after exercise was discontinued because 
of pain. ST segment elevation was similar in the treated and control 
groups prior to exercise, but rose significnatly higher in the control 
group during the 8 minutes after starting exercise. The duration of 
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exercise prior to onset of chest pain was not altered. The authors 
interpreted the diminution in ST segment elevation in treated patients as 
reflecting an improved myocardial metabolic milieu as a result of 
decreased FFA uptake by the myocardium. They could offer no explanation 
for the lack of correlation between ST segment elevation and pain, but 
noted that Borer et al (1975) had reported similar findings. 
Patients treated with a nicotinic-acid analogue shortly after AMI 
(Russell & Oliver, 1978) showed an increased rate of decline of ST segment 
elevation in the absence of any change in heart rate or Q-wave evolution. 
FFA concentrations were rapidly and effectively reduced to within normal 
limits in association with the ST segment changes when optimal doses of 
the antilipolytic were given, though these resulted in an unacceptably 
high incidence of side-effects. Lowering FFA concentrations appears to 
modify myocardial ischaemia as monitored by ST segment elevation in man. 
Correlation between FFA concentrations and the extent of myocardial 
necrosis, as reflected by raised plasma enzyme activity, has produced 
inconsistent results. No correlation was found between FFA levels and 
maximum SGOT activity (Kurien & Oliver, 1966) or creatine kinase activity 
(Oliver et al, 1968) after AMI. Subsequently Vetter et al (1974) found 
a correlation between mean FFA values within the first 5 hours of AMI and 
the subsequent peak creatine kinase (r = 0.9, P<0.001) and peak SGOT 
( r = 0.62, P<0.01) levels. The value of such correlations is questionable 
in view of the non-specificity of SGOT as a marker of myocardial necrosis, 
and the factors which influence CK activity in the blood after AMI, as 
described in detail in the section on estimation of myocardial infarct 
size by serial measurements of creatine kinase activity. 
When first describing the rise in FFA concentrations after AMI, 
Kurien and Oliver (1966) noted no difference in the pattern of FFA levels 
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in patients with and without heart failure. Rutenberg et al (1969) 
attempted to predict the development of shock, congestive cardiac failure, 
and late deaths with the admission fasting FFA concentration in patients 
with AMI, but found no relationship. Though plasma-FFA concentrations 
were usually elevated at the time of these complications, it was felt 
that this was effect (possibly catecholamine-mediated) rather than cause. 
This study therefore failed to support the findings of Oliver et al (1968) 
that there was a correlation between FFA concentrations in excess of 1.2 mM/1 
and the incidence of shock and late deaths (though not with heart failure) 
after AMI. The time of admission after onset of symptoms were apparently 
similar in the two studies, but sampling for FFA level estimation was less 
frequent in the former study so that peak FFA concentrations might have 
been missed. Infrequent sampling was a feature of both these studies 
however, as it was in that of Gupta et al (1969) who showed daily fasting 
FFA concentrations in patients with left ventricular failure, cardiac 
failure or shock were significantly higher on the third, fourth and 
fifth days post-infarction than in patients without these complications. 
Again, it was impossible to deduce from the results whether the higher FFA 
concentrations were the cause or the effect of the complications. 
As in the experimental studies, the results of clinical observations 
are conflicting and no clear association between elevated FFA concentrations, 
myocardial ischaemic injury and complications of AMI emerge. The effect 
of FFA in elevating and of antilipolytic agents in reducing the post-
infarction rise in precordial ST segments in man is relatively conclusive. 
The interpretation of these results is not straight-forward however. 
If the degree of ST elevation correlates with the degree of underlying 
ischaemia (Reid et al, 1971; Madias et al, 1975) and raised FFA 
concentrations increase the degree and extent of ischaemia, an association 
with the incidence of heart failure and shock might be expected, since 
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these are clinical manifestations of the extent of impaired myocardial 
function (Braunwald, 1976). There is no evidence that in man elevated 
FFA concentrations increase the extent of myocardial ischaemia; thus 
increasing the degree of ischaemia in tissue which is already ischaemic 
might not appreciably impair the function of that tissue further. The 
lack of an association between FFA levels, heart failure and shock after 
AMI in most reports would therefore be understandable. Studies to date 
correlating FFA concentrations with the magnitude of myocardial necrosis, 
as reflected by plasma SGOT and CK activity, have not been extensive 
enough to draw any conclusions. Clinical evidence that elevated FFA 
concentrations impair myocardial function after AMI is not as strong as 
the experimental evidence. 
CHAPTER VI 
THE BEHAVIOUR OF PLASMA FREE FATTY ACIDS IN 
INDIVIDUAL PATIENTS IN THE FIRST 24 HOURS OF 
ACUTE MYOCARDIAL INFARCTION 
12? 
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INTRODUCTION AND SCOPE OF THE STUDY 
A large number of clinical investigations have been carried out to 
determine whether there is a relationship between plasma free fatty acid 
concentrations and the occurrence of complications after acute myocardial 
infarction (Oliver et al, 1968; Gupta et al, 1969; Rutenberg, 1969; 
Prakash et al, 1972; Hagenfeldt & Wester, 1973; Mueller & Ayres, 1978). 
Despite the important clinical implications of some of the results, no 
study has yet been reported in which the behaviour of FFA concentrations 
in the early phase of AMI in individual patients has been analysed from 
the results of frequent serial measurements. Vetter et al (1974) carried 
out an intensive investigation of the metabolic disturbances in the first 
5 hours of AMI, but all the studies referred to above, as well as the 
original study describing the rise in FFA after AMI (Kurien & Oliver, 1966) 
reported that FFA concentrations were elevated for much longer than 5 hours 
after the onset of symptoms. 
The scope of this study was to carry out frequent FFA estimations 
in the first 24 hours of AMI in patients who, within practical limits, 
were not subjected to any treatment which might influence FFA levels. 
In this way the observed pattern of FFA rise and fall might lead to a 
better understanding of the relationship. between FFA concentrations and 
complications after AMI, and might help in the evaluation of therapy to 
reduce FFA levels. 
Patients and Methods 
Fifteen patients admitted to the coronary care unit of Groote Schuur 
Hospital were studied. The criteria for selection were as outlined in 
Chapter I. All patients were starved for at least 12 hours after the 
onset of symptoms, and for longer where possible. Blood sampling, 
storage and assay of free fatty acids were carried out as described in 
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Chapters I and II. Statistical analysis was carried out using the 
coefficient of correlation and the Mann-Whitney U test (Appendix C). 
RESULTS 
Fifteen patients, 13 males and 2 females with a mean age of 53 years 
( range 37 - 69 years) were studied. Relevant biochemical details and 
drug therapy during the study period are shown in Table 1, where patients 
are listed in ascending order of peak FFA. 
The FFA concentrations in the 24 hours after the onset of acute 
myocardial infarction are set out for each of the 15 patients in Table 2, 
and are shown graphically in Fi~s 1a,b,c. All patients showed a rise in FFA 
concentration within 12 hours of myocardial infarction above the upper 
limit of normal of 0.8 mM/1 (Oliver et al, 1968). The subsequent fall 
was followed by a transient rebound in FFA concentrations in all but 5 
patients (Numbers 14, 14, 15, 23 and 24) and the second peak was higher 
than the initial peak in patients numbers 18, 19 and 23. Most values 
remained below 1.0 mM/1 after the first 12 hours and the majority of these 
were within the normal range. Mean FFA concentrations for all the 
patients are given in Table 2 and Figure 2. 
FFA peaks of 1.5 mM/1 or greater within the first 12 hours of acute 
myocardial infarction occurred earlier than FFA peaks of less than 1.5 mM/1 
(Table 1). + + The mean time of the peaks were 6 - 1 hour (mean - SEM) and 
10 ! 0.4 hours after the onset of symptoms in the two groups respectively 
(P = 0.002, Mann-Whitney U test). The mean time lapse from onset of 
symptoms to arrival in hospital was 4 ! 0.7 hours in patients with peak 
FFA ~1.5 mM/1 and 5 ! 0.6 hours in those with peak FFA <1.5 mM/1. 
The mean fall from peak FFA values in the 6 hours following the FFA 
peak in absolute figures and as a percentage are shown for all patients 
together and for the two subgroups with high and low FFA peaks in Table 3 
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and Figure 3. The major fall from peak FFA values occurred within the 
first 2 hours after the peak, irrespective of the height of the peak. 
There was a correlation between the fall in FFA concentrations 
within the first 2 hours after the FFA peak and the peak FFA concentration 
itself (Figure 4, r = 0.74, P<0.01). The rate of fall of FFA levels 
in the 2 hours after the FFA peak was greater in patients with high than 
in patients with low FFA peaks (Figure 5, P = 0.003, U = 7, Mann-Whitney 
U test). 
DISCUSSION 
This is the first time that frequent, serial estimations of plasma-
FFA concentrations in the first 24 hours after AMI have been reported in 
patients who were starved for at least the first 12 hours. In their original 
paper describing elevation of FFA concentrations after AMI, Kurien and 
Oliver ( 1966) analysed 2-hourly blood samples, starting as soon as possible 
a fter admission, but they only reported the results of between one and three 
samples taken on the first day in each patient, and only a brief description 
of the behaviour of mean FFA concentrations was given. Opie et al (1975) 
measured FFA levels 2-hourly for up to 66 hours from the time of admission 
in 9 patients with AMI, but the interval between onset of symptoms and 
admission in individual patients was not stated. No accurate assessment 
of the behaviour of FFA concentrations relative to the time of onset of 
. symptoms in individual patients could therefore be made. Furthermore, 
their patients were immediately allowed free access to food, which was 
associated with a significant fall in FFA values in many cases. Vetter et al 
(1974) measured FFA concentrations hourly after AMI but only for the first 
5 hours. 
The importance of the first 24 hours of AMI lies in the fact that 
the major FFA rise occurs during this time. Elevation of FFA concentrations 
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may start as soon as 30 minutes after the onset of symptoms (Kurien & 
Oliver, 1966; Vetter et al, 1974), and elevated levels in individual 
patients have been noted at 36 hours post-infarction (Oliver et al, 1968) 
and possibly even later (Kurien & 0.liver, 1966; Opie et al, 1975). In 
the present study FFA concentrations were above the upper limit of normal 
(0.8 mM/ 1, as described by Oliver et al, 1968) within 12 hours of AMI in 
all patients studied, and admission values were elevated in all but 4 
patients. Admission values did not reflect subsequent values however. 
The major FFA rise occurred within 12 hours of the onset of symptoms in all 
but 2 patients, during which time a rapid fluctuation in FFA concentrations 
was noted. Highest peaks occurred early, thus emphasizing the importance of 
including only patients admitted very early after the onset of symptoms to 
any clinical trials involving FFA measurements. By 24 hours, FFA levels 
had returned to within normal limits in 9 of 14 patients who survived that 
~eriod. Mean FFA concentrations (Figure 2) did not reflect the large 
individual variations which occurred. 
These observations may partly explain some of the conflicting results 
arising from the studies in which FFA concentrations after AMI have been 
related to ventricular arrhythmias and other complications of AMI. Oliver 
et al (1968) estimated FFA concentrations twice in the first 24 hours of 
AMI, whilst Gupta et al (1969) and Prakash et al (1972) only analysed one 
. sample during this time. Their results conflicted with those of Rutenberg 
et al (1969), who based their conclusions on FFA values taken on admission 
and again whilst the patients were fasting~ and those of Hagenfeldt and 
Wester ( 1973) who took samples a maximum of four times in the first 24 hours, 
immediately prior to meals. Such infrequent sampling could not result in 
a true reflection of the FFA concentrations in the first 24 hours of AMI, 
as described in this study, and, in particular, FFA peaks may well have been 
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missed altogether. 
Oral intake and administration of drugs may have an effect on FFA 
concentrations. Patients in this study were carefully selected to exclude 
patients with prior administration of heparin, catecholamines, steroids, 
clofibrate or intravenous glucose, all of which might influence plasma-
levels of FFA (Oliver et al, 1968; Gupta et al, 1969). None of the 
patients had eaten from the time of onset of their symptoms, and all were 
starved for at least 12 hours post-infarction. Opie et al (1975) have 
shown a significant fall in FFA levels after every intake of calories 
exceeding 90 Kcals (378 KJ) on the first day after AMI. In the present 
study, 10 of the patients received food between 12 and 24 hours after the 
onset of symptoms, and in 7 of these patients (Numbers 14, 18, 21, 22, 24, 
25 and 26) a subsequent fall, sometimes dramatic (Numbers 14, 21 and 22) 
was observed. The significance of these falls in relation to the intake 
of food must be considered in the light of the rapid fluctuations in FFA 
levels which were noted to occur spontaneously. 
Of the drugs administered to the patients during the study period 
(Table 1) the 8-blockers given to patients 14 and 19 and the diazepam 
administered to almost half the patients require further comment. 8-
adrenergic blockade has been shown to cause inhibition of peripheral 
lipolysis (Himms-Hagen, 1967; Whittington-Coleman et al, 1973) and can 
prevent increases in plasma free fatty acid concentrations (Pinker & Pattee, 
1967; Imura et al, 1971; Taggart et al, 1973). In healthy, fasting, 
non-stressed subjects, 8-blockers decreased free fatty acid serum levels by 
about 35% compared with placebo (Deacon, 1978) and antagonized isoprenaline 
induced increases in free fatty acid concentrations (Harms et al, ·1978). 
The effect on FFA concentration~ after AMI is less certain. Mueller and 
Ayres (1977) administered propranolol intravenously to 20 patients with AMI 
133 
and found an insignificant decrease in plasma FFA concentrations 20 minutes 
later, whilst in 11 selected patients, a small but significant decrease 
occurred (Mueller & Ayres, 1978). In the absence of definite data, an 
effect by s-adrenergic blockade on plasma FFA concentrations after AMI 
should probably be assumed. 
Melsom et al (1976) found that patients sedated with diazepam after 
AMI had lower circulating catecholamines than a control group. Any 
catecholamine-mediated FFA rise due to the stress and anxiety of AMI, over 
and above that rise due to the generalised metabolic response (Opie, 1968; 
Oliver, 1972; Vetter et al, 1974) might therefore be reduced. In the same 
study, Melsom et al (1976) noted that FFA concentrations fell more rapidly 
in the first 4 hours in diazepam-treated patients than in the control group, 
and ascribed this more rapid fall to the effects of diazepam. This 
conclusion might be false however; diazepam-treated patients had higher 
initial FFA concentrations than control patients; in view of the results 
of the present study, it is possible that a naturally-occurring phenomenon, 
uninfluenced by diazepam, was observed by the authors. In view of the 
observations that catecholamines were lower in diazepam-treated patients 
after AMI, it could theoretically follow that catecholamine-mediated 
lipolysis, and thus circulating FFA concentrations, would be reduced, but 
there is no conclusive evidence that this in fact occurred. 
In the present study, the major fall in FFA concentrations from peak 
levels within 12 hours of AMI had occurred by 2 hours after the peak, and 
was completed by 3 hours after the peak, irrespective of the height of the 
peak (Figure 3). There was a correlation between peak values and the 
fall in the subsequent 2 hours (Figure 4) and the fall in FFA concentrations 
was more rapid after a high peak than after a low peak (Figure 5). A 
possible interpretation of these results is that FFA concentrations might 
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rapidly reach similar levels after they have peaked, irrespective of the 
height of the peak. Thus in order to compare the effect of an agent 
designed to reduce FFA concentrations in one group of patients with a 
control group, it would be essential that initial FFA concentrations in 
the two groups were similar. 
Table 1 
Patient 
Number Aoe 
1 35 
CLINICAL AND BIOCHEMICAL DETAILS OF 15 PATIENTS FASTED FOR AT LEAST 12 HOURS A
FTER THE ONSET 
OF AMI 
Sex 
Time after 
onset of 
pain to 
admission 
(Hours ) · 
Hours after 
onset of 
pain to 
peak FFA 
Peak 
FFA 
Fall in 
FFA in 
the 2 hours 
after the 
peak 
Time after 
onset of 
pain to 
first meal 
(Hours ) 
Site of 
infarct 
Drugs given in the 
first 24 hours 
A. Patients with peak FFA <1.5 mmol / 1 in the first 12 hours after acute myocardial infarctio
n 
13 
25 
14 
18 
19 
23 
, 24 
Mean 
(±SEM) 
39 
55 
69 
37 
61 
58 
39 
51 ( ±5 ) 
(37-69 ) 
M 
M 
M 
M 
M 
M 
M 
4 
6 
7 
4 
6 
6 
6 
5(±0.6 ) 
10 
10 
10 
6 
10 
12 
12 
10 (±0.4) 
0.87 
0.98 
0.99 
1.05 
1.23 
1. 31 
1.38 
1.12(±0.07 ) 
0.18 
0.07 
a.oz 
0.12 
0.44 
0.17 
0.26 
0.18 (±0.05 ) 
20 
18 
18 
18 
23 
32 
18 
21 (±2 ) 
B. Patients with peak FFA ~ 1.5 mmol / 1 in the first 12 hours after acute mvocardial infarction 
.1 15 
22 
20 
17 
26 
Mean 
(±SEM) 
Overall 
Mean 
(±SEM ) 
66 
54 
55 
64 
48 
48 
41 
58 
54 (±3 ) 
(41-66 ) 
53 (±3 ) 
07-69 ) 
M 
M 
M 
M 
F 
M 
M 
F 
4 
7 
6 
2 
6 
3 
2 
3 
4(±0. 7) 
5(±0.4) 
8 
7 
12 
4 
7 
3 
6 
4 
6(±1 ) 
8(±0.8 ) 
1.57 
1.58 
1.63 
1 .68 
1. 79 
1.87 
2.05 
2.92 
1 .89 
±0.16 
1. 53 
±0.14 
0.06 
D.23 
0.62 
· 0.99 
1.08 
1 .15 
1 .01 
0.95 
0.76 
±0.15 
0.49 
±0.11 
24 
12 
25 
24 
12 
15 
23 
16 
19±2 
20±1 
Inferior 
Inferior 
Inferior 
Inferior 
Inferior 
Inferior 
Anterior 
Inferior 
Inferior 
Inferior 
Inferior 
Anterior 
Inferior 
Anterior 
Anterior 
Frusemide 40 mg 
Morphine 15 mg 
Lignocaine 100 mg 
Morphine 5 mg 
Dxprenolol 20 mg 
Diazepam 15 mg 
Lignocaine 2.6 gm 
Nil 
Propranolol 80 mg 
Diazepam 10 mg 
Morphine 5 mg 
Lignocaine 2 gm 
Morphine 10 mg 
Lignocaine 2 gm 
Nitroprusside 
Methyldopa 750 mg 
Diazepam 10 mg 
Digoxin 0.25 mg 
Lasix 80 mg 
Allopurinol 300 mg 
Colchicine 1.5 mg 
Morphine 5 mg 
Moduretic x 2 
Lignocaine 100 mg 
Disopyramide 150 ms 
Procainamide 500 ms 
Lignocaine 1 gram 
Procainamide 100 me 
Methyldopa 750 mg -
Frusemide 80 mg 
Nitrazepam 10 mg 
Diazepam 10 mg 
Digoxin 0.25 mg 
War far in 7. 5 mg 
Morphine 5 mg 
Nil 
Atropine 0.6 mg 
Diazepam 15 mg 
Lignocaine 2 gms 
Diazepam 10 mg 
Frusemide 20 mg 
Morphine 10 mg 
Lignocaine 200 mg 
Morphine 20 mg 
Diazepam 10 mg 
Frusemide 40 mg 
Lignocaine 2 gms 
Morphine 5 mg 
Frusemide 20 mg 
K+ supplements 
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HOURS - POST- INFARCTION 
Mean FFA concentrations in the first 24 hours of AMI 
in 15 patients fasted for at Zeast the first 12 hours. 
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CHAPTER VII 
THE RELATION OF COMPLICATIONS OF ACUTE MYOCARDIAL 
INFARCTION TO INFARCT SIZE AND TD FREE FATTY ACIDS 
145 
146 
INTRODUCTION AND PURPOSE OF IHE PRESENT STUDY 
The method of estimating infarct size by serial measurements of 
plasma CK activity after AMI (Shell et al, 1971; Norris et al, 1975; 
Roberts et al, 1975c) provided a means of assessing the relationship 
between infarct size and prognosis in individual patients with AMI (Sobel 
et al, 1972). In this way, the efficacy of interventions designed to 
reduce infarct size could be tested. The validity of this method of 
sizing infarcts in assessing prognosis after AMI was reasonably substantiated 
by the strong associations found between enzymatically estimated infarct 
size and mortality (Sobel et al, 1972; Mathey et al, 1974; Shell & Sobel, 
1976; Bleifeld et al, 1977), the degree of left ventricular dysfunction 
(Sobel et al, 1972; Kostuk et al, 1973; Mathey et al, 1974; Norris et al, 
1975; Rogers et al, 1976; Bleifeld et al, 1976; Inoue et al, 1977; Hori et al, 
1979) and the incidence of ventricular arrhythmias (Roberts et al, 1975c; 
Bleifeld et al, 1976; Cox et al, 1976; Ehsani et al, 1978). Similar 
comparisons were made in the present study as a measure of the validity of 
the enzymatically estimated infarct sizes as used extensively in the studies 
presented in this thesis. 
In 1970 Kurien and Oliver put forward the hypothesis that there might 
be a metabolic cause for arrhythmias during acute myocardial hypoxia in 
which elevated FFA concentrations might play a major role. Support for 
this theory came from the association between elevated FFA and ventricular 
arrhythmias in patients with AMI found by Oliver et al (1968), Gupta et al 
(1969) and Prakash et al (1972), but Rutenberg et al (1969) and Hagenfeldt 
and Wester (1973) could not confirm these results. The correlation of 
high circulating FFA with shock and mortality after AMI also remains 
controversial (Oliver et al, 1968; Rutenberg et al, 1969). A feature of 
all these studies was infrequent blood sampling for FFA estimation in the 
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early phase of AMI, when FFA concentrations were likely to be high (Kurien 
& Oliver, 1966; Oliver et al, 1968). The purpose of this study was to 
correlate ventricular arrhythmias and other complications of AMI with FFA 
concentrations estimated frequently during the first 12 hours of AMI, so 
that no peak values would be missed and the mean FFA concentrations during 
this period could also be considered. 
Patients and Methods 
Thirty-six of the patients, 35 males and one female, were included 
i n this study. Patient selection, blood sampling and storage, and 
biochemical analysis of plasma FFA and potassium concentrations and CK 
activity were carried out as described in Chapters I, II and III. 
Statistical analysis (Appendix C) was by the exact four-fold table test or 
Student's t test, as indicated in the text. Observations were made in 
all patients regarding the duration of chest pain, the occurrence of 
ventricular arrhythmias, the development of heart failure and the 6-month 
mortality after AMI; for the purpose of this study, these were collectively 
called the complications of AMI. The number of patients with these 
complications were compared according to infarct size index or free fatty acid 
concentrations in the first 12 hours post-infarction. 
The FFA concentration of 1.2 mM/1 was used as a dividing point 
because up to this level, with normal serum albumin levels, most of the FFA 
·will be albumin-bound (Kurien & Oliver, 1970), whilst above this level, 
when the FFA/ albumin molar ratio exceeds 2, the proportion of unbound FFA 
i ncreases. Experimental studies (Spector, 1968; Willebrands et al, 1973) 
have shown that myocardial uptake of FFA increases when the FFA/ albumin 
molar ratio is elevated so that unbound circulating FFA increase. In 
order to determine any association between very high FFA concentrations 
and the complications of AMI, a level of 1.5 mM/1 was arbitrarily used as a 
dividing point. 
Treatment 
14 8 
All patients received intravenous morphine, metoclopromide or 
prochlorperazine as required, and oral diazepam was given three times daily 
to most patients. Arrhythmias were treated as stated below. Other 
essential treatment was initiated or continued as before, and included 
furosemide, a-adrenergic blockers, sodium nitroprusside, methyldopa, digoxin, 
allopurinol, colchicine, disopyramide, lignocaine, procainamide and warfarin. 
None of this therapy has been shown to alter FFA concentrations with 
t he exception of a-blockers, which were considered essential to the manage-
ment of 4 patients (Numbers 9, 12, 19 and 35). The possible effects of 
a-blockade on FFA concentrations have been discussed in Chapter VI. Plasma 
potassium levels were measured at the first opportunity in all patients, 
and patients whose plasma potassium was less than 4.0 mM/1 were given 
effervescent potassium supplements until a level of 4.0 mM/1 was reached, 
unless the initial level was less than 3.5 mM/1, in which case intravenous 
potassium was given. No patients had a plasma potassium of less than 
4 .0 mM/ 1 within, at the most, one hour of the recorded arrhythmias. 
Calculation of infarct size index 
!SI was calculated according to the method described in Chapter III, 
where details concerning infarct size measurements in patients 5, 6, 11 
and 33 are also given. Patients were divided according to !SI <40 or 
>40 CK-g-eq/ m2 because of the significant differences in mortality and 
heart function found by Shell and Sobel (1976) in patients divided in this 
way . 
Patient Number 11 had an extension of his infarction approximately 
28 hours after the initial episode. Duration of chest pain on admission 
and ventricular arrhythmias in the first 24 hours could only be related to 
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the initial episode, whilst congestive heart failure and 6-month mortality 
were related to the total extent of infarction. Two figures are 
therefore given for !SI in Tables 1 and 2, the first relating to the initial 
infarct and the second to the combined initial infarct plus the extension 
( 21 and 55 CK-g-eq/m2 , respectively). 
Ventricular arrhythmias 
Only ventricular arrhythmias occurring within 24 hours of the onset 
of symptoms were considered. Patients with ventricular fibrillation were 
not studied because of the effect of DC cardioversion on CK activity. The 
first episode of ventricular tachycardia (defined as a run of three or more 
consecutive ventricular premature beats), of second or third degree heart 
block or of a ventricular premature beat (VPB) rate of greater than 30 per 
minute lasting for at least one minute was recorded in each patient. 
Appropriate treatment was given immediately for ventricular tachycardia; 
a VPB rate of greater than 30 per minute was only treated if prolonged, if 
the R-on-T phenomenon was observed or if there were paired, or multifocal 
VPBs. The number of times each arrhythmia was observed, whilst noted, was 
not included iri this study because of the varying efficacy of the anti-
arrhythmic therapy. Arrhythmias were continuously monitored as described. 
Duration of chest pain 
Duration of chest pain was timed from the onset of symptoms until 
·the last, effective dose of intravenous morphine was giv~n in the coronary 
care unit. Many patients received analgesia prior to admission, and 
were subsequently treated as often as requi~ed to remain pain-free. In 
11 cases the duration of pain was less than half an hour, having passed 
spontaneously or as a result . of an analgesic, and in these cases the 
duration was recorded as zero hours. 
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Duration of CK release 
The duration of CK release was measured from the time of onset of 
symptoms until the serum release curve reached a plateau (see example, 
Figure 1, Chapter III). 
Heart Failure 
Patients with heart failure were classified by the method of Killip 
and Kimball (1967) as described in Chapter I. 
Post-mor,tem studies 
Patients Numbers 1 and 5 underwent post-mortem examination and were 
reported as having well defined homogenous infarcts, both macroscopically 
and histologically. 
RESULTS 
Relevant clinical and biochemical data and the complications of AMI 
in the 36 patients studied are shown in Table 1. There was no correlation 
between the site of the infarct (anterior or inferior) and ISI, FFA 
concentrations, or any of the complications. 
a. Infarct size index and complications 
Twenty patients with ISI <40 CK-g-eq/m2 were compared with 11 patients 
whose ISI was ~40 CK-g-eq/m2 (Table 2). Duration of CK release was greater 
in the patients with large than in the patients with small ISI (46 ! 5 and 
34 ! 3 hours respectively, t = 2.365, P<0.05) but the time after onset of 
. symptoms at which the peak CK release occurred was similar in the two groups. 
There was no difference in the duration of chest pain, the frequency of 
ventricular arrhythmias, or the 6-month mo~tality when the two groups were 
compared. Mean ISI in patients who died within 6 months was not 
significantly different from that in patients who survived (47 ! 12 and 
30 ! 4 CK-g-eq/m2 respectjvely). Elimination of patients with previous 
infarcts made no difference to these results. Mean ISI in 4 patients 
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with newly developed heart failure was larger (74 + 16 CK-g-eq/m2) than in 
+ I 2 25 patients who did not develop heart failure (31 5 CK-g-eq m , t = 3.3, 
P<0.01). Whilst all patients with newly developed heart failure had 
ISI ~40 CK-g-eq/ m2, and none of the patients with ISI <40 developed 
heart failure, these differences were not statistically significant. 
b . Free fatty acid concentrations and complications 
Patients were compared according to peak FFA concentrations (Table 3) 
and mean FFA concentrations (Table 4) within 12 hours of AMI. There was 
no difference in duration of chest pain, 6-month mortality, or the 
frequency of ventricular arrhythmias or heart failure when groups of 
patients divided according to the following peak FFA concentrations were 
compared: ~1.2 mM/1 and >1.2 mM / 1, <1.5 mM/1 and ,1.5 mM/ 1, and ~1.2 mM / 1 
and ,1.5 mM/ 1 (Table 3). 
Mean FFA concentrations correlated strongly with peak FFA concen-
trations in the first 12 hours of AMI (r = 0.797, P<0.001, Figure 1), but 
peak concentrations were significantly higher than mean concentrations and 
onl y 12 of the 20 patients with peak FFA concentrations greater than 1.2 mM/ 1 
had mean FFA concentrations greater than 1.2 mM/1 during this time. 
Significant differences were found when mean FFA concentrations in 
the first 12 hours of AMI were considered (Table 4 ,Figure 2 ) . More 
patients with mean FFA concentrations greater than 1.2 mM / 1 had ventricular 
.tachycardia as compared with patients whose mean FFA concentrations were 
1 .2 mM/1 or less (83% and 35% respectively, P<D.05, Figure 2). All 12 
patients with mean FFA concentrations greater than 1.2 mM / 1 had ventricular 
or heart block compared with 8 of the 23 patients with mean FFA concentrations 
of 1.2 mM/1 or less (P<0.002). No significant differences were observed 
for any of the other complications. 
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DISCUSSION 
This study comprised two distinct parts: the correlation of 
specified complications of AMI with infarct size, expressed as the infarct 
size index, and with plasma FFA concentrations in the first 12 hours after 
onset of symptoms. The former part of the study was not intended to 
explore new ground, but to compare the results with those of previously 
reported studies as a measure of the validity of this method of sizing 
infarcts. The conflicting results require explanation. 
Of greater importance is the second part of the study, as this was 
the first time that regular, serial estimations of plasma FFA concentrations 
had been made within 12 hours of the onset of AMI and correlated with the 
incidence of ventricular arrhythmias and other complications. 
Infarct size index and complications of AMI 
No correlation was found between infarct size index and the duration 
of chest pain after the onset of symptoms of AMI, contrary to the findings 
of Mathey et al (1975) and Inoue et al (1977). There are good theoretical 
grounds for believing that the .duration of chest pain might be related to 
the extent of infarction because, though the exact mechanism of cardiac 
pain remains unknown ( Inoue et al, 1977), it has been observed that pain 
ceases once the ischaemic myocardium has died (Friedberg, 1966). 
Continuing pain therefore suggests continuing ischaemia, though it does not 
. follow that all ischaemic tissue will ultimately undergo necrosis. 
Mathey et al (1975) observed that patients with a longer duration of CK 
release had larger infarcts and chest pain persisting longer than patients 
with a short duration of CK release. Inoue et al (1977) reported similar 
findings: prolonged chest pain was associated with a longer duration of 
CK release , total CK release being greater in these patients and the major 
release of CK occuured during chest pain. They noted that CK release was 
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shorter in patients who had suffered a previous infarction, but elimination 
of such patients did not alter the results of the present study. A 
number of factors may have been responsible for the present results. The 
efficacy of analgesia given prior to admission was difficult to assess, 
as chest pain might have subsided spontaneously. Analgesia given in this 
hospital might have been more effective and have lasted longer than in the 
other studies. Pain is a very subjective sensation, so the possibility 
that it was over-reported by some and under-reported by other patients, even 
under careful direct questioning, must be considered. The patients in 
the present study who had larger infarcts need not necessarily have had 
prolonged ischaemia, even though larger infarcts were associated with a 
longer duration of CK release than ·smaller infarcts (P<0.05). This 
observation may be explained by the experimental findings of Cairns et al 
(1978) that homogeneous infarcts were associated with a later cumulative 
CK plateau than scattered infarcts. In contrast, necropsy in patients 
with short duration of CK release and chest pain in the study of Mathey 
et al (1975) revealed homogeneous infarcts, whilst patients with prolonged 
CK release and pain showed a heterogeneous composition of the infarcted 
myocardium. If myocardial infarction in all the patients studied 
here was the result of rapid necrosis without prolonged ischaemia, the lack 
of prolonged chest pain might be explained. This possibility is 
supported by the fact that the time of peak CK release occurred at 
similar times after the onset of infarction in patients with large and patients 
with small IS!. In such cases the intensity rather than the duration of 
chest pain might be relevant. An attempt to define the intensity of 
chest pain, using the criteria of Waagstein and Hjalmarson (1975) was 
abandoned owing to the lack of objectivity which was noted in several 
patients during the acute phase of their infarction. Retrospective 
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assessment could not be made in many patients owing to partial amnesia 
brought on by heavy sedation. 
Patients in this study who died within 6 months did not have 
significantly larger !SI than those who survived. Patients with shock 
were excluded from the study because of the large increase in extracardiac 
CK noted in such patients, and the only comparable reports are those of 
Sobel et al (1972) and Shell and Sobel (1976), where patients with shock 
were also excluded. In both studies patients with large infarcts 
(EIS ~65 GK-g-eq and !SI ~40 CK-g-eq/m2 respectively) had a significantly 
higher 6-month mortality (67% and 68% respectively) than patients with 
smaller infarcts (5% and 2% respectively). No explanation for the 
conflicting results can be given - overall mortality in the three studies 
was similar (27%, 23% and 32% respectively) and the method of estimating 
infarct size was identical. However, Bleifeld et al (1977), who included 
patients with shock, concluded that infarct size alone, calculated from 
serial CK measurement, could not predict mortality. In an earlier study 
(Mathey et al, 1974) the same authors had found that the combination of 
haemodynamic changes and infarct size was able to predict immediate and 
long-term prognosis; in this study haemodynamic measurements were not 
made, which with the small numbers involved, may explain the lack of 
agreement between the present and previous reports. 
Fall-off in ventricular function in relation to loss of viable 
myocardium is an accepted sequence (Braunwald, 1976), and has been 
demonstrated in several studies. Loss of 32% and 40% of the left ventricle 
resulted in cardiogenic shock (Harmarayan et al, 1970; Page et al, 1971) 
and the early development of shock in patients with AMI was associated 
with larger areas of necrosis at post-mortem than in patients who developed 
shock late (Caulfield et al, 1976). The degree of left ventricular 
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impairment, as assessed by haemodynamic measurements (Kostuk et al, 1973; 
Mathey et al, 1974; Shell & Sobel, 1976; Hori et al, 1979) and by the 
clinical manifestations of heart failure (Sobel & Shell, 1972; Norris 
et al, 1975; Bleifeld et al, 1976), correlated well with the extent of 
estimated infarction. In this study 6 patients had heart failure, but 
in 2 it was pre-existing. Mean !SI in the 4 patients with new failure 
was higher than in the 25 patients with no failure (74 and 31 CK-g-eq/m2 
respectively, P<0.01), and all the former patients had !SI greater than 
2 40 CK-g-eq/ m . 
· Ventricular arrhythmias were not significantly more common in patients 
with large than with small infarcts. Ventricular ectopic beats occurring 
at a rate of more than 30 per minute were seen with equal frequency in 
both groups, both patients with second or third degree heart block had 
small infarcts, and though ventricular tachycardia was seen more frequently 
in patients with large than with small infarcts, the difference was not 
significant, nor was mean !SI in 17 patients with VT greater than mean 
ISI in 14 patients without (41 ! 8 and 26 ! 5 CK-g-eq/m2 respectively). 
Comparison with other studies is difficult. Both Roberts et al (1975) 
and Cox et al (1976) studied the frequency of premature ventricular beats 
and the amount of therapy required to treat them and found a positive 
correlation with infarct size index. Only the first episode of 
prolonged and frequent (>30 beats/min) ventricular ectopic activity was 
recorded here however; this may not reflect either overall ventricular 
ectopic activity or the peak rate of activity, and its value as an index 
of ventricular irritability may be questioned. Roberts et al (1975) 
found a significant correlation between the incidence of ventricular tachy-
cardia and coupled ventricular ectopic beats, taken together, and IS!. 
The incidence of each individual arrhythmia was not recorded so no 
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comparison can be made with the present study, where the incidence of 
coupled VPBs was not recorded. All that can positively be stated as 
a result of this study is that VT and infarct size were not significantly 
related, although proportionately more patients with VT had larger infarcts. 
Early treatment of VPBs in some patients might have prevented the develop-
ment of VT, and spontaneously remitting VT might have occurred prior to 
admission, but otherwise it is very unlikely that any episode of VT was 
missed. Infarct size per se might not be entirely responsible for the 
genesis of arrhythmias however, and concurrent metabolic and haemodynamic 
disturbances might also play a part. 
Plasma free fatty acid concentrations and complications 
of AMI 
The lack of any correlation between duration of chest pain, 6-month 
mortality, heart failure and ventricular arrhythmias with single peak FFA 
concentrations within 12 hours of infarction, whether above or below 
1.2 mM/1 or 1.5 mM/1, may have a very fundamental explanation. Transient 
FFA peaks greater than 1.2 mM/1, or even 1.5 mM/1, need not result in 
manifestations of myocardial toxicity if FFA concentrations rapidly fall 
again and to levels where all circulating bound FFA can once again be bound 
by albumin. The overall duration of elevation FFA concentrations might . 
be more pertinent. This could explain the conflicting results of previous 
experimental studies. Oliver et al (1968), Gupta et al (1969) and 
Prakash et al (1972) found an association between raised FFA concentrations 
after AMI and some of the complications of AMI, particularly ventricular 
arrhythmias, but these results could not be confirmed by Rutenberg et al 
(1969) or by Hagenfeldt and Wester (1973). A feature common to all these 
studies was infrequent sampling for FFA estimation, as described in detail 
in Chapter VI. 
Mean FFA concentrations in the 12 hours post-infarction were studied 
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because this was the duration of FFA elevation in most patients and 
because, as argued above, it was felt that any adverse effects of FFA would 
be most likely to appear when FFA concentrations were consistently high. 
FFA levels were estimated as soon as the patient was admitted to hospital 
and then hourly, where possible, or at the most 2-hourly. The number 
of estimations within 12 hours of infarction varied from 4 to 11 (mean! 
SEM 7.0 ! 0.3). The correlation between mean and peak FFA concentrations 
i n the first 12 hours of AMI was very strong (r = 0.797, P = <0.001, 
Figure 1) , but peak values were significantly higher than mean values and 
only 12 of the patients with peak FFA greater than 1.2 mM / 1 had mean FFA 
greater than 1.2 mM/ 1. Patients with mean FFA concentrations greater 
t han 1.2 mM/ 1 (high mean FFA concentrations) in the first 12 hours post-
i nfarction were therefore compared with patients with mean values of 1.2 mM / 1 
or less ( low mean FFA concentrations). 
A possible p9sitive association between duration of chest pain after 
ru~I and the degree of FFA elevation was sought in view of the suggestion 
by Opie (1971 ) that pain might result in anxiety which might in turn result 
i n further elevation of plasma FFA concentrations. No such association 
was found, though early and effective sedation with oral diazepam and 
intravenous morphine might have been the cause. Melsom et al (1976) found 
reduced catecholamine excretion in patients sedated with diazepam after 
AM I; since catecholamines can activate the release of FFA into the 
~ . 
circulation (Gordon & Cherkes, 1956; Carlso et al, 1965; Pinter et al, ~ 
1967 ) any reduction in anxiety-mediated catecholamine release may prevent 
an associated rise in FFA concentration. Any anxiety-related rise in 
FFA might be dependent on the severity rather than the duration of chest 
pain, but the severity was not measured, for reasons stated above. 
although no relation between chest pain and FFA concentrations were 
Thus, 
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apparent after AMI in this study~ the results were not conclusive. 
Mean FFA concentrations did not correlate with heart failure or 6-
month mortality. Although none of the previous clinical studies found 
relationship between FFA concentrations and heart failure (Kurien & Oliver, 
1966; Oliver et al, 1968; Rutenberg et al, 1969; Gupta et al, 1969), FFA 
concentrations were higher in patients who were more seriously ill 
(Oliver et al, 1968; Gupta et al, 1969; Allison et al, 1969). Oliver et al 
(1968) were able to correlate FFA concentrations in excess of 1,2 mM/1 with 
the incidence of shock and late deaths, but these findings were not 
confirmed by Rutenberg et al (1969), despite their observation that FFA 
concentrations were elevated at the time when patients developed shock or 
heart failure. The authors suggested that FFA elevation at these times 
was effect, possibly catecholamine-mediated, rather than cause. 
Of possible clinical significance was the very strong association 
observed between serious ventricular arrhythmias (ventricular tachycardia 
and second and third degree heart block) in the first 24 hours of AMI and 
mean plasma FFA concentrations greater than 1.2 mM/1 in the first 12 hours 
(Figure 2). These findings correspond with those of Oliver et al(1968), 
Gupta et al (1969 ) and Prakash et al (1972), and contradict those of 
Rutenberg et al (1969) and Hagenfeldt and ·Wester (1973), but the possible 
influence of infrequent sampling in those studies, as described above, 
may make any comparisons invalid. FFA concentrations were closely 
monitored, but for short periods, in three studies (Gupta et al, 1969; 
Russo et al, · 1970; Nelson, 1970) where heparin was infused in normal 
therapeutic doses in patients with AMI in order to detect whether the 
ensuing FFA rise would provoke ventricular arrhythmias, as had been 
suggested might happen by Kurien et al (1969). Peak plasma FFA of well 
over 1.2 mM/ 1 were achieved in most patients, with no increase in ventricular 
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arrhythmias. These studies were not conclusive however, and comparison 
with the FFA rise provoked by AMI may be invalid for two reasons. First, 
the duration of the study period was short (the longest period reported 
was two hours by Russo et al (1970), whilst after AMI abnormally high FFA 
concentrations may be found for up to 12 hours, if not longer (Kurien & 
Oliver, 1966; Oliver et al, 1968). Second, AMI provokes a generalised 
metabolic response (Opie, 1971) of which elevation of FFA concentrations 
is only one part. FFA elevation in isolation might therefore not be 
sufficient to provoke arrhythmias, and there is some evidence that 
circulating catecholamines, which also increase after AMI (Gazes et al, 
1959; McDonald et al, 1969; Siggers et al, 1971; Christensen & Videbaek, 
1974; Vetter et al, 1974) may sensitize the myocardium to the effects of 
FFA, as shown in experimental (Opie et al, 1971; Opie, 1975) and clinical 
(Simonsen & Kjekshus, 1978) studies. 
In view of the high mortality and morbidity associated with AMI, 
which represents the most common serious health problem of contemporary 
western society (Braunwald, 1976), no available therapeutic approach should 
be neglected. The association between high FFA levels and arrhythmias 
observed in this study, lends support to the hypothesis that FFA play a 
role in the genesis of cardiac arrhythmias after AMI (Kurien & Oliver, 1970). 
In view of the reduction in serious, ventricular arrhythmias after ~he 
initiatioQ of early, effective antilipolytic (Rowe et al, 1975) the 
inclusion of such therapy might be justified as an integral part of the 
management of all patients with AMI. 
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Figure 1 · 
Correlation between peak and mean FFA concentrations in 
the first 12 hours of acute myocardial infarction. 
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Percentage of patients with ventricular tachycardia or heart 
block (20 or 30) according to whether mean FFA >1 . 2 mM/l or 
<1 . 2 mM/l in the first 12 hours of AMI . 
CHAPTER VIII 
THE RELATION BETWEEN PLASMA FREE FATTY ACIDS IN 
THE FIRST 12 HOURS OF ACUTE MYOCARDIAL INFARCTION 
AND INFARCT SIZE - A PROPOSED METABOLIC VICIOUS 
CIRCLE 
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16? 
INTRODUCTION AND PURPOSE OF THE STUDY 
Myocardial ·infarct size, as measured by the enzymatic method of 
Shell et al (1971), has been reported as influencing prognosis (Sobel et 
al, 1972; Mathey et al, 1974; Shell & Sobel, 1976; Bleifeld et al, 1977) 
and morbidity (Sobel et al, 1972; Norris et al, 1975; Roberts et al, 1975); 
Bleifeld et al, 1976; Cox et al, 1976) after acute myocardial infarction. 
Other studies (Maroko et al, 1972; Pierce et al, 1973; Maroko & Braunwald, 
1973; Maclean et al, 1978) have shown that myocardial infarction is a 
dynamic process, which can be modified by therapy initiated early enough 
after the onset of symptoms. Thus the identification of any factor 
which may have a harmful effect on the ischaemic myocardium would have 
important prognostic and therapeutic implications. 
Plasma free fatty acids may be one such factor. Concentrations 
were raised in patients with AMI (Kurien & Oliver, 1966; Oliver et al, 
1968; Janusjewicz et al, 1971; Christensen & Videbaek, 1974), within one 
hour of the onset of symptoms (Kurien & Oliver, 1966; Vetter et al, 1974). 
Experimental evidence suggests that elevated FFA concentrations may 
increase both the degree and the extent of myocardial ischaemia (Kjekshus 
& Mj~s, 1973) as monitored by epicardial ST-segment elevation and that 
treatment to reduce plasma FFA concentrations may reduce the degree of 
ischaemia (Mj~s et al, 1975) and the extent of necrosis (Kjekshus & Mjds, 
/ 
1973) after coronary artery ligation in the dog. Clinical studies have 
shown that reduction of FFA levels can reduce the degree of myocardial 
ischaemia, as monitored by precordial ST segment elevation, in patients 
with ischaemic heart disease (Luxton et al, 1976) and in patients with 
acute myocardial infarction (Russell & Oliver, 1978). Whilst there is 
evidence that FFA can influence the degree of myocardial ischaemia 
in patients, information concerning the 
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relationship between FFA concentrations and the extent of myocardial 
necrosis is inadequate. No correlation was found between FFA levels and 
maximum SGOT activity (Kurien & Oliver, 1966) or maximum CK activity 
(Oliver et al, 1968) after AMI, though Vetter et al (1974) subsequently 
found a correlation between mean FFA concentrations in the first 5 hours 
of AMI and the subsequent peak CK and SGOT levels. 
The purpose of this study, therefore, was to investigate the 
relation between enzymatically estimated infarct size and the raised plasma 
FFA concentrations found in the early stages of AMI in man. 
Patients and Methods 
Twenty-eight patients, selected according to the criteria described 
previously and in whom both infarct size and free fatty acid estimations 
were available were included in this study. Biochemical analysis for CK 
activity and FFA concentrations, and calculations of estimated infarct 
size, infarct size index, total cumulative CK release and FFA/albumin 
molar ratio were carried out as detailed in previous chapters. 
Statistical analysis was by Student's t test or by the Mann-Whitney U test 
as appropriate (Appendix C). 
Patient number 5 died before infarct size could be estimated enzyma-
tically, and infarct sizewas therefore determined by weight at post-
mortem, as described in Chapter III. Patient number 11 had an 
extension of his initial infarct approximately 24 hours later; in this 
study FFA concentrations within the first 12 hours were correlated with 
the initial infarct only. 
The patients were divided into two groups according to estimated 
infarct size or infarct size index. Patients were considered to have had 
large infarcts if EIS was 6~ CK-g-eq or greater and if ISI was 40 CK-g-eq/m2 
or greater, because of the significantly higher mortality in these patients 
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as compared with patients with EIS less than 65 CK-g-eq or !SI less than 
40 CK-g-eq/m2 (Sobel et al, 1972; Shell & Sobel, 1976). All patients 
with EIS >65 CK-g-eq had !SI >40 and vice versa. 
Ten of the patients (numbers 1, 2, 3, 5, 7, 8, 9, 10, 11 and 35) 
had a mean oral intake of 256 Kcal given as sucrose, a mean of 6 hours 
after the onset of symptoms. Mean peak FFA in these patients was 
similar to mean peak FFA in the remaining 18 patients, who had been 
deliberately fasted for at least 12 hours after the onset of symptoms 
(mean 1.56 ! 0.21 and 1.44 ! 0.07 mM/1 respectively) so all the patients 
were considered together. 
RESULTS 
Eleven patients had large infarcts and 17 patients small infarcts. 
The relevant details concerning EIS, !SI, total cumulative CK release, 
peak CK activity, peak and mean FFA concentrations, and FFA/albumin molar 
ratios are given in Table 1. 
Patients with large infarcts had significantly higher mean FFA 
concentrations (Table 2) than patients with small infarcts (Table 3) from 
3 to 7 hours after the onset of symptoms of AMI (Figure 1). Mean values 
were similar after 12 hours and had fallen to within the normal range 
(<0.8 mM/1, Oliver et al, 1968) by 24 hours. 
Mean peak FFA concentrations and FFA/albumin molar ratios within 
12 hours of AMI were higher in patients with large than with small infarcts 
( t = 4.46, P<0.001 and t = 3.8, P<0.001 respectively), as were mean FFA 
values within 12 hours (t = 4.44, P<0.001). · 
There were strong positive correlations between peak FFA in the first 
12 hours and EIS (r = 0.68, P<0.001, Figure 2), !SI (r = 0.71, P<0.001; 
Figure 3), total cumulative CK release (r = 0.78, P<0.001, Figure 4) and 
peak CK activity ( r = 0.74, P<0.001). Weaker correlations were noted 
between the mean FFA concentrations in the first 12 hours and EIS 
( r = 0.43, P<0.05), ISI (r = 0.46, P<0.02), total cumulative CK release 
( r = 0.46, P<0.02) and peak CK activity (r = 0.44, P<0.05). 
DISCUSSION 
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This is the first time that .free fatty acid concentrations in the 
early phase of AMI have been studied in relation to the extent of myocardial 
necrosis. Apart from enzymatically estimated infarct size and infarct 
size index, total cumulative CK release and peak CK activity were used as 
less direct measurements of the extent of necrosis. Total cumulative CK 
release bore a direct relationship to the amount of CK depleted ~o the 
myocardium and hence to the extent of necrosis (Shell et al, 1971), and 
was positively correlated with EIS and ISI in this study (r = 0.95). 
Peak CK activity was included so that comparisons could be made between 
the results of this study and those of Oliver et al (1968) and Vetter 
et al (1974). Peak CK activity is theoretically less likely to reflect 
the extent of myocardial necrosis than the total dumulative CK release 
because it takes no account of the amount of CK cleared from the circulation 
prior to the peak value occurrence, or of the amount of CK released after 
the peak. There was nevertheless a positive correlation between EIS 
and peak CK activity in this study (r = 0.8). 
The results of this study showed a positive correlation between 
infarct size and both peak and mean plasma FFA concentrations in the first 
12 hours of AMI. Patients with large infarcts had significantly higher 
mean and peak FFA concentrations and peak FFA/albumin molar ratios than 
patients with small infarcts. FFA levels during the first 12 hours of 
AMI were used because this was noted to be the period when the major FFA 
rise occurred, and although FFA concentrations above the upper limit of 
normal were noted up to 24 hours post-infarct, most of these were well 
below 1.2 mM/1, the level at which the FFA/albumin molar ratio exceeds 
2 and the unbound proportion of circulating FFA may start to increase 
(Kurien & Oliver, 1970). 
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Two possible explanations for the close relation& observed between 
FFA and infarct size are that larger infarcts increase circulating FFA 
concentrations or that raised FFA levels increase infarct size. There 
is evidence to support both sequences. 
The size of a myocardial infarct has been shown to correlate well 
with the subsequent degree of left ventricular dysfunction, which has in 
turn been associated with increased circulating catecholamine levels. 
-Increased catecholamine secretion plays a major role in stimulating 
lipolysis, leading to increased circulating FFA concentrations. Sobel et al 
(1972 ) found significantly higher mean estimated infarct sizes in 
survivors of acute myocardial infarction with clinical left ventricular 
failure than in those with minimal or no failure. Patients with pulmonary 
oedema or congestion on chest X-ray had twice the mean cumulative CK 
release of patients who were free from congestion (Norris et al, 1973). 
Inoue et al (1977) found that patients without clinical failure had a 
shorter period of CK release than patients with failure. Using haemo-
dynamic criteria, infarct size was shown to correlate well with impaired 
left ventricular function (Kostuk et al, 1973; Mathey et al, 1974; 
Rogers et al, 1976; Bleifeld et al, 1976; Inoue et al, 1977; Hori et al, 
1979) . 
Heart failure may, in turn, further increase the circulating 
catecholamine levels, which are initially raised as part of the general 
metabolic response to AMI (Gazes et al, 1959; McDonald et al, 1969; 
Siggers et al, 1971; Griffiths & Leung, 1971; Januszewicz et al, 1971; 
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Lukomsky & Uganov, 1972; Christensen & Videbaek, 1974; Vetter et al, 1974). 
Lukomsky and Uganov (1972) were able to link enhanced blood-catecholamine 
values with left ventricular failure, whilst Gupta et al (1969) found a 
higher urinary excretion of noradrenaline and adrenaline of the first day 
of AMI in patients with left ventricular failure, congestive heart failure 
or shock. Jewitt et al (1969) and Prakash et al (1972) reported similar 
findings. Catecholamines probably play a major role in stimulating 
lipolysis from adipose tissue (Gordon & Cherkes, 1956; Carlson et al, 
1965; Pinter et al, 1967). 
Fasting has also been reported as increasing plasma FFA concentrations 
(Opie, 1972), so that patients with larger infarcts, who might be expected 
to feel more ill than patients with small infarcts, could be less willing 
to eat and the resulting fast might contribute to the higher FFA 
concentrations found. In this study starved patients did not have higher 
peak or mean FFA concentrations than those given sucrose orally a mean of 
6 hours after the onset of symptoms, so that fasting in the first 12 hours 
of Al~I did not appear to influence FFA concentrations. 
The results of these studies strongly support a catecholamine-
mediated relationship between the extent of myocardial ischaemic injury 
and the extent of the rise in circulating FFA levels after AMI. There is 
also experimental and clinical evidence that raised FFA concentrations may 
inciease myocardial ischaemic injury, in~ependent of the effect of 
catecholamines. It is therefore proposed that the very high FFA 
concentrations .observed in patients with large infarcts may not only 
reflect the severity of the infarct process, but may also increase the 
infarct size by means of a vicious circle, as illustrated in Figure 5. 
The evidence for this hypothesis is as follows. Firstly, studies 
with experimental myocardial infarction have shown that increasing the FFA 
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concentrations can extend the ischaemic damage as demonstrated by 
increased enzyme release from the heart Kjekshus & Mj0s, 1972; de Leiris 
et al, 1975), impaired myocardial function (Mj0s, 1971; Liedtke et al, 
1978) increased epicardial ST segment elevation (Kjekshus & Mj0s, 1972) and 
by increased microscopic mitochondrial abnormalities (de Leiris & 
Feuvray, 1977). Conversely lowering plasma FFA by antilipolytic agents 
such as s-pyridylcarbinol, its analogues, or glucose-insulin-potassium 
infusions can decrease ischaemic injury, as shown histologically or by 
increased epicardial ST segment elevation (Maroko et al, 1972; Mj0s et al, 
1976; Opie & Owen, 1976; Mjds et al, 1976) and by marked reduction in 
myocardial CK depletion after coronary artery ligation (Kjekshus & Mj0s, 
1973 ) . Furthermore, decreased FFA use by the ischaemic zone appears 
to be one way by which s-adrenergic blockade can beneficially influence 
the outcome of experimental myocardial infarction (Opie & Thomas, 1976). 
Secondly, there is clinical evidence. Treatment with anti-
lipolytic agents decreased precordial ST segment elevation in patients 
with myocardial ischaemia (Luxton et al, 1976) and infarction (Russell & 
Oliver, 1978). Although Oliver et al (1978) found no correlation between 
\ 
peak CK activity and plasma FFA levels after AMI, a subsequent study 
(Vetter et al, 1974), in which FFA estimations were carried out earlier 
and more frequently, demonstrated ·a positive correlation (r = 0.9) 
between mean FFA concentrations in the first 5 hours of AMI . and peak CK 
activity. Peak CK activity may have limitations as an index of the 
extent of myocardial necrosis (Wilkinson, 1970; Posen, 1970) but it never- : 
theless correlated strongly with estimated infarct size in the present 
study ( r = 0.8). 
The mechanism of FFA toxicity has not yet been fully elucidated but 
may include increased myocardial oxygen consumption (Mj0s, 1971; Kjekshus 
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& Mj~s, 1972; Mj~s et al, 1974; Liedtke et al, 1978; Simonsen & Kjekshus, 
1978), endogenous lipolysis (Kurien & Oliver, 1970), and decreased 
glucose use (Opie, 1970). Arrhythmias, which may be induced by high 
FFA concentrations after AMI (Oliver et al, 1968; Gupta et al, 1969; 
Prakash et al, 1972), could indirectly increase infarct size (Adgey et al, 
1971 ) by causing haemodynamic imbalance (Fozzard, 1976) and by increasing 
myocardial oxygen consumption (Shell & Sobel, 1973b). There is also 
evidence that catecholamines may sensitize the myocardium to the effects 
of circulating FFA (Opie et al, 1971b; Kjekshus & Mjds, 1972; Kjekshus & 
Mjds, 1973; Simonse~ & Kjekshus, 1978). 
It could be argued that, since increased circulating catecholamines 
can per se increase myocardial ischaemic damage (Raab et al, 1962; Jewitt 
et al, 1969; Herbaczynska-Cedro, 1970), the intermediate action of FFA 
is not necessary for the establishment of another vicious circle 
involving infarct size and catecholamine secretion. The independent, 
harmful action of FFA has, however, been demonstrated in the isolated 
rat heart (de Leiris et al, 1975), in dogs (Mjds, 1971; Mjds et al, 1974), 
and in man (Simonsen & Kjekshus, 1978). Thus catecholamines probably 
act both directly and by increasing circulating FFA concentrations to 
increase the severity of ischaemic injury in patients with developing 
infarction. The administration of therapy to lower FFA concentrations 
very early after AMI might therefore reduce the extent of myocardial 
necrosis, though this effect has yet to be studied. 
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Table 1 FFA AND INFARCT SIZE MEASUREME
NTS IN 11 PATIENTS WITH LARGE AND 17 PATIENTS 
WITH SMALL INFARCTS 
Total 
Estimated Infarct size cumulated Peak CK 
Peak FFA/ 
Patient Age infarct size index CK
 release activity Peak FFA Mean FFA albumin 
Number ( lears ) (CK-g-eg. ) (CK-g-eg/m2 ) (i.u. / 1) 
(i.u. / 1) (mM/ 1 ) (mM/ 1) molar ratio 
Graue I - Large estimated infarct size (n=11 ) 
1 43 195 91 3
898 1307 2.39 1. 24±0 .17 3.5 
3 49 117 69 362
9 2030 2.23 1.2 ±0.24 3.8 
5 69 110 52 
2.58 1.62±0.15 4.5 
16 41 262 119 4672 
1796 2.05 1.24±0.10 3.5 
17 64 125 68 2977 
1223 1.68 1.14±0.09 2.9 
21 48 88 55 2616 
1465 1.79 1.14±0.14 3.0 
24 39 77 41 1934 
991 1.38 1.27±0.03 2.3 
27 54 131 66 3021 
1152 1.59 1.50±0.04 2.4 
28 58 94 46 1925 
872 1.58 1.25±0.08 2.3 
29 58 76 40 1731 
1129 1.49 1.05±0.12 2.2 
31 37 108 64 3043 
1389 1.64 1.32±0.07 2.5 
Mean 51 126 65 
1.85 1.29* 3.0 
(±SEM) ( ±SD 11 ) (±17) (±7) (±0
.12) (±0.04) (±0.2) 
Graue II - Small estimated infarct size (n:17) 
2 48 19 10 482 16
9 1.35 0.78±0.13 2.4 
7 66 36 20 956 503 
1.96 1.34±0 .11 3.3 
8 51 32 16 744 246 
0.86 0.72±0.05 1.6 
9 46 26 14 698 465 
1.2 0.63±0.10 2.0 
10 33 46 25 1233 649 
1.04 0.58±0.09 1. 7 
11 43 44 21 983 926 
1.23 1.05±0.06 2.1 
13 39 9 4 185 122 
0.87 0.66±0.05 1.4 
15 66 58 31 1340 552 
1.57 1.47±0.03 2.5 
18 37 59 30 1286 389 1.05
 - 0.89±0.04 1.7 
19 61 34 21 1121 850 1
.23 1.0 ±0.06 2.3 
20 55 52 34 1804 1075 
1.63 1.31±0.08 2.9 
22 54 31 18 591 265 
1.58 1.48±0.04 2.5 
23 58 17 9 393 239 1
.14 0.81±0.10 2.0 
25 55 54 23 767 340 0
.98 0.89±0.06 1. 7 
30 53 26 13 636 467 1.16
 1.04±0.04 1. 8 
34 61 19 10 404 274 1.55
 1.46±0.05 2.3 
35 63 19 10 434 255 0.77 0
.55±0.08 1.8 
Mean 52 34 18 1.25 0.9
4* 2.1 
(±SEM) ( ±SD 10 ) ( ±4) ( ±2 ) (±0.01) (±0.04) (±0.1 ) 
p <0.001 <0.001 <O.OG1 
*Calculated from all FFA values within 12 hours of acute myocardial
 infarction. 
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HOURS AFTER ONSET OF SYMPTOMS 
Figure 1 
Mean FFA concentrations in 11 patients with large and 17 
patients with small EIS in the first 72 hours of AMI. 
Patients with large infarcts had higher mean FFA levels 
at 3, 4, 5, 6 and 7 hours post-infarct. 
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Figure 3 
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Proposed metabolic vicious circle in acute myocardial 
infarction . 
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CHAPTER IX 
THE EFFECT OF ORAL SUCROSE ON PLASMA FREE FATTY 
ACIDS IN THE EARLY PHASE OF ACUTE MYOCARDIAL 
INFARCTION 
183 
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INTRODUCTION AND PURPOSE OF THE STUDY 
The increase in plasma free fatty acid concentrations which occurs 
in the early stages of acute myocardial infarction (Kurien & Oliver, 1966; 
Oliver et al, 1968; Janusjewicz et al, 1971; Christensen & Videbaek, 1974; 
Vetter et al, 1974) correlates with arrhythmias (Oliver et al, 1968; 
Gupta et al, 1969; Prakash et al, 1972; Chapter VII, present study) and 
with infarct size (Vetter et al, 1974; Chapter VIII, present study). It 
has been proposed that such increases in FFA have harmful effects in the 
i schaemic myocardium (Kurien & Oliver, 1970; Kurien et al, 1974; Opie, 1975), 
whilst lowering FFA levels by inhibition of lipolysis may help to reduce . 
t he severity of ischaemic injury (Luxton et al, 1976; Russell & Oliver, 1978). 
Blood FFA rise within 2 hours after the onset of symptoms of AMI (Vetter 
et al, 1974), but most patients seek help after this time (Armstrong et al, 
1972 ) . If lowering FFA concentrations were beneficial it would be 
desirable to do so as early as possible after the onset of symptoms of AMI, 
and a cheap and easily available substance which could be administered 
either by a physician or by the patient would be extremely valuable. 
Oral carbohydrate can lower FFA in normal persons (Gordon & Cherkes, 
1956; Swan et al, 1965) and in patients with AMI (Oliver et al, 1972; . 
Opie et al, 1975), so the effects of oral carbohydrate, in the form of 
sucrose, on plasma FFA and glucose in the early stages of AMI were studied. 
·Patients and Methods 
The 22 patients who took part in this study were selected according 
to the criteria outlined in Chapter I and were assigned to one of two groups 
by random numbers. A venous blood sample was taken on admission to 
hospital and the first group (sucrose-fed) received sucrose orally as soon 
as a second blood sample had been taken one hour later, after which they 
were starved until at least 12 hours had elapsed since the onset of symptoms. 
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The second group (starved) were starved for at least 12 hours after the 
onset of AMI. Both groups of patients were allowed to drink water. 
Sucrose was given as a 25 g/100 ml solution in water flavoured with pure 
lemon juice. Mean ages (! SD) were 50 ! 10 years (range 33 - 69 years) 
in the sucrose-fed group and 53 ! 11 years (range 37 - 69) in the starved 
group. + Sucrose-fed patients received a mean of 90 - 9 grams of sucrose 
( range 50 - 150 grams). 
Blood sampling, storage, biochemical estimations of FFA and glucose, 
and calculations of infarct size were carried out as described in Chapters 
I, II and III. The t test or the Mann-Whitney U test, as identified in 
the text, were used for statistical analysis (Appendix C). 
RESULTS 
Eleven sucrose-fed and 11 starved patients were studied. All the 
sucrose-fed patients were male and one of the starved patients was female. 
The relevant biochemical and pharmacological details are given in Tables 
1 and 2. Mean time of admission was similar in the sucrose-fed and 
starved groups (4.5 ! 0.6_and 4.6 ! 0.6 hours after the onset of symptoms 
respectively) as was the mean time of the peak FFA (7.9 ! 0.9 and 
7.5 ! 0.08 hours after the onset of symptoms respectively) and the mean 
peak FFA concentration (1.49 ! 0.21 and 1.48 ! 0.04 mM/1 respectively). 
One sucrose-fed patient and two starved patients received e-adrenergic 
· blockers during the study period; the pOS$ible influence on FFA levels is 
discussed in Chaper VI. 
The mean plasma FFA and glucose concentrations in the sucrose-fed 
and starved patients in the first 12 hours after the onset of myocardial 
infarction are shown in Table 3 and Figure 1. FFA levels were consistently 
higher in starved than in sucrose-fed patients in the 6 hours following 
+ the administration of sucrose, a mean of 5.6 - 0.6 hours after the onset 
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of symptoms. 
Table 4 and Figure 2 show mean FFA and glucose concentrations in 
the two groups from the time of admission and from the time of sucrose 
administration (since sucrose was given one hour after the admission in all 
patients ) . In the sucrose-fed patients, mean glucose levels rose by 
40 mg/ 100 ml to a peak of 161 ! 17 mg/ 100 ml in the 2 hours following sucrose 
administration (P<0.05, U = 13, Mann-Whitney U test, compared with mean 
glucose levels in starved patients). Mean FFA levels fell by 0.38 mM/1 
i n the 3 hours following sucrose administration, whilst FFA levels in the 
s tarved group did not change significantly during the comparable period. 
Mean FFA concentrations were sig~ificantly lower in the 5-hour period 
f ollowing sucrose administration in the sucrose-fed than in the starved 
patients (0.85 ! 0.08 and 1.12 ! 0.05 mM/1 respectively; t = 2.14, 
degrees of freedom 61, allowing for unequal variances, P<0.05). 
In view of the similar mean interval between the onset of symptoms 
and the peak FFA in the two groups, mean FFA concentrations were adjusted 
so that individual peak FFA values coincided with time zero (Table 5, 
Figure 3) . The rate of fall from mean peak levels was similar in 
sucrose-fed and in starved patients in the 2 hours following the peak. 
There was then an early rebound in FFA levels in the starved patients 
from 3 to 5 hours after the peak, at which time the mean FFA concentration 
_was significantly higher than in the sucrose-fed patients (P<0.05, U = 29, 
Mann-Whitney U test); mean FFA levels then fell to within normal limits 
11 hours after the peak. In contrast FFA levels in sucrose-fed patients 
remained lower initially but there was a later rebound to abnormal levels 
from 9 to 18 hours after the peak. 
Table 6 compares the mean fall in FFA concentrations from the peak 
level to the nadir in subgroups of the sucrose-fed and the starved patients 
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according to the peak FFA level or the amount of sucrose administered. 
Patients with peak FFA 1.5 mM/1 or greater had larger estimated infarct 
sizes (115 ! 32 and 103 ! 35 CK-g-eq in sucrose-fed and starved patients 
+ respectively) than patients with peak FFA less than 1.5 mM/1 (33 - 5 and 
34 ~ 14 CK-g-eq respectively). The larger FFA fall was always observed 
i n the sucrose-fed patients, though the differences never reached 
significant levels. In patients with peak FFA less than 1.5 mM/1, a 
significantly greater fall in FFA concentrations was observed in sucrose-
fed than in starved patients in the second hour after the FFA peak 
+ . + (0.33 - 0.1 and Oi09 - 0.04 mM/1 respectively, P = 0.036, U = 4, Mann-
Whitney U test) (Figure 4); no differences were observed in patients with 
peak FFA 1.5 mM / 1 or greater (Figure 5). 
DISCUSSION 
Oral sucrose did not modify the peak FFA within 12 hours of the 
onset of symptoms of AMI in the patients studied here. There are a number 
' 
of possible explanations for this. It may be that too little sucrose was 
given, it may have been given too late after the onset of chest pain, it 
may have been poorly absorbed, or it may not have been an effective anti-
lipolytic agent. The dose of sucrose varied between 50 and 150 grams 
(mean 90 grams), which would seem to be an adequate quantity; Oliver et al 
(1972 ) found that 75 grams of glucose given as a single oral dose caused a 
. fall in serum FFA to within normal limits in 3 patients with AMI, and that 
the effect was identical when the same quantity of glucose was given as an 
i ntravenous infusion over 3 hours. Furth_ermore, patients in the present 
study given 100 grams of sucrose or more (mean 106 ! 4 grams) did not have a 
s i gnificantly greater fall in FFA compared with patients given less than 
+ 100 grams (mean 66 - 7 grams, Table 6). Sucrose was given too late to 
i nfluence peak FFA in 6 patients, and did not appear to have had any 
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influenci in the 5 patients who received it before the peak. The 
earliest that any patient received sucrose was 3 hours after the onset of 
symptoms, so that early peak FFA levels might have already occurred 
(Vetter et al, 1974) and the effect of early sucrose administration still 
requires investigation. It is also unlikely that inadequate absorbtion 
occurred. The mean rise in plasma-glucose (40 mg/100 ml) was similar to 
the mean rise of 43 mg/100 ml observed in normal volunteers after ingestion 
of 100 grams of sucrose (Swan et al, 1966). The efficacy of sucrose as 
an antilipolytic agent, as discussed below, may be doubtful in some patients, 
but the main reason why it did not influence peak FFA levels is most likely 
to be th~ delay in administration after the onset of AMI. 
FFA concentrations were lower in sucrose-fed than in starved patients 
for 5 hours after sucrose was given (Figure 2) and this effect was observed 
after the peak FFA levels had occurred (Figure 3). Although not always 
within normal limits during this time, FFA concentrations after sucrose 
remained well below 1.2 mM/1, the level at which unbound FFA may increase 
(Kurien & Oliver, 1970). Thus sucrose would appear to be an effective 
antilipolytic agent. In starved patients, FFA concentrations rose again 
immediately after the initial fall from peak levels, and did not return to 
normal levels until 8 hours later. This rebound was delayed for 5 hours 
in sucrose-fed patients, but was then more prolonged, A similar rebound 
effect was observed after inhibition of lipolysis with a nicotinic-acid 
analogue (Rowe et al, 1975), and repeated doses of sucrose for up to 
24 hours post-infarction might be necessary to prevent this, as was the case 
for a nicotinic-acid analogue (Russell & Oliver, 1978). 
The influence of sucrose on the rate and extent of fall of FFA 
levels after the peak was examined with respect to peak levels above and 
below 1.5 mM/ 1 (Table 6, Figures 4 and 5). This was done for two reasons. 
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Firstly, the higher FFA peaks were associated with larger estimated infarct 
sizes, which may be associated with a more intensive metabolic response 
which might in turn have influenced the effect of sucrose. Secondly, the 
rate of fall after the peak may be influenced by the peak level itself, so 
that patients with high peak FFA might have obscured the effect of sucrose 
in patients with low peak FFA. The mean fall in FFA in patients with 
high peaks (~1.5 mM/1) was greater in sucrose-fed than in starved patients 
(Table 6). This could be entirely accounted for by the higher mean FFA 
peak in the former group, especially as FFA concentrations fell to similar 
absolute levels in the two groups (Figure 4). In patients with low FFA 
peaks (<1.5 mM/1) there was a greater overall subsequent fall in sucrose-fed 
then in starved patients (Table 6), although the difference was not 
statistically significant. The fall was. significantly larger in sucrose-
fed than in starved patients in the second hour after the FFA peak however 
~ (Figure ~ ), suggesting that sucrose was a more effective antilipolytic 
agent in patients with smaller than i~ patients with larger infarcts. 
Oral sucrose may not be as effective an antilipolytic agent as 
nicotinic-acid analogues after AMI (Rowe et al, 1975; Russell & Oliver, 
1978 ) but ·it has several advantages. It is a cheap, commonly-available 
substance which could be administere& very early after the onset of sympto~s 
by a medical practitioner or even by the patient himself. The nicotinic-
acid analogues used in clinical trials to date (Rowe et al, 1975; Russell 
& Oliver, 1978) were associated with an unacceptably high incidence of 
gastro-intestinal side-effects when used in doses high enough and frequent 
enough to maintain FFA concentrations within normal levels. I~ the 
present study, as given with lemon juice sucrose was acceptable to all 
patients. . One patient, not included in the study, vomited after taking 
sucrose but morphine had been administered concurrently, so that which of 
the two caused the vomiting was not known. 
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Large, frequent doses of 
sucrose given to patients over many hours might induce nausea, but 
patients could be given dextrose intravenously once admitted to hospital 
with equal effect (Gupta et al, 1969; Oliver et al, 1972). A final 
possible advantage of _oral sucrose over nicotinic-acid analogues or other 
antilipolytic agents might be the beneficial effect that increased blood 
glucose levels may have on the ischaemic myocardium (Opie, 1970). 
If it is desirable to decrease circulating FFA as early as possible 
in patients with symptoms of acute myocardial infarction, then oral sucrose 
could be a simple, cheap and easily available antilipolytic agent, at 
least in patients with smaller infarcts. 
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Table 3 
Hours 
post-
infarct 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
14 
16 
18 
20 
22 
24 
MEAN FFA (mM/1) AND BLOOD GLUCOSE (mg/100 ml) 
CONCENTRATIONS IN THE FIRST 24 HOURS OF AMI. 
19 3 
+ Mean FFA - SEM + Mean Blood Sugar - SEM 
Sucrose-fed Starved Sucrose-fed Starved 
0.72±0.01 0.94±0.11 142±16 150±12 
1.16±0.31 1.38±0.29 150±15 143±18 
1.21±0.41 1 .12±0 .15 125±25 145±15 
1.12±0.24 1.09±0.14 135±19 1-28± 9 
0.96±0.19 1.11±0.18 151±24 131± 8 
1.01±0.23 1.07±0.10 142±28 114± 6 
0.87±0.14 1.11±0.09 136±18 121± 6 
0.90±0.13 1.12±0.09 112±11 103± 1 
0. 95±0.14 1.13±0.09 144±22 119± 8 
0.78±0.14 1.02±0.07 166±33 
0.86±0.12 1.02±0.11 133±19 116± 8 
0.94±0.16 0.89±0.09 145±19 111± 7 
0.94±0.12 0.95±0.09 109± 9 113±10 
0.99±0.08 0.91±0.07 118±10 120± 7 
0.87±0.11 0.76±0.08 121± 9 135±16 
0.90±0.12 0.64±0.12 123±10 122± 7 
0.83±0.15 0.72±0.11 128± 7 124±14 
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Figure 1 
Mean plasma FFA and glucose concentrations in the first 
24 hours of AMI in 11 sucrose-fed and 11 starved patients. 
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· Table 4 
. Hours 
post-
admission 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
MEAN PLASMA FFA (mM/1) AND GLUCOSE (mg/100 ml) 
CONCENTRATIONS FROM THE TIME OF ADMISSION 
Plasma FFA Plasma Glucose 
Sucrose-fed Starved Sucrose-fed Starved 
1.09±0.17 1 • 12±0 .11 117±11 125± 6 
1.17±0.18 1.10±0 .12 121± 9 128± 8 
1.04±0.20 1 .15±0 .10 145±13 128±11 
1.02±0.22 1 .12±0 .1 O 161±17 113± 7 
0.78±0.17 1 .11 ±0 .14 140±32 125±10 
0.87±0.17 1.17±0.09 135±24 114± 7 
0.83±0.18 1.07±0.11 140±11 121±13 
0.90±0.13 0.92±0.08 145±24 118±13 
0.66±0.16 1.10±0 .13 96±16 111±10 
1. 24±0 .18 0.90±0.13 146±32 117± 9 
0.84±0.17 1.02±0.11 118±12 112±11 
1.07±0.14 0.82±0.15 119±20 121±11 
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Figure 2 
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Mean plasma FFA and glucose conc e ntrations in 11 sucrose-fed 
and 11 starved patients in the 12 hours following admission. 
Sucrose was given one hour after admission, and plasma 
glucose was higher in sucrose-fed than in starved patients 
3 hours post-admission. 
Table 5 
Hours 
after 
peak 
FFA 
-3 
-2 
-1 
Peak FFA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
. 12 
13 - 14 
15 16 
17 - 18 
19 - 20 
21 - 22 
23 - 24 
MEAN FFA CONCENTRATIONS . AFTER THE PEAK OCCURRING WITHIN 
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Sucrose-fed patients Starved patients 
(Mean± SEM) (Mean± SEM) 
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1.29±0.21 1 .15±0 .10 
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0.48±0.09 D.70±0.03 
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Figure 3 
Mean FFA concentrations in 11 sucrose-fed and 11 starved 
patients adjusted so that individual peak FFA coincided 
with time zero. 
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Mean FFA concentrations from peak levels in ? sucrose-fed 
and 4 starved patients with peak FFA levels <1 . 5 mM/l , FFA 
levels in sucrose - fed patients fell significantly lower than 
in starved patients after 2 hours . 
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Mean FFA concentrations from peak levels in 4 sucrose - fed 
and? starved patients with peak FFA levels> 1. 5 mM/l . 
There is no difference in the rate of fall from peak levels 
in the two groups . 
CHAPTER X 
THE EFFECT OF ESTIMATED INFARCT SIZE ·ON THE METABOLISM 
OF PLASMA FREE FATTY ACIDS, PLASMA GLUCOSE AND SERUM INSULIN 
IN THE EARLY PHASE OF ACUTE MYOCARDIAL INFARCTION 
202 
203 
INTRODUCTION AND PURPOSE OF THE STUDY 
The disturbed metabolism of free fatty acids (Kurien & Oliver, 1966; 
Janusjewicz et al, 1971; Christensen & Videbaek, 1974; Vetter et al, 1974), 
glucose (Raab & Rabinowitz, 1936; Sowton, 1962; Daley & Nanda, 1967; 
llison et al, 1969; Vetter et al, 1974), and insulin (Allison et al, 1967, 
1969; Lebowitz et al, 1969; Taylor et al, 1969; Vetter et al, 1974) in 
patients with acute myocardial infarction are well documented. So far, 
these biochemical disturbances, with the exception of plasma FFA levels, 
have been correlated with the severity of infarction only on clinical 
grounds (Ellenberg et al, 1952; Gupta et al, 1969; Taylor et al, 1969), 
although clinical severity correlates well with estimated infarct size 
(Sobel et al, 1972; Shell & Sobel, 1976). The purpose of this study 
was to determine the relation between the degree of biochemical disturbance 
and estimated infarct size. 
Patients and Methods 
Twenty-two patients in whom estimated infarct size and plasma free 
fatty acids, plasma glucose and serum insulin had been estimated in the 
first 12 hours of acute myocardial infarction were included here. Ten 
of the patients received sucrose one hour after admission and the remaining 
12 patients were starved for at least 12 · hours after the onset of symptoms. 
The sucrose-fed and starved groups of patients were divided according to 
infarct size. Large infarcts were 65 CK-g-eq or greater and small 
infarcts less than 65 CK-g-eq, as described previously. Patient 6 
was included in the small-infarct group as described in Chapter III. 
+ Sucrose-fed patients with large infarcts received a mean of 77 - 15 grams 
+ of sucrose and those with small infarcts 88 - 8 grams one hour after 
admission, as described in Chapter IX. 
Patient selection, blood sampling and storage, calculation of infarct 
204 
size and biochemical methods have been detailed in Chapters I, II and III. 
Statistical analysis was by the Mann-Whitney U test (Appendix C). 
RESULTS 
Eight patients had large and 14 had small EIS. Relevant clinical 
and biochemical details are given in Table 1. The mean delay in admission 
+ from the time of onset of symptoms was similar in the two groups (4.1 - 0.7 
+ and 4.6 - 0.4 hours respectively. Plasma glucose on admission was higher 
in patients with large infarcts than in patients with small infarcts 
(mean 168 ! 20 and 112 ! 6 mg/100 ml respectively, P<0.002, U = 11, 
Mann-Whitney U test). Eight of 9 patients with large infarcts had admission 
blood sugars greater than 130 mg/%, whilst 10 of 13 patients with small 
infarcts had admission blood sugars less than 130 mg% (P<0.05, exact fourfold 
table test). Admission values for plasma FFA and serum insulin were also 
higher in patients with large infarcts (Table 1), but not significantly so. 
Mean FFA, glucose and insulin in 5 patients with large infarcts and 
7 with small infarcts were compared (Table 2, Figure 1) during the first 
12 hours of AMI. Plasma FFA were significantly higher at 6 hours and 
plasma glucose and serum insulin at 6, 8, 10 and 12 hours after onset 
of symptoms in patients with large than with small infarcts. 
In Table 3 and Figure 2, the mean FFA, glucose and insulin concentra-
tions in 3 sucrose-fed patients with large infarcts and 7 sucrose-fed 
. patients with small infarcts were compared relative to the time that sucrose 
was given. Plasma FFA concentrations were higher in the large infarct 
patients throughout. Plasma glucose concentrations reached higher and 
more sustained levels in patients with large than with small infarcts. 
Oral sucrose provoked a significant insulin response in patients with 
small infarcts, whereas no such response was found in patients with large 
infarcts. The response of FFAs, glucose and insulin to 100 gram oral 
sucrose in 9 normal subjects (Swan et al, 1966) have been included in 
Figure 2 for comparison. 
DISCUSSION 
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In this study a marked difference in the circulating levels of plasma 
FFA, plasma glucose and serum insulin in the first 12 hours of acute 
myocardial infarction was found according to infarct size. Admission 
glucose values were significantly higher in patients with large infarcts, 
and remained so for the first 12 hours of AMI. Patients with large 
infarcts also had higher FFA and insulin ·values during the study period 
than patients with small infarcts. A marked difference in the response 
of FFA, glucose and insulin to oral sucrose was also found according to 
infarct size; in patients with small infarcts, the response was similar 
to that found in normal volunteers (Swan et al, 1966), whilst patients with 
large infarcts had higher peak FFA and higher glucose concentrations with 
a minimal insulin response. 
Increased catecholamine release after AMI (Gazes et al, 1959; 
McDonald et al, 1969; Siggers et al, 1971; Januszewixz et al, 1971; 
Lukomsky & Uganov, 1972; Christensen & Videbaek, 1974; Vetter et al, 1974) 
appears to be basic to the general biochemical disturbance (Opie, 1971), 
and higher levels are associated with a poor prognosis (Jewitt et al, 1969; 
Griffiths & Leung, 1971; Prakash et al, 1972). The relation between FFA 
and catecholamines has been described in detail in Chapter V. Raised 
FFA levels may also be due in part to decreased insulin release (Allison 
et al, 1969; Lebowitz et al, 1969; Vetter et al, 1974) which is especially 
reduced in shocked patients (Taylor et al, 19q9) and when there are 
increased catecholamine levels (Porte et al, 1966; Miller & Soeldnet, 1969). 
Suppression of insulin release was noted in this study in patients with 
large infarcts given oral sucrose, but not in patients with small infarcts. 
However, in starved patients insulin levels were higher during the first 
12 hours of AMI in those with large than in those with small infarcts, 
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though glucose levels in the former group remained high. These 
observations suggest that insulin secretion, though very much reduced 
after AMI, is not totally abolished, and that a degree of insulin 
resistance may also be present, as proposed by Gupta et al (1974). 
Decreased insulin release and insulin resistance may also partly account 
for the glucose intolerance observed after AMI (Raab & Rabinowitz, 1936; 
Sowton, 1962; Allison et al, 1969). Ellenberg et al (1952) showed that 
there was a greater degree of hyperglycaemia in shocked than in non-shocked 
patients with AMI, and postulated that mobilization of glycogen by 
adrenaline and gluconeogenesis under the influence of adrenocortical 
hormones might be the cause. 
In view of the finding that a significantly larger number of patients 
with large than with small infarcts had an admission blood sugar exceeding 
130 mg/100 ml, this value could be used as a crude indirect index of the 
extent of myocardial infarction. Blood sugar levels on admission, 
which can be simply and rapidly estimated, might therefore be of ~se to 
indicate which patients might benefit most from early metabolic intervention. 
The results of this study show that the degree of biochemical 
disturbance is related to infarct size, and that patients with small infarcts 
have a normal insulin response to a sucrose load in the first 12 hours of 
AMI whilst patients with large infarcts do not. This might explain the 
failure of oral sucrose to influence FFA concentrations in patients with 
large infarcts, as described in Chapter IX. Oral sucrose might, 
therefore, be a more effective antilipolytic agent in these patients if 
insulin were given at the same time. 
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Mean FFA, glucose and insulin levels in 5 patients with large 
and 7 patients with small EIS who were starved for the first 
12 hours of AMI. 
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Mean FFA, glucose and insulin levels in 3 sucrose-fed patients 
with large infarcts and 7 sucrose-fed patients with small 
infarcts relative to the time sucrose was given. Levels in 
9 normal subjects given oral sucrose (Swan et al, 1966) are 
included for comparison. 
SUMMARY AND CONCLUSIONS 
Measurement of serial levels of plasma creatine 
kinase activity and calculation of infarct size 
Plasma creatine kinase activity was measured using commercially 
available kits. The main problem encountered with the method was that 
212 
of diluting plasma with CK activity greater than 1000 i.u./1, which was 
above the limits capable of being read by the equipment used. Dilution 
with Tris buffer, heat-inactivated human serum or distilled water was shown 
to be unsuitable, but the addition of smaller amounts of sample to the 
reaction mixture was shown to produce no significant error up to levels 
of CK activity encountered. 
Infarct size was calculated by serial measurement of CK activity and 
the errors inherent in this method were reviewed in detail. The calculation 
is dependent in part on knowing the concentration of CK in normal and in 
infarcted myocardium. These concentrations were determined using the 
same methods of measuring CK activity as were used for plasma CK; in this 
way a possible source of error in using results from previous studies 
arrived at by different methods was eliminated. Whilst reviewing the 
literature an error in the published method for enzymatic estimation of 
infarct size was identified, and the error was acknowledged by the authors. 
In order to determine whether patients requiring direct current 
cardioversion could be included in the studies the effect of administering 
different levels of electrical energy on total CK and MB-CK were studied. 
Though low-energy shocks did not greatly elevate CK activity, if at all, 
the effect was not predictable so that accurate calculation of infarct 
size could not be guaranteed, and patients requiring cardioversion were 
therefore not included in the study. Cumulative shocks to a level 
greater than previously reported did not elevate MB-CK activity, which 
could therefore be used to calculate infarct size after cardioversion. 
Free fatty acids in the first 12 hours of AMI 
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This was the first time that frequent, serial measurements were 
used to study the pattern of FFA rise and fall in the first 12 hours of 
AMI. A rise in plasma FFA concentrations above normal levels was noted 
in all 15 patients who were studied within 7 hours of the onset of symptoms 
of AMI. The major rise in FFA occurred within 12 hours of AMI, during 
which time all patients were starved, and was characterized by rapid 
fluctuations with one or more peak levels within this time. The mean FFA 
concentrations in the 15 patients did not reflect the enormous variations 
observed in individual patients. Plasma FFA estimated on admission did not 
reflect subsequent levels. High peaks occurred significantly earlier than 
low FFA peaks. Following peak levels CJ'fj' FFA concentrations fell at a rate 
which was related to the peak, so that after a high peak the fall was more 
rapid than after a low peak. A fall in FFA concentrations was seen after 
oral intake in several patients, but the exact association between the two 
was not investigated. 
Practical conclusions drawn from this study are that any investigations 
to correlate plasma FFA concentrations with complications of AMI should be 
based on frequent, early FFA estimations so as to take into account the 
fluctuation in FFA levels observed in the first 24, and especially the first 
12 hours of AMI, and so as not to miss FFA peak concentrations. 
Comparison of agents designed to influence plasma FFA concentrations 
after AMI should only be made between groups where the pre-treatment levels 
are similar. 
Free fatty acids, infarct size and complications of acute 
myocardial infarction 
The relation of heart failure, ventricular arrhythmias, 6-month 
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mortality and duration of chest pain to infarct size and to plasma free 
fatty acid concentrations was studied. 
Patients who developed heart failure were found to have higher 
mean ISI than patients who did not, in keeping with the findings reported 
from other clinical studies. ~There was no association between infarct size 
duration of chest pain, 6-month mortality and ventricular arrhythmias, 
contrary to some previous reports, and possible reasons for the lack of 
agreemert have been discussed. 
All patients with mean FFA concentrations greater than 1.2 mM/1 in 
the first 12 hours of AMI devel~ped serious ventricular arrhythmias within 
24 hours of AMI, as compared with 35% of patients with mean FFA of 1.~ mM/1 
or less (P<0.002). No other relations were observed. Whilst the role 
of FFA in the genesis of arrhythmias after AMI is controversial, this is 
the first study in which frequent and regular FFA estimations have been 
carried out within 12 hours of Al1I, and it is argued that as a result a 
more valid assessment of the relationship between FFA and the complications 
of myocardial infarction has been made. 
In the light of these results, the important therapeutic 
i mplications of early, effective antilipolytic therapy to reduce FFA 
concentrations after AMI have been emphasized. 
Free fatty acids and infarct size 
Peak FFA concentrations in the first 12 hours of AMI were correlated 
with enzymatically estimated infarct size. 
A very strong relation was found between high plasma FFA 
. 
concentrations and patients with large mycoardial infarcts. It was 
therefore proposed that the association between high plasma FFA and infarct 
s ize may give rise to a vicious circle which increases the severity of the 
i schaemic process in patients with high plasma FFA. This hypothesis was 
supported by evidence from previous experimental and clinical studies. 
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It was concluded that treatment to reduce plasma FFA levels after AMI, if 
initiated early enough, might reduce the extent of myocardial necrosis. 
The effect of oral sucrose on FFA concentrations 
Oral carbohydrate has been shown to lower FFA concentrations in 
normal volunteers and patients with AMI. If it were beneficial to lower 
FFA levels after AMI, sucrose would be a cheap and easily available substance 
to administer. The effect of oral sucrose on FFA concentrations after AMI 
was therefore examined. In sucrose-fed patients, mean FFA concentrations 
were significantly lower in the 5 hours following sucrose administration than 
in starved patients over the comparable period. FFA rose to a peak and then 
fell spontaneously by J2% of the peak level in 2 hours. Sucrose had no 
effect on the peak FFA level, possibly because it was administered too late, 
and did not accelerate the initial rate of fall in the first 2 hours, except 
in patients with FFA peaks less than 1.5 mM/1, who also had smaller infarcts 
than patients with higher peak FFA levels. A subsequent rebound of FFA 
values, as seen in starved patient~, was delayed for about6hours in sucrose- · 
fed patients. 
Thus sucrose was an effective antilipolytic agent in patients with 
smaller infarcts. The possible advantages of oral sucrose over the 
nicotinic-acid analogues used to date are ·discussed. It is proposed that 
sucrose should be given much earlier after the onset of symptoms of AMI if 
it is to have any influence on early peak FFA concentrations, and that it 
should be given for a longer period, possibly 24 hours, to prevent the late 
rebound in FFA observed with this and other antilipolytic agents. 
Infarct size, plasma glucose and serum insulin 
Glucose intolerance and suppression of insulin secretion have 
previously been noted after AMI. The degree of these metabolic disturbances 
was examined in relation to infarct size. Patients with large infarcts 
were found to have higher glucose and insulin levels in the first 12 hours 
of AMI than patients with small -infarcts. 
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Insulin secretion was therefore 
not totally abolished, but glucose levels remained high, suggesting the 
possibility of insulin resistance. These observations may explain the 
poor antilipolytic effect of sucrose in patients with high FFA peaks and 
large infarcts observed in the previous section. The results indicate 
that the addition of insulin to regimes where glucose is administered to 
improve myocardial metabolism after AMI is essential in patients with large 
infarcts, but not in patients with small infarcts. Most patients with 
large infarcts might be identifiable by the admission blood glucose level, 
since significantly more patients with large than with small infarcts had 
admission blood sugar values exceeding 130 mg/100ml. Thus patients most 
likely to benefit from metabolic interventions could be identified on 
admission by means of a simple and readily available investigation. 
APPENDIX A 
PLASMA FREE FATTY ACIDS, PLASMA GLUCOSE 
AND SERUM INSULIN CONCENTRATIONS IN THE 
PATIENTS STUDIED 
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DATA RELATING TO CALCULATION OF ESTIMATED INFARCT SIZE 
Time of 
Total Duration peak CK 95~~ Estimated 
Peak CK cumulative of CK release Kd confidence Surface infarct Infarc
t 
ient activity CK release release (Hrs post- (mins-1) 
limits for area size size index 
Jer (i.u. / 1 ) (i.u. / ml) (hours ) infarct) the sloee (m2) (CK-g-eg.) (CK-9-e9/ m2) 
1307 3.87 73 17 0.0013 -0.024 2.1 195 93 
±0.0033 
2 169 0.48 36 14 0.0019 -0.04 , 1.9 19 
10 
±0.003 
3 2030 3.59 46 10 0.0007 -0.02 1.7 117 69 
±0.0009 
6* 69 0.14 28 9 0.002 5 
7 503 0.93 48 10 0.007 -0.02 1.8 36 20 
±0.00098 
8 254 0.73 28 10 0.002 -0.05 1.98 33 17 
±0.006 
9 465 0.62 18 8 0.0008 -0.02 1.9 26 14 
±0.003 
0 649 1.18 36 8 0.0009 -0.02 1.87 46 25 
±0.0018 
1* 926/ 878 0.94/ 2.34 20 10 0.0008 -0.02 2.05 44/ 110 21 / 54 
±0.0012 
3 122 0.16 22 10 0.0013 -0.03 2.15 95 44 
±0.004 
5 552 1.33 54 8 0.0009 -0.02 1.9 58 31 
±0.0012 
6 1796 4.67 40 14 0.0013 -0.03 2.2 262 119 
±0.0038 
7 1265 2.98 54 18 0.0011 -0.03 1.85 125 68 
±0.00015 
8 389 1.29 36 . 10 0.002 -0.04 1.95 59 30 
±0.0048 
9 850 1.07 44 14 0.0005 -0.01 1.6 34 21 
±0.001 
10 1075 1.80 40 18 0.0009 -0.02 1.55 52 34 
±0.0009 
l1 1465 2.62 40 14 0.0012 -0.03 1.6 88 55 
±0.002 
12 271 0.59 50 10 0.0013 -0.03 2.1 31 15 
±0.0016 
23 239 0.38 24 8 0.0012 -0.03 1.98 17 9 
±0.003 
24 991 1.93 54 10 0.0012 -0.03 1.88 77 41 
±0.0015 
25 340 0.75 56 18 0.0012 -0.03 2.35 54 21 
±0.0015 
27 1152 3.00 60 9 0.0016 -0.03 2 131 66 
±0.0016 
28 917 1.92 40 9 0.002 -0.04 
±0.0019 2.05 94 46 
29 1129 1.66 16 9 0.0014 -0.0J 1.9 76 40 
±0.003 
30 467 0.61 32 10 0.0016 -0.03 1.95 26 13 
±0.0033 
31 1378 3.01 40 7 0.001 -0.02 1.7 108 64 
±0.0014 
32 468 1.06 40 9 0.0011 -0.02 1. 95 49 25 
±0.002 
33* 182 0.51 18 11 0.002 7 4 
34 274 0.40 30 8 0.0015 -0.03 2.0 19 10 
±0.0047 
35 255 0.41 22 12 0.0017 -0.04 1.95 19 10 
±0.0016 
*See Chapter III. 
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STATISTICAL METHODS 
tests. 
Statistical analysis of results was carried out using the following 
Unless otherwise stated, the statistical tables in Geigy (Seventh 
Edition) were used. 
1. Students t test for the differences between means of 2 samples, 
where the variances were similar (Swinscow, 1976). 
2. The F distribution, for comparison of the variances of 2 samples 
(Geigy, Seventh Edition, p. 168). 
3. The modification of the t test to allow for unequal variances 
(Geigy, Seventh Edition~ p. 173). 
4. The Mann-Whitney U test, for the comparison of samples with une~ual 
variances (Siegel, International Edition). Tables for the derivation 
of p from U published in the same reference were used. 
5. The exact fourfold table test (Geigy, Seventh Edition, p. 109-123). 
This was used when the number of values in a fourfold table were less 
than 20, or when the number of values was between 20 and 39 and the 
smallest expected value less than 5. 
6. The line of regression and the coefficient of correlation 
(Colton, 1974). 
224 
Abbreviations used in the text in relation to statistical methods 
n = The number of observations 
r = The coefficient of correlation 
a = The intercept 
b = The slope 
Sa = The standard error of the intercept 
Sb = The standard error of the slope 
Sy.x = The standard deviation of the points above the fitted line. 
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